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ABSTRACT 
Persistent infection with hepatitis B virus (HBV) is associated with an increased 
risk for development of serious life-threatening complications such as cirrhosis and 
hepatocellular carcinoma (HCC). This common malignancy is aggressive and has a very 
poor prognosis. Currently available HBV therapies have variable efficacy and do not 
diminish the risk for development of HCC associated with infection with the virus. 
Consequently the development of novel therapies aimed at providing effective treatment 
for chronic HBV infection remains a medical priority.  
The therapeutic potential of harnessing the RNA interference (RNAi) pathway to 
achieve specific and potent silencing of pathology-causing genes has been explored for the 
development of novel and improved therapy to counter chronic HBV infection. Highly 
effective expressed anti-HBV RNAi-based sequences have been demonstrated to be 
capable of mediating impressive silencing of viral gene expression in vitro and in vivo. 
Nevertheless, accomplishing stable delivery to hepatocytes and sustained, long-term 
expression of therapeutic effecters remains the greatest challenge impeding the clinical 
translation of RNAi-based anti-HBV gene therapy. 
Stable integration of transgenes that may be achieved with recombinant 
lentiviruses, derived from the human immunodeficiency virus type 1 (HIV-1), makes these 
vectors particularly useful for attaining sustained expression of RNAi activators. This 
property is suited to countering HBV persistence, making these delivery vehicles 
advantageous for gene transfer of expressed RNAi anti-HBV sequences to infected 
hepatocytes. To advance potential clinical application of RNAi-based anti-HBV gene 
therapy, second generation self-inactivating (SIN) lentiviral vectors were engineered to 
include liver specific, RNA polymerase II (Pol II) cassettes that generate HBV-silencing 
primary micro RNA (pri-miR) mimics. The antiviral pri-miR sequences, placed under the 
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control of the liver-specific mTTR promoter, are derived from natural pri-miR-31 and 
engineered to generate anti-HBV RNAi guide sequences targeting single (monocistronic 
pri-miR sequences) or multiple (polycistronic pri-miR sequences) sites within the highly 
conserved multifunctional HBV X protein (HBx) open reading frame (ORF) of the viral 
genome. The HBV silencing lentiviruses (LVs) stably transduced liver-derived Huh7 and 
HepG2.2.15 cells. Northern blot analysis of RNA extracted from stably transduced Huh7 
cells verified that the integrated anti-HBV pri-miR sequences were processed to form 
RNAi-activating guide strands according to the intended design. When stably transduced 
Huh7 cells were transfected with a HBV replication-competent plasmid, potent inhibition 
of markers of viral replication was achieved. Sustained, hepatotropic HBV silencing was 
effected with limited disruption of endogenous miR function. Silencing of a mutated HBV 
sequence in stably transduced cells was caused by HBV-silencing LV expressing a 
polycistronic pri-miR effecter. Rigorous evaluation of the anti-HBV efficacy of the 
polycistronic silencing LV in the HepG2.2.15 HBV replication cell line demonstrated 
potent antiviral activity.  
Preclinical analysis of the efficacy of the RNAi-activating lentiviral vector system 
was assessed using the HBV transgenic mouse model. HBV silencing LVs encoding a 
liver-specific polycistronic pri-miR 31/5-8-9 sequence was delivered to young adult 
animals via a tail-vein injection as well as to neonatal mice via a superficial temporal vein 
injection. The HBV-silencing LV was capable of mediating stable hepatic delivery and 
sustained expression of anti-HBV pri-miR sequences in vivo. Furthermore, the therapeutic 
sequences were processed in vivo according to the intended design and mediated powerful 
knockdown of HBsAg, circulating viral particle equivalents and intrahepatic viral RNA 
without inducing hepatotoxicity. To our knowledge this is the first study to evaluate the 
efficacy of RNAi-activating anti-HBV lentiviral vectors in the HBV transgenic mouse 
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model. Although the investigation constitutes a preliminary step towards clinical 
application of HBV silencing RNAi-based lentiviral vectors, this study has provided proof 
of principle for a therapeutic strategy that can be potentially useful for the treatment of 
chronic HBV infection.  
 
 
 
Acknowledgements 
 [ix]  
 
ACKNOWLEDGEMENTS 
 
1. First and foremost I am profoundly indebted to my supervisor Professor Patrick 
Arbuthnot who was generous in sharing his time, knowledge and expertise to assist 
me in every step of the completion of this degree. His assistance is greatly 
appreciated and valued. 
2. I would like to thank my co-supervisor Dr Abdullah Ely who has been instrumental 
in assisting me with the design and completion of experimental procedures and has 
been a great source of support during challenging times. 
3. I would like to thank my husband Nicholas. His faith in my abilities, love and 
support have been my source of hope and strength in the completion of my PhD.  
4. I would like to thank my family, my parents Vinko and Mirjana and my sister 
Tijana. Completing this thesis would have not been possible without their continual 
encouragement, support, unconditional love and care. 
5. I would also like to thank Dr Nicolas Ferry for his assistance in the design of 
experimental procedures, many useful discussions and the practical training he 
provided during his sabbatical in our laboratory.  
6. In addition I would like to thank Dr Tuan Nguyen for providing the lentiviral 
plasmids that had been used to generate useful constructs for the purposes of this 
research project as well as for providing useful practical advice.  
7. Moreover, I would like to thank Dr Simon Waddington and Juliette Delhove for 
providing the following plasmids used during my PhD: pENTR™1A and pLNT-
GW-JDG. 
8. I would like to thank the following funding bodies for financial support, the 
University of Witwatersrand Postgraduate Merit Award, the Poliomyelitis Research 
Acknowledgements 
 [x] 
 
Foundation, National Research Foundation, DAAD German Academic Exchange 
Service and the Stella and Paul Loewenstein Charitable and Educational trust.  
Table of Contents 
 [xi]  
 
TABLE OF CONTENTS  
 
DECLARATION ................................................................................................................ II 
DEDICATION .................................................................................................................. III 
PUBLICATIONS AND PRESENTATIONS RELATED TO THESIS ........................ IV 
ABSTRACT ....................................................................................................................... VI 
ACKNOWLEDGEMENTS .............................................................................................. IX 
TABLE OF CONTENTS .................................................................................................. XI 
LIST OF FIGURES ...................................................................................................... XVII 
LIST OF TABLES .......................................................................................................... XIX 
LIST OF SYMBOLS ....................................................................................................... XX 
LIST OF ABBREVIATIONS ........................................................................................ XXI 
1 INTRODUCTION ........................................................................................................ 1 
1.1 Hepatitis B virus biology, pathogenesis, epidemiology and current treatment ........... 1 
1.1.1 Hepatitis B virus biology and life-cycle ................................................................ 1 
1.1.2 Epidemiology, immunopathogenesis and HBV-associated hepatocarcinogenesis 4 
1.1.3 Current treatment................................................................................................... 7 
1.2 Harnessing RNA interference to counter chronic HBV ............................................... 9 
1.2.1 The endogenous RNAi pathway ........................................................................... 9 
1.2.2 Exogenous RNAi effecters .................................................................................. 13 
1.2.3 Developing RNAi-based anti-HBV gene therapy ............................................... 16 
1.2.4 Engineering expressed effecters for RNAi-based anti-HBV gene therapy ......... 18 
1.3 Viral vector delivery of expressed anti-HBV RNAi effecters ..................................... 22 
1.3.1 Adenoviral vectors .............................................................................................. 23 
Table of Contents 
 [xii]  
 
1.3.2 Adeno-associated viral vectors............................................................................ 25 
1.3.3 Lentiviral vectors................................................................................................. 28 
1.4 Models of HBV replication and infection .................................................................. 37 
1.5 AIMS.......................................................................................................................... 39 
2 MATERIALS AND METHODS............................................................................... 41 
2.1 Generation of expression vectors encoding liver-specific anti-HBV pri-miR mimics41 
2.1.1 Assessing functionality and tissue-specificity of the liver-specific mTTR 
promoter ....................................................................................................................... 41 
2.1.1.1 Construction of the pmTTR Fluc expression vector .................................... 41 
2.1.1.2 Transfections of cultured liver- and kidney- derived mammalian cells ....... 42 
2.1.1.3 Quantification of luciferase reporter enzyme activity .................................. 43 
2.1.2 Construction of liver-specific anti-HBV pri-miR expression vectors ................. 43 
2.2 Construction of recombinant lentiviral vectors encoding liver-specific anti-HBV pri-
miR mimics ....................................................................................................................... 46 
2.3 Assessment of the efficacy of expressed liver-specific anti-HBV pri-miR mimics ..... 46 
2.3.1 Target and reporter plasmids ............................................................................... 46 
2.3.2 Assessing HBV knockdown efficacy and tissue-specificity of expressed liver-
specific anti-HBV pri-miR mimics .............................................................................. 48 
2.3.3 Assessing inhibition of HBsAg secretion by expressed liver-specific anti-HBV 
pri-miR mimics ............................................................................................................ 49 
2.3.3.1 Transfections ................................................................................................ 49 
2.3.3.2 HBsAg ELISA .............................................................................................. 49 
2.4 Production, concentration and titration of pLVTH-derived recombinant lentiviral 
vectors expressing liver-specific anti-HBV pri-miR mimics ............................................ 50 
2.4.1 Production of VSV-G pseudotyped recombinant lentiviruses ............................ 50 
2.4.2 Concentration of recombinant lentiviruses ......................................................... 53 
2.4.2.1 Ultrafiltration ................................................................................................ 53 
2.4.2.2 Ultracentrifugation........................................................................................ 53 
2.4.3 Titration of recombinant lentiviruses .................................................................. 54 
2.5 Transduction of Huh7 cells with recombinant lentivirus expressing liver-specific 
anti-HBV pri-miR mimics ................................................................................................ 55 
2.5.1 Determination of the number of proviral lentiviral vector copies in transduced 
Huh7 cells ..................................................................................................................... 56 
2.6 Assessment of anti-HBV pri-miR mimic processing and sequence rearrangement in 
stably transduced Huh7 cells ........................................................................................... 56 
Table of Contents 
 [xiii]  
 
2.6.1 Polyacrylamide gel electrophoresis and Northern blot analysis ......................... 56 
2.6.2 PCR recombination analysis of integrated polycistronic pri-miR mimic 
sequences in stably transduced Huh7 cells .................................................................. 58 
2.7 Evaluation of the HBV knockdown efficacy of LV-delivered anti-HBV pri-miR 
mimics in stably transduced Huh7 cells........................................................................... 59 
2.7.1 Target and reporter plasmids ............................................................................... 59 
2.7.1.1 psiCHECK-mHBx ........................................................................................ 59 
2.7.1.2 psiCHECK-5T, psiCHECK-8T and psiCHECK-9T .................................... 59 
2.7.2 Assessment of HBV knockdown efficiency........................................................ 59 
2.7.3 Assessment of knockdown efficiency against individual HBV target sequences
 ...................................................................................................................................... 60 
2.7.4 Assessment of anti-HBV pri-miR mediated knockdown against a mutant HBx 
sequence ....................................................................................................................... 60 
2.7.5 Assessment of inhibition of viral replication by integrated anti-HBV pri-miR 
mimics .......................................................................................................................... 61 
2.8 Evaluation of saturation of the endogenous miR pathway by LV-delivered anti-HBV 
pri-miR mimics ................................................................................................................. 61 
2.8.1 Assessment of disruption of endogenous miR-16 function in stably transduced 
cells............................................................................................................................... 61 
2.8.1.1 Sponge and target plasmids .......................................................................... 61 
2.8.1.2 Saturation assay ............................................................................................ 62 
2.9 Evaluation of the HBV knockdown efficacy of LV-delivered anti-HBV pri-miR 
mimics in stably transduced HepG2.2.15 cells ................................................................ 62 
2.9.1 Transduction of HepG2.2.15 cells with recombinant LV expressing  a liver-
specific anti-HBV polycistronic pri-miR sequence ..................................................... 62 
2.9.2 Quantification of HBsAg and HBeAg secretion in stably transduced HepG2.2.15 
cells............................................................................................................................... 63 
2.9.3 HBV DNA quantification in stably transduced HepG2.2.15 cells ...................... 64 
2.10 Assessment of long-term transgene expression mediated by the liver-specific mTTR 
promoter in vivo ............................................................................................................... 64 
2.10.1 Generation of a recombinant lentiviral vector expressing the Firefly luciferase 
transgene from an internal mTTR promoter ................................................................ 64 
2.10.2 Production and titration of recombinant pLNT-mTTR-JDG LV ...................... 69 
2.10.3 Neonatal liver gene transfer of recombinant LV expressing a Firefly luciferase 
transgene....................................................................................................................... 70 
2.10.4 In vivo bioluminescence imaging ...................................................................... 70 
Table of Contents 
 [xiv]  
 
2.11 In vivo assessment of the antiviral efficacy and toxicity of the therapeutic LVTH-
LUC miR-31/5-8-9 lentivirus ........................................................................................... 71 
2.11.1 Construction of recombinant pLVTH- and pLVTH miR-31/5-8-9- derived 
lentiviral vectors expressing a Firefly luciferase transgene ......................................... 71 
2.11.2 Production and titration of recombinant LVTH-LUC and LVTH-LUC miR-
31/5-8-9 LV .................................................................................................................. 71 
2.11.3 LVTH-LUC and LVTH-LUC miR-31/5-8-9 LV gene transfer in neonatal and 
adult HBV transgenic mice .......................................................................................... 74 
2.11.3.1 LV gene transfer via temporal vein injection in neonatal HBV transgenic 
mice .......................................................................................................................... 74 
2.11.3.2 LV gene transfer via tail vein injection in adult HBV transgenic mice ..... 74 
2.11.4 Quantification of serum alanine transaminase .................................................. 74 
2.11.5 Quantification of serum HBsAg ........................................................................ 75 
2.11.6 Quantification of serum HBV DNA.................................................................. 75 
2.11.7 Tissue collection ................................................................................................ 75 
2.11.8 Determination of vector copy number in mouse liver tissue ............................ 76 
2.11.9 Quantitative reverse transcriptase PCR of intrahepatic HBV RNA .................. 76 
2.11.10 Detection of mature miR-31/5 in liver tissue of lentivirus-injected HBV 
transgenic mice ............................................................................................................. 77 
Statistical analysis ........................................................................................................... 77 
3 ENGINEERING SECOND GENERATION SIN RECOMBINANT 
LENTIVIRAL VECTORS FOR ANTI-HBV RNAI GENE THERAPY ..................... 79 
3.1 Introduction................................................................................................................ 79 
3.2. Design and efficacy of monocistronic and polycistronic liver-specific anti-HBV pri-
miR mimics ....................................................................................................................... 81 
3.2.1 The mTTR promoter is capable of driving tissue-specific expression of the 
Firefly luciferase transgene .......................................................................................... 81 
3.2.2 Pri-miR mimics expressed from the mTTR promoter mediate tissue-specific 
HBV knockdown .......................................................................................................... 83 
3.3 Design of the second generation SIN pLVTH-derived lentiviral vectors encoding 
liver-specific anti-HBV pri-miR mimics........................................................................... 86 
3.3.1 Lentiviral vector-encoded liver-specific pri-miR mimics mediate effective 
knockdown of viral replication .................................................................................... 90 
3.4 Conclusion ................................................................................................................. 93 
Table of Contents 
 [xv]  
 
4 CHARACTERISATION OF THE RNAI-BASED HBV-SILENCING 
LENTIVIRAL VECTORS IN VITRO ............................................................................. 95 
4.1 Introduction................................................................................................................ 95 
4.2 Propagation of HBV silencing LVs and processing of LV-delivered anti-HBV pri-
miR mimics in stably transduced cells ............................................................................. 97 
4.3 Recombination between repeated pri-miR scaffold sequences is not detectable in 
LVTH miR-31/5-8-9-transduced Huh7 cells .................................................................. 100 
4.4 Expression of lentiviral vector-delivered anti-HBV pri-miR mimics does not disrupt 
the endogenous miR pathway......................................................................................... 102 
4.5 Silencing efficacy of the lentiviral vector-based anti-HBV miR system in stably 
transduced Huh7 cells.................................................................................................... 106 
4.5.1 LV-delivered anti-HBV pri-miR mimics silence HBV gene expression and viral 
replication ................................................................................................................... 106 
4.5.2 Integrated polycistronic anti-HBV pri-miR mimics mediate effective knockdown 
of individual viral target sequences ............................................................................ 108 
4.5.3 Integrated polycistronic anti-HBV pri-miR mimics mediate knockdown of a 
mutant HBx target sequence ....................................................................................... 110 
4.6 Evaluation of the knockdown efficacy of the lentiviral vector-based anti-HBV miR 
system in stably transduced HepG2.2.15 cells............................................................... 112 
4.6.1 Integrated anti-HBV pri-miR mimics mediate powerful inhibition of HBsAg and 
HBeAg secretion in HepG2.2.15 cells ....................................................................... 112 
4.6.2 Integrated anti-HBV pri-miR mimics mediate effective reduction of viral particle 
equivalents in HepG2.2.15 culture supernatants ........................................................ 114 
4.7 Conclusion ............................................................................................................... 116 
5 COUNTERING VIRAL REPLICATION IN VIVO WITH HBV-SILENCING 
LENTIVIRUSES ............................................................................................................. 119 
5.1 Introduction.............................................................................................................. 119 
5.2 The mTTR promoter is capable of driving long-term stable transgene expression in 
vivo ................................................................................................................................ 121 
5.3 pLVTH- and pLVTH miR-31/5-8-9- derived LVs encoding the Firefly luciferase 
transgene mediate stable transgene delivery in vivo ..................................................... 124 
5.4 The LVTH-LUC miR-31/5-8-9 LV silences HBV replication in vivo ...................... 129 
5.5 LV-delivered polycistronic pri-miR sequences mediate intrahepatic knockdown of 
HBV gene expression ..................................................................................................... 133 
5.6 HBV-silencing lentiviruses do not induce hepatotoxicity ........................................ 136 
Table of Contents 
 [xvi]  
 
5.7 The polycistronic pri-miR-31/5-8-9 sequence is efficiently processed in the livers of 
LV-injected mice ............................................................................................................ 138 
5.8 Conclusion ............................................................................................................... 140 
6 DISCUSSION ........................................................................................................... 142 
APPENDIX....................................................................................................................... 158 
A1 GENERAL LABORATORY METHODS AND PROTOCOLS................................... 158 
A1-1 Plasmid DNA purification ................................................................................ 158 
A1-2 qPCR vector copy number quantification data ................................................. 161 
A1-2 Cell culture ........................................................................................................ 162 
Maintenance of cultured cells ................................................................................. 162 
Transfection of cells ............................................................................................... 163 
A3 ANIMAL ETHICS CLEARANCE CERTIFICATES .................................................. 165 
7 REFERENCES ......................................................................................................... 167 
 
 
 
 
 
List of Figures 
 [xvii]  
 
LIST OF FIGURES 
Figure 1.1: Hepatitis B virus genome organisation. .............................................................. 2 
Figure 1.2: The canonical miR biogenesis pathway. ........................................................... 11 
Figure 1.3: The evolution and design of expression systems encoding RNAi effecters. .... 19 
Figure 1.4: Production of SIN recombinant lentivirus. ....................................................... 30 
Figure 2.1: Schematic illustration of the construction of liver-specific anti-HBV pri-miR 
expression vectors................................................................................................................ 45 
Figure 2.2: Schematic illustration of the cloning strategy used to construct HBV-silencing 
lentiviral vectors encoding liver-specific pri-miR mimics. ................................................. 47 
Figure 2.3: Schematic representation of the cloning strategy used for the construction of 
the pENTR™1A-mTTR entry vector. ................................................................................. 67 
Figure 2.4: Schematic representation of Gateway cloning strategy for the generation of 
the pLNT-mTTR-JDG lentiviral vector. ............................................................................. 68 
Figure 2.5: Schematic illustration of the cloning strategy used to construct the pLVTH-
LUC and pLVTH-LUC miR-31/5-8-9 lentiviral vectors. ................................................... 73 
Figure 2.6: TaqMan Small RNA Assay-based quantification of mature miR sequences. 78 
Figure 3.1: Firefly luciferase expression from CMV and mTTR promoter sequences in 
liver- and kidney-derived cells. 82 
Figure 3.2: HBV knockdown efficacy of liver-specific pri-miR expression cassettes. 85 
Figure 3.3: Schematic illustration of the mono- and poly- cistronic liver-specific pri-miR 
expression cassettes. 87 
Figure 3.4: Schematic illustration of the second-generation SIN pLVTH- derived HBV-
silencing lentiviral vectors. 88 
Figure 3.5: Assesement of inhibition of HBsAg secretion by lentiviral vector encoded 
liver-specific anti-HBV miR mimics. 92 
Figure 4.1: Processing of lentiviral vector-delivered liver-specific pri-miR mimics in stably 
transduced Huh7 cells. ......................................................................................................... 99 
Figure 4.2: PCR analysis of integrated anti-HBV pri-miR expression cassettes. ............. 101 
Figure 4.3: Illustration of constructs used to assess saturation of endogenous miR-16 
function. ............................................................................................................................. 104 
Figure 4.4: Assessment of off target effects of integrated anti-HBV pri-miR mimics on 
endogenous miR-16 function............................................................................................. 105 
Figure 4.5: HBV knockdown in stably transduced Huh7 cells. ........................................ 107 
Figure 4.6: Silencing of individual HBV targets by polycistronic LV-delivered anti-HBV 
pri-miR mimics. ................................................................................................................. 109 
Figure 4.7: Pri-miR-mediated silencing of wild-type HBx and mutant HBx target gene  
expression. ......................................................................................................................... 111 
Figure 4.8: HBV antigen quantification in HepG2.2.15 culture supernatants. ................. 113 
Figure 4.9: HBV DNA quantification in stably transduced HepG2.2.15 cells. ................ 115  
Figure 5.1: LNT-mTTR-JDG LV transfer to neonatal HBV transgenic mice. ................. 122 
Figure 5.2: Long-term follow-up of Firefly luciferase expression in LNT-mTTR-JDG LV-
injected mice. ..................................................................................................................... 123 
List of Figures 
 [xviii]  
 
Figure 5.3: Schematic of pLVTH-LUC and pLVTH-LUC  miR-31/5-8-9  lentiviral vectors.
 ........................................................................................................................................... 126 
Figure 5.4: Long-term follow-up of Firefly luciferase expression following LVTH-LUC 
and LVTH-LUC miR-31/5-8-9 LV delivery to neonatal HBV transgenic mice. .............. 127 
Figure 5.5: Bioluminescence imaging of Firefly luciferase expression following systemic 
LV delivery to adult HBV transgenic mice. ...................................................................... 128 
Figure 5.6: Evaluation of long-term effects of HBV-silencing LV on HBsAg production 
and circulating viral particle equivalents in vivo. .............................................................. 131 
Figure 5.7: Assessment of the effects of HBV-silencing LV on HBsAg production and 
circulating viral particle equivalents after LV administration to adult HBV transgenic mice.
 ........................................................................................................................................... 132 
Figure 5.8: Concentration of core and surface HBV mRNA in the livers of temporal vein 
LV-injected HBV transgenic mice. ................................................................................... 134 
Figure 5.9: Concentration of core and surface HBV mRNA in the livers of tail vein LV-
injected HBV transgenic mice. .......................................................................................... 135 
 
 
 
 
 
 
List of Tables 
 [xix]  
 
LIST OF TABLES 
Table 2.1: Description of second-generation, recombinant lentiviral plasmids used for the 
production of HBV-silencing LVs. ..................................................................................... 52 
Table 3.1: Average viral titres obtained for pLVTH and pLVTH-derived HBV- silencing 
LVs. ..................................................................................................................................... 90 
Table 5.1: Alanine transaminase (U/L) in sera of HBV transgenic mice that received LV 
intravenously. .................................................................................................................... 137 
Table 5.2: Detection of mature miR-31/5 sequence in liver tissue of LV-injected HBV 
transgenic mice. ................................................................................................................. 139 
Table 6.1: Preparation of transfection grade plasmid DNA using Qiagen Plasmid Maxi and 
Giga Kits. ........................................................................................................................... 159 
 
List of Symbols 
 [xx]  
 
LIST OF SYMBOLS 
α - alpha 
 -beta 
γ -gamma 
µ - micro 
Ψ - psi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Abbreviations 
 [xxi]  
 
LIST OF ABBREVIATIONS 
5'-OAS 5'-oligoadenylate synthetase 
AAV adeno associated virus 
Ad adenovirus 
ADA adenosine deaminase 
Ago2 Argonaute 2  
ALT alanine transaminase 
APCs antigen presenting cells 
ATP adenosine triphosphate 
C/EBP  CCAAT/enhancer binding protein 
cccDNA covalently closed circular DNA 
CMV cytomegalovirus 
cPPT central polypurine tract 
CREB cyclic AMP response element binding protein 
DGCR8 DiGeorge critical region 8  
DMEM Dulbecco's Modified Eagle Medium  
DMSO dimethylsulphoxide 
DPBS Dulbecco's Phosphate-Buffered Saline  
ds double stranded 
E. coli Escherichia coli 
EF-1 alpha the human elongation factor- 1 alpha  
eGFP enhanced GFP 
ELISA enzyme linked immunosorbent assay 
endo-siRNAs endogenous siRNAs  
List of Abbreviations 
 [xxii]  
 
FCS foetal calf serum 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GFP green fluorescent protein 
hBA human   Actin 
HBcAg hepatitis B virus core antigen 
HBeAg hepatitis B virus E antigen 
HBsAg hepatitis B virus surface antigen 
HBV hepatitis B virus 
HBx hepatitis B virus X protein 
HCC hepatocellular carcinoma 
HDAd helper dependent Ad 
HEK  human embryonic kidney cells 
HIV human immunodeficiency virus 
HIV-1 human immunodeficiency virus type 1 
HNF hepatic nuclear factor 
IFN interferon 
ITR inverted terminal repeats 
kb kilobases 
lhRNA long hairpin RNA 
lhRNA long hairpin RNA  
LTR long terminal repeat 
LV lentivurus 
miR micro RNA 
MOI multiplicity of infection 
mTTR murine transthyretin  promoter 
List of Abbreviations 
 [xxiii]  
 
MW molecular weight 
nt  nucleotide 
NTCP sodium taurocholate cotransporting polypeptide 
ORF open reading frame 
PEG polyethylene glycol 
PEI polyethylenimine 
pgRNA pregenomic RNA 
PIC pre integration complex 
piRNAs  PIWI-interacting RNAs  
PKR protein kinase R 
Pol II RNA polymerase II 
pre-miR precursor miR 
pri-miR primary miR 
qPCR quantitative PCR 
rcDNA relaxed circular DNA 
RIG- 1 retinoic-acid-inducible protein I 
RISC RNA induced silencing complex 
RNAi RNA interference 
RRE Rev-responsive element 
RSV Rous sarcoma virus 
SCID severe combined immunodeficiency disorder 
SDS sodium dodecyl sulphate 
SEM standard error of the mean 
shRNA short hairpin RNA 
SIN self-inactivating 
List of Abbreviations 
 [xxiv]  
 
siRNA small interfering RNA 
snRNA small nucleolar RNA 
TAR trans-activation-responsive region 
TBE Tris-Borate EDTA 
TLR toll-like receptor 
TRBP TAR RNA binding protein 
TU transducing units 
UTR untranslated region 
VSV-G vesicular stomatitis virus G glycoprotein 
VPEs viral particle equivalents 
WPRE 
 
woodchuck hepatitis virus posttranscriptional 
regulatory 
Chapter 1 
 [1]  
 
1 INTRODUCTION 
 
1.1 Hepatitis B virus biology, pathogenesis, epidemiology and 
current treatment 
1.1.1 Hepatitis B virus biology and life-cycle 
The hepatitis B virus (HBV) is a member of the hepadnavirus family, a family of 
hepatotropic viruses with partly double stranded DNA genomes (1). The virus has a 
relaxed circular (rc), partly double stranded DNA genome consisting of a negative strand 
of 3.2 kilobases (kb) and a positive strand DNA that is variable in length (2) (Figure 1.1). 
The infectious virion, also known as a Dane particle (3), consists of an inner nucleocapsid 
core enclosing the viral genome and an outer lipid envelope in which small, middle and 
large surface glycoproteins (HBV surface antigens (HBsAgs)) are embedded. In addition to 
infectious Dane particles, an excess of spherical and filamentous subviral particles, which 
exclusively consist of a lipid envelope and surface glycoproteins, are found in the blood of 
individuals infected with the virus. These particles lack the nucleocapsid core, are non-
infectious and play an important role in immune evasion as antibody decoys (reviewed in 
(4)).  
The Australia antigen, now known as HBsAg, was the first HBV-specific infection 
marker identified (5). The discovery of the HBsAg heralded the development of sensitive 
HBV detection assays commonly used today, such as the HBsAg enzyme linked 
immunosorbent assay (ELISA) which has become an indispensable tool in the screening 
and diagnosis of viral infection as well as in monitoring the efficacy of anti-viral therapy 
(reviewed in (6)). The HBV surface glycoproteins have been the subject of numerous 
investigations aiming to identify the receptor used by the virus to gain access to 
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Figure 1.1: Hepatitis B virus genome organisation.  
The partially double stranded genome is indicated with transcription regulatory elements. 
Viral open reading frames are shown as black arrows immediately surrounding the 
genome. The outermost, pink arrows represent the four major viral transcripts that 
terminate at a single polyadenylation site. The figure has been adapted from reference (7). 
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hepatocytes. Recently, the sodium taurocholate cotransporting polypeptide (NTCP) 
receptor was identified as the receptor used by the virus to enter hepatocytes. This hepatic 
transmembrane transporter is expressed on the surface of liver cells and interacts with the 
large surface protein of HBV (8). Following entry via the NTCP receptor, HBV 
nucleocapsids translocate to the nucleus where the rcDNA is offloaded and subsequently 
converted to covalently closed circular DNA (cccDNA) (9).  
The cccDNA encodes four overlapping open reading frames (ORFs) from which 
seven HBV viral proteins are synthesised. Four different viral promoters and two 
enhancers drive unidirectional transcription of four viral RNAs from the cccDNA template 
(10) (Figure 1.1). A single polyadenylation signal terminates the transcription of all viral 
mRNAs at a universal 3' end.  Viral mRNAs include: the 0.9, 2.1 and 2.4 kb subgenomic 
mRNAs and the 3.5 kb greater-than-genome length pregenomic RNA (pgRNA).  
Translation of the 0.9 kb mRNA yields the HBV X protein (HBx), while translation of the 
2.1 and 2.4 kb mRNA sequences produces the small, middle and large surface envelope 
glycoproteins. The 3.5 kb pregenomic RNA serves as the template for reverse transcription 
as well as translation of polymerase and core proteins (11). An additional viral mRNA 
exists, which is slightly longer than the pgRNA at its 5' end. This mRNA is translated to 
the precore/core protein, which is the precursor of secreted HBV e antigen (HBeAg) (11). 
The viral polymerase binds covalently to an RNA stem-loop structure at the 5' end 
of the pgRNA and triggers packaging of the viral pgRNA into core particles (12). Viral 
replication occurs within nucleocapsids in the cytoplasm and proceeds from reverse 
transcription of the pgRNA. The viral polymerase has reverse transcriptase activity and 
acts as a primer for DNA synthesis (13). Encapsidation initiates reverse transcription of 
pgRNA to synthesize the negative DNA strand. The minus strand serves as template for 
the synthesis of the plus strand to form a complete rcDNA genome. Nucleocapsids bud 
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through the endoplasmic reticulum where they are enveloped and soon after secreted from 
host cells, to continue infection or traffic to the nucleus of the same cell where additional 
cccDNA is formed and a stable pool of cccDNA is established (14-16). HBV DNA persists 
in the nucleus of infected hepatocytes as an episomal cccDNA minichromosome (17). In 
addition, the virus has a propensity to randomly integrate portions of its DNA into the host 
genome via recombination (18-22).  
Since the sophisticated replication strategy employed by HBV hinges on production 
of the pgRNA, the development of therapeutic strategies that target and/or degrade this 
RNA replication intermediate is important, as this class of therapeutic agents may 
potentially deplete intrahepatic cccDNA and counter persistent viral replication. 
 
1.1.2 Epidemiology, immunopathogenesis and HBV-associated 
hepatocarcinogenesis 
HBV is a non-cytopathic human virus that causes both acute and chronic infection 
of the liver. It is estimated that over 2 billion people have been infected with the virus and 
more than 350 million individuals have progressed to chronicity (23). Geographically, sub-
Saharan Africa, east and south east Asia and the western Pacific islands are the regions 
most affected by chronic HBV infection, followed by regions in the Amazon and some 
southern parts of central and eastern Europe (23). Ten diverse HBV genotypes (A-J) have 
been described (24). These have varied geographical prevalence and have been reported to 
influence the clinical course of the infection as well as responsiveness to antiviral therapy.  
In highly endemic regions, the virus is generally transmitted perinatally from 
mother to child or horizontally among young children. Parenteral transmission via sexual 
contact in adults or the use of contaminated needles is more common in areas of low 
endemicity. While 90% of infants that have acquired the infection at birth and up to 50% 
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of children that have acquired the infection before the age of 6 will develop chronic 
hepatitis, clinical symptoms are resolved and protective immunity is developed by the 
majority of acutely infected adults (reviewed in (25)). Viral infection is usually undetected 
by the innate immune system and consequently does not result in the induction of a 
vigorous innate immune response (26). Viral spread following infection is typically slow, 
however HBV is capable of infecting the entire hepatocyte population in the liver (26-28). 
Despite the absence of a vigorous innate immune response, an effective adaptive immune 
response involving the clearance of cells expressing viral antigens by cytotoxic CD8+ T 
cells is considered responsible for the viral clearance typically observed in 
immunologically competent adults (28). Nevertheless, failure of the adaptive immune 
response to mount an efficient response and to clear HBV-infected cells leads to the 
development of chronic infection. The above has been attributed to evasion and/or 
inhibition of adaptive immune responses including T-cell anergy, ignorance and 
exhaustion (reviewed in (29)). High levels of HBsAg in chronically infected individuals 
contribute to exhaustion of the functional HBV-specific cytotoxic T cell reservoir and a 
blunted T-cell response which results in viral immunotolerance instead of viral eradication 
(30, 31). In addition, specific HBV proteins have been proposed to function in inducing 
tolerance to adaptive anti-HBV immune responses. The X protein has been reported to be 
capable of mediating inhibition of the cellular proteosome which can result in reduced 
antigen processing and presentation (32). The HBeAg has been proposed to play a role in 
viral persistence by suppressing HBV core antigen (HBcAg)-specific T cell responses and 
inhibiting the clearance of HBcAg-expressing infected cells (33). Finally, viral persistence 
induces an immune-mediated, chronic necroinflammatory disease which has been 
identified as one of the triggers of HBV-induced hepatocarcinogenesis (34). Together 
hepatitis B and C virus infection are the two major risk factors for the development of liver 
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cancer (35). Individuals who are chronically infected with the virus are at an increased risk 
of developing hepatocellular carcinoma (HCC) and cirrhosis (36). Together hepatitis B and 
C virus infection are the two major risk factors for the development of liver cancer (35). 
Worldwide, HCC is the second leading cause of cancer-related death in men and the sixth 
leading cause of cancer-related death in women (37). Chronic HBV infection is commonly 
observed in the rural, black South African population (38, 39). Approximately 10 % of 
individuals in the South African black population have been chronically infected with 
HBV and infection with the virus is typically the cause of majority of cases of HCC that 
occur in the respective population (38, 39). Unfortunately, HCC is one of the most 
aggressive malignancies and it has a very poor prognosis (40). Viral mutations (41), age, 
gender, HBeAg status, serum HBsAg, HBV DNA levels (42, 43) as well as the viral 
genotype are among some of the factors that influence the development and severity of 
chronic inflammation and HCC (reviewed in (44)). For instance, infection with 
subgenotype A1 (45), which is endemic in South Africa, and genotype C (46) has been 
reported to be associated with high risk for developing liver cancer.  
Several mechanisms have been proposed to play a role in the pathogenesis of HBV-
associated HCC. As mentioned previously, HCC may develop as a result of virus-induced 
chronic necroinflammatory disease (34). In addition, oncogenic gene transactivation by the 
carcinogenic HBx protein as well as insertional mutagenesis mediated by HBV DNA 
integration have been implicated in the onset and progression of HCC (19, 47-49). HBV 
integration promotes tumorigenesis via three mechanisms. These include virus-mediated 
cis transactivation of oncogenes or altered activity of tumour suppressor genes (49-51), 
enhanced genomic instability (19) and lastly the generation of mutated viral proteins with 
carcinogenic potential such as truncated HBx and large surface proteins (52, 53). The 
critical function of the HBx protein in the induction of HBV-associated HCC has been 
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highlighted in a plethora of reports (reviewed in (47)).  HBx has been proposed to promote 
carcinogenesis by several mechanisms. This oncogenic protein is well known for its ability 
to induce transactivation of host and viral genes involved in cell survival and proliferation 
by enhancing transcription directly or modulating the activity of various transcription 
factors, such as the Yes-associated protein (54), cyclic AMP response element binding 
protein (CREB) (55) and p53 (56, 57). The interaction of HBx with the UV-damage DNA 
binding factor UV-DDB1, a protein that plays a key role in cellular DNA repair, has been 
well documented and reported to contribute to malignant cell transformation (58, 59). 
Other mechanisms of HBx-mediated induction of tumorigenic transformation include: the 
activation of signalling pathways involved in cell survival (60, 61) as well as the 
stimulation of epigenetic changes (reviewed in (62)). 
Globally, chronic HBV infection and associated life-threatening sequelae such as 
the development of cirrhosis, liver-failure and HCC remain a significant cause of public 
health problems. A safe and effective vaccine against HBV has been available for over 
three decades and implementation of mass immunisation on the recommendation of the 
World Health Organization has indeed contributed to a significant reduction in the rate of 
chronic infection (23, 63, 64). However, new cases of HBV infection continue to be 
reported as a result of poor immunisation coverage, particularly in some of the countries 
with the highest incidence of new infections (65, 66). Moreover, the vaccine is 
prophylactic and although it has reduced the number of new infections, it does not benefit 
individuals that have already developed chronic HBV infection.  
 
1.1.3 Current treatment  
Currently seven therapies are licensed for use in the management of chronic HBV, 
these include: immunomodulators (interferon-α (IFN-α) 2b and IFN-α 2a modified with 
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polyethylene glycol (PEG) (PEG-IFN-α 2a)), nucleoside analogues (lamivudine, 
telbivudine and entecavir) and nucleotide analogues (adefovir dipivoxil and tenofovir) 
(67). As a natural immunomodulator, the use of interferon in the treatment of HBV has a 
long-standing history (68). Standard interferon has been replaced with PEG-modified 
interferon which has an improved pharmacokinetic profile and hence improved efficacy 
(69, 70). IFN exerts its antiviral effect by two distinct mechanisms (71). Firstly, interferons 
stimulate the expression of numerous genes leading to the initiation of multiple antiviral 
pathways and inhibition of viral replication. Secondly, interferon amplifies the cellular 
immune response against HBV-infected hepatocytes by stimulating the activity of B cells 
and cytotoxic T cells. However, interferon treatment causes sustained antiviral effects in 
only a third of patients who have chronic HBV and its use is associated with numerous side 
effects thus limiting the tolerability of the treatment (68, 69). 
In contrast to interferon, nucleoside/nucleotide analogues have an improved safety 
profile and can be taken orally. The nucleoside/nucleotide analogues resemble endogenous 
nucleotides and are phosphorylated following cellular uptake. Phosphorylated 
nucleoside/nucleotide analogues are subsequently incorporated into the growing viral DNA 
chain and function as chain terminators or by direct inhibition of HBV polymerase. This 
class of therapeutic agents has been shown to be capable of mediating potent reduction of 
viraemia in chronically infected patients. Nevertheless, long-term treatment with 
nucleoside/nucleotide inhibitors, especially lamivudine and adefovir, has been shown to be 
associated with the emergence of viral escape mutants (72-74). Although some of the 
recently approved therapeutic agents from this class seem to have a somewhat improved 
barrier to resistance (75, 76), preclinical studies have shown that long-term administration 
of nucleoside/nucleotide analogues does not lead to complete clearance of cccDNA from 
infected cells (77, 78). As a result, treatment interruption results in recurrence of viraemia, 
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limiting the curative efficacy of these agents (reviewed in (79)). Currently available HBV 
treatments are costly, have limited therapeutic efficacy and their use is associated with the 
emergence of viral escape mutants. Consequently the development of novel therapies 
aimed at providing effective treatment for chronic HBV infection remains a medical 
priority. Novel and improved therapies should ideally be safe, provide a high barrier to 
emergence of escape mutants and exhibit potent and durable silencing of persistent viral 
replication to avert the progression of cirrhosis and the development HCC. Harnessing the 
RNA interference (RNAi) pathway to accomplish powerful silencing of pathology-causing 
genes represents a new avenue that could be exploited for the development of improved 
therapy to counter chronic HBV infection. 
 
1.2 Harnessing RNA interference to counter chronic HBV 
 
1.2.1 The endogenous RNAi pathway 
The RNAi pathway was originally discovered by Fire and colleagues, following 
their observations of potent gene silencing activity consequent to the introduction of 
double-stranded (ds) RNA molecules into the nematode Caenorhabditis elegans (80). 
Subsequent studies identified RNAi as a highly-conserved posttranscriptional gene 
silencing mechanism which functions in diverse multicellular eukaryotic organisms (81-
83). In addition, RNAi was associated with previously documented gene silencing events 
in plants ('co-suppression') (84) and fungi ('quelling') (85). The molecular mechanism of 
RNAi was initially elucidated using Drosophila in vitro assay systems (86, 87). 
Introduction of exogenous long dsRNA typically resulted in the generation of small (21 to 
23 nucleotide (nt) long) RNA duplexes with characteristic 5' terminal phosphates and 2 nt 
Chapter 1 
[10] 
 
3' overhangs. These small dsRNAs or small interfering RNAs (siRNAs) were identified to 
be the activators of the RNAi pathway. 
The applicability and functionality of the RNAi pathway in mammals remained in 
doubt following the discovery of the novel pathway, as long dsRNA molecules had been 
shown to stimulate a non-specific IFN response in mammalian cells. Yet, it was not long 
after the discovery of siRNAs that artificially synthesised siRNA molecules were 
demonstrated to be capable of activating the endogenous RNAi pathway (Figure 1.2) in 
mammalian cells without triggering the innate immune system (88). This discovery was set 
to herald a revolution in the development of novel therapies as the knockdown of any gene 
of interest in mammalian cells could be achieved with artificially engineered siRNAs. 
A new class of ~22 nt long non-coding RNAs, known as micro RNA (miR),  was 
recognised as the principal group of activators of the mammalian RNAi pathway (89). 
Additional non-coding small RNA sequences capable of activating the RNAi pathway in 
mammals include endogenous siRNAs (endo-siRNAs) (90) as well as small RNAs that 
interact with the PIWI subfamily of Argonaute proteins, PIWI-interacting RNAs (piRNAs) 
(91). Genes encoding miRs have been identified in introns, exons, intergenic regions as 
well as in antisense orientation to previously described genes (89, 92-94). Since their 
discovery, miRs have been associated with the regulation of a wide spectrum of 
physiological and pathological cellular processes such as differentiation, proliferation, 
apoptosis, development and tumorigenesis (95, 96). Canonical miR biogenesis typically 
entails two-step processing of primary miR (pri-miR) transcripts to precursor miR (pre-
miR) and finally mature miR sequences (Figure 1.2). Pri-miRs are transcribed by RNA 
polymerase (Pol) II, and have characteristic hairpin motifs. These molecules may contain a 
single stem-loop (monocistronic) or multiple stem-loops (polycistronic). Initially, pri-miRs 
are processed in the nucleus to form pre-miR intermediates of 60-80 nt in length.   
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Figure 1.2: The canonical miR biogenesis pathway. 
Canonical miR biogenesis involves the production of mature miRs from RNA Pol II-
derived pri-miR transcripts. pri-miRs are cleaved in the nucleus by the microprocessor 
complex (Drosha-DGCR8) to generate pre-miR molecules. Nuclear export of the miR 
precursors is mediated by the karyopherin Exportin 5. In the cytoplasm, pre-miRs are 
further processed by the RNase Dicer and its dsRNA binding protein TRBP to mature miR 
duplexes and loaded into RISC. Once the passenger strand is released, activated RISC is 
guided by the mature miR guide strand to the target mRNA and effects silencing. The 
endogenous RNAi pathway can be activated to effect therapeutic silencing following the 
delivery of exogenous pri-miR and/or pre-miR mimics. 
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This step is catalysed by the nuclear microprocessor complex, which includes Drosha (an 
RNase III enzyme) and its dsRNA binding partner, DiGeorge critical region 8 (DGCR8) 
(94, 97, 98). Drosha-mediated processing of pri-miRs transcribed from Pol II promoters, as 
well as intron-encoded pri-miRs, occurs co-transcriptionaly (99, 100). Recent studies have 
revealed the existence of alternative pathways for miR biogenesis, involving generation of 
miRs from pre-miRs encoded within debranching introns (mirtrons) (101), small nucleolar 
RNAs as well as tRNA transcripts (reviewed in (102)). 
Pre-miRs are exported to the cytoplasm by the Ran-GTP dependent 
nucleocytoplasmic transport factor Exportin 5 (103) where they are processed by the 
RNase III endonuclease- Dicer (104). In vitro studies have demonstrated that human Dicer 
cleaves pre-miRs ~22 nt away from the 3' (105) and the 5' end (106), which removes the 
loop to generate a miR duplex with characteristic dinucleotide 3' overhangs and 
monophosphorylated 5' ends. Recently published data has also highlighted the importance 
of the loop position in pre-miRs and shRNAs for accurate Dicer processing in vivo (107). 
This study showed that a distance of 2 nt between the cleavage site and upstream 
bulge/loop structures is necessary for precise Dicer-mediated cleavage and preventing the 
generation of heterogeneous miR duplexes. Processed miR duplexes are loaded into the 
RNA-induced silencing complex (RISC) by Dicer and the trans-activation-responsive 
region (TAR) RNA binding protein (TRBP) (108). One of the strands in the duplex is 
selected as the mature miR guide, based on differential thermodynamic stabilities of the 
RNA duplex ends, while the passenger strand is released and degraded (109). Typically, 
the strand with lower 5' thermodynamic stability is selected as the guide strand and 
retained within RISC. The miR guide sequence directs activated RISC to the 3' 
untranslated (UTR) region of target mRNA to effect silencing by sequence-specific 
cleavage or translational repression (110). Typically, miRs are partly complementary to 
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their targets and hybridisation between the seed region of the miR guide sequence (nt 2 to 
8 from the 5' end) and target mRNA results in the decrease of mRNA translational 
efficiency or mRNA deadenylation. Localisation of mRNA associated with activated 
RISCs within cytoplasmic processing bodies is likely to play an important role for 
translational repression (111) (reviewed in (110)). Initially, the predominant mechanism of 
miR-mediated suppression of protein synthesis was thought to be translational suppression 
of mRNA transcripts (reviewed in (110)). miR-mediated translational suppression can 
occur at different stages of translation. For example, blocking the recognition of the 
mRNA 5′-terminal 7-methylguanosine cap (112, 113) or the joining of the 60S ribosomal 
subunit (114) inhibits translation at the initiation stage. Additionally, translational 
repression can be caused by slowed elongation or ribosome 'drop-off' resulting in 
termination of elongation (115, 116). Nevertheless, recent data has revealed that miR-
mediated mRNA deadenylation which in turn promotes destabilisation and degradation of 
targeted mRNA transcripts is accountable for the observed reduction of translation and 
decrease in protein production (117).  
Less frequently, endogenous miR sequences can be completely complementary to 
their cognate mRNA targets and mediate sequence-specific mRNA degradation. This 
mechanism is caused by the slicing effecter of RISC, the Argonaute 2 (Ago2) protein 
(118). The potency and specificity of gene silencing is amplified when the miR guide is 
perfectly complementary to its cognate mRNA target, a silencing mechanism that has been 
exploited in the rational design of potentially therapeutic exogenous RNAi activators.  
 
1.2.2 Exogenous RNAi effecters  
The natural RNAi pathway can be activated by exogenous RNAi effecters to 
accomplish specific and potent knockdown of gene expression. These molecules are 
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delivered as synthetic or expressed RNAi effecters capable of entering and thereby 
activating the RNAi pathway (119). Typically, activators of the RNAi pathway are 
designed to be completely complementary to genes of interest to effect sequence-specific 
degradation of target mRNA. Synthetic siRNA sequences are generally in the form of 21-
25 nt duplexes with characteristic 2 nt 3' overhangs and thus resemble Dicer cleavage 
products that can enter and activate RISC. In contrast, expressed RNAi effecters generally 
mimic pri-miR or pre-miR sequences and are encoded in DNA cassettes downstream of a 
Pol III or Pol II promoter. Expressed pri- or pre-miR mimics enter the RNAi pathway as 
substrates for the microprocessor complex or Dicer/TRBP (Figure 1.2).  
The most important considerations for designing potentially therapeutic antiviral 
RNAi activators concern safety and efficacy. RNAi activators have been shown to cause 
cytotoxicity by mediating unintended silencing of endogenous genes as well as triggering 
the innate immune system (120-122).  
Cytotoxicity as a result of unintended silencing of endogenous genes may occur as 
the requirement for miR-mediated silencing is not rigorous and it is limited to 
hybridisation of the guide seed region (nucleotides 2-8) to mRNA (122, 123). In addition, 
the passenger strand of the RNAi effecter sequence could potentially be incorporated into 
RISC and cause unintended silencing. Various chemical modifications are being employed 
to overcome unintended silencing of cellular transcripts by synthetic siRNAs (reviewed in 
(124)), some of these have included the incorporation of DNA as well as 2'-O-Me 
modifications of nucleotides in the seed region. Unlike synthetic siRNAs, expressed RNAi 
effecters cannot be chemically modified to reduce unwanted off-target effects. Design 
algorithms may be used to facilitate the generation of RNAi effecters with improved safety 
and efficacy (125). Importantly, the  efficacy and safety of expressed RNAi effecters can 
be improved by optimizing their design to allow for accurate processing and biased 
Chapter 1 
[15] 
 
incorporation of the intended miR guide sequence, the sequence designed to have lower 
thermodynamic stability at its 5' end, into RISC (107, 126-128). Recent data elucidating 
the mechanism of Dicer-mediated cleavage of shRNAs and pre-miRs (107) has highlighted 
some important features that should be incorporated in the design of therapeutic 
shRNAs/pre-miRs, such as the inclusion of an optimal distance between the cleavage site 
and upstream loop or bulge structures. Inaccurate Dicer processing can result in the 
generation of mature miR guides with altered seed region as well as the duplex ends (107, 
129), which are likely to mediate non-specific silencing of untargeted genes. 
In addition to non-specific gene silencing, therapeutic RNAi effecters can induce 
innate immune responses. The factors responsible for recognising foreign RNA or DNA 
generated during viral infection (reviewed in (130, 131)) have been shown to be triggered 
by exogenous RNAi activators particularly synthetic siRNAs. Non-viral vector-delivered 
synthetic siRNAs enter target cells via endosomal compartments and as a consequence 
activate Toll-like receptors (TLRs) and subsequent secretion of inflammatory cytokines 
(type I interferon, interleukin-1/6 and tumour necrosis factor α). siRNA activation of TLR 
3, TLR 7 and TLR 8, which are activated by dsRNA sequences or RNA sequences with 
guanosine and/or uridine rich sequence motifs, has been reported to trigger innate immune 
responses (120, 121). A number of different chemical modifications of siRNAs can be 
utilised to attenuate unwanted immunostimulatory effects (reviewed in (132)) .  
In contrast to non-viral vector delivered siRNAs, RNAi activators encoded in 
various expression systems circumvent TLR activation as they originate in the  nucleus 
(133). Nevertheless, CpG motifs, frequently present in DNA expression cassettes, can 
trigger an immune response via TLR 9 signalling (134). A recent study has demonstrated 
that shRNA expressed from an integrated lentiviral vector exhibits little or no unintended 
immunostimulatory effects compared to equivalent synthetic siRNA sequence (135).  
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In addition to TLR receptor activation, expressed RNAi effecters may also activate other 
intracellular receptors responsible for detecting foreign RNA, including the RNA helicase 
retinoic-acid-inducible protein I (RIG-1), the protein kinase RNA-activated receptor 
(PKR), 5'-oligoadenylate synthetase (5'-OAS) and the melanoma differentiation-associated 
protein 5 (MDA5) (136-138). Nevertheless, traditional siRNA sequences and Dicer-
generated miR mimics possess 2 nt 3' overhangs and resemble self RNA, thus these 
sequences are non immunostimulatory (139) and avoid detection by intracellular receptors 
(140). 
Several groups have developed synthetic anti-HBV siRNA effecters and these have 
been demonstrated to mediate potent inhibition of viral replication (141-143). Efficient 
delivery of therapeutic siRNA effecters can be accomplished with the aid of synthetic 
conjugates or non-viral vectors (reviewed in (144)). Nevertheless, siRNA-mediated 
knockdown is transient, necessitating repeated administration to maintain a durable 
therapeutic effect. Accomplishing durable silencing is critical for successful treatment of 
persistent viral infections, such as chronic HBV. As a result, the use of synthetic siRNA 
technology for anti-HBV RNAi-based gene therapy is limited. Unlike siRNAs, expressed 
anti-HBV RNAi effecters can be incorporated into viral vectors to enable long-term 
expression of therapeutic sequences as well as durable silencing following a single 
administration. These properties make expressed RNAi effecters particularly useful to 
counter chronic viral infections such as HBV.  
 
1.2.3 Developing RNAi-based anti-HBV gene therapy 
A plethora of reports has provided overwhelming evidence that RNAi effecters can 
be exploited to knockdown virtually any gene of therapeutic interest (reviewed in (145-
147)). Indeed, just a decade after its discovery, RNAi-based therapeutic agents were being 
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evaluated for their efficacy in a number of clinical trials, highlighting the potential of this 
exciting novel technology to transform conventional therapeutic approaches (119, 148, 
149). Harnessing the RNAi pathway can be a potentially effective strategy to develop 
improved therapeutics against chronic viral diseases that cannot be effectively treated with 
conventional therapies (150-154). Antiviral RNAi strategies have typically involved 
targeting the genome of RNA viruses, RNA intermediates of DNA viruses, transcripts 
encoding essential viral genes or host factors necessary for viral replication (155).  
The replication cycle of HBV, involves the use of an RNA intermediate which 
makes the virus amenable to RNAi-mediated silencing. The compact arrangement of the 
HBV genome, embodied by its small size and partially overlapping ORFs limits the ability 
of the virus to alter its genetic sequence. In addition, HBV has a single polyadenylation 
signal and thus all major viral transcripts terminate at a common 3' end. The 
aforementioned points allow for the development of RNAi-based effecters capable of 
targeting highly conserved viral sequences with a shared 3' end thus enabling simultaneous 
silencing of all HBV mRNAs while limiting the potential of escape mutants.  
Importantly, successful application of this novel technology can be potentially 
effective in overcoming some of the major limitations of currently licensed treatments for 
chronic HBV infection. This includes the inability of licensed therapy to eradicate or cause 
sustained suppression of chronic viral replication or provide a high barrier to emergence of 
escape mutants. The enormous potential of RNAi to silence pathology-causing genes as 
well as the amenability of HBV to therapies based on nucleic-acid hybridisation prompted 
the development of RNAi-based approaches for the treatment of chronic HBV infection 
(153, 156-158). 
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1.2.4 Engineering expressed effecters for RNAi-based anti-HBV gene 
therapy 
To date a number of different strategies employing expressed RNAi effecters has 
been utilised to accomplish knockdown of HBV gene expression (153, 156, 157, 159, 160). 
The expression of shRNA sequences from Pol III promoters, such as the U6 and H1 
transcriptional elements, was the initial method employed to activate the RNAi pathway 
with expressed RNAi effecters (161, 162) (Figure 1.3). This approach has been applied 
extensively to induce RNAi and several groups have demonstrated potent knockdown in 
vitro and in vivo, using anti-HBV shRNA sequences expressed from Pol III promoters 
(153, 156-158). Since shRNAs are structurally very similar to pre-miRs, these sequences 
enter the RNAi pathway as substrates of Dicer, are subsequently processed to siRNAs, 
incorporated into RISC and mediate silencing of target mRNA. shRNA technology was 
further adapted for the expression of anti-HBV long hairpin RNA (lhRNA) sequences, 
characterised by long (62 bp) stem regions (163) (Figure 1.3). lhRNAs are processed by 
Dicer into multiple siRNA sequences, allowing for simultaneous targeting of several 
genes, which is potentially beneficial if long-term silencing of a mutable virus is required 
(163, 164). However, processing of individual siRNAs across the span of the lhRNA 
duplex is not equally effective resulting in varying concentrations of mature miR guides 
and consequently variable silencing efficacy. 
U6-driven expression of these types of sequences, especially of shRNAs, has 
however been shown to result in severe toxicity in vivo as a consequence of saturation of 
components of the RNAi pathway (165, 166). Overexpression of shRNA sequences in vivo 
was demonstrated to result in saturation of Exportin 5 leading to perturbation of 
endogenous miR function and ultimately fatality in the mice (165). A subsequent study 
revealed that saturation of the Argonaute protein family also plays a role in  
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Figure 1.3: The evolution and design of expression systems encoding RNAi effecters. 
Different RNAi effecters are shown in order of increasing safety and efficacy beginning 
with Pol III compatible shRNA effecters. Schematics of the transcript structure are shown 
with encoded guide sequences highlighted in green. Promoters compatible with the 
individual effecters are indicated. 
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shRNA-induced toxicity in vivo (166). These studies highlighted the need to improve the 
existing RNAi expression systems. Optimising RNAi expression systems has involved 
altering the promoter sequence as well as designing potent RNAi activators which exert a 
therapeutic effect at a low concentration. Alternative promoters, such as the inherently 
weaker H1 Pol III promoter (167), as well as tRNA promoters which generate a 
tRNA/shRNA hybrid that circumvents Exportin5-mediated nuclear export (168-170), have 
been used as a safer alternative to Pol III promoters (Figure 1.3). Moreover, Pol II 
promoters have been incorporated into RNAi-based expression cassettes in an attempt to 
overcome overexpression of RNAi effecters and saturation of cellular RNAi components 
(171) (Figure 1.3). Pol II promoters allow for exogenous control over the onset and level of 
transgene expression as well as tissue-specific and inducible expression, enabling spatial 
and temporal control of gene expression (172-174).  
The functionality of a number of different Pol II transcriptional sequences in 
hepatocytes has been explored. The widely used, promiscuous Pol II cytomegalovirus 
(CMV) immediate-early enhancer promoter mediates effective transgene expression in 
hepatocytes (175) and its utility and functionality in driving efficient RNAi effecter 
expression in the liver has been established (160). Nevertheless shutdown of CMV 
promoter activity in the murine liver has been reported (176, 177), making this promoter 
unsuitable for applications requiring long-term transgene expression. Mammalian Pol II 
promoters, such as the ubiquitously expressing human elongation factor-1 alpha (EF-1 
alpha) promoter, can be used to drive robust transgene expression in hepatocytes (178). 
Ideally, the use of hepatospecific promoters (179, 180) would enable efficient and 
controllable expression of therapeutic anti-HBV RNAi effecters in hepatocytes while 
limiting unintended off-target effects in non-targeted tissues. Investigations aimed at 
improving the safety profile of RNAi expression systems ultimately led to the development 
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of the novel Pol II expression systems encoding siRNA guide sequences embedded within 
naturally occurring pri- or pre-miR scaffolds (159, 160, 181, 182). Utilisation of Pol II-
expressed artificial pri-miR mimics allows for low level expression and efficient 
processing of desired RNAi effecters, limiting the risk of potential saturation of the 
endogenous miR biogenesis pathway (159, 160, 181). In addition, pri-miRs often occur as 
polycistrons, a property that has been exploited to generate polycistronic pri-miR mimics 
capable of targeting multiple targets (159, 182, 183). The efficacy of novel, artificial miR-
based expression systems encoding multiple miRs has to be determined empirically. 
Silencing may be influenced by the selection of the natural miR scaffold (159), the number 
and sequential order of individual miR effecters encoded in the scaffold (159, 184, 185) as 
well as potential recombination between equivalent sequences in multimeric scaffolds 
when used in the context of lentiviral vectors (183, 185, 186).  
The use of a multitargeted RNAi approach is a potentially beneficial strategy for 
long-term gene silencing of chronic HBV infection. HBV replication is error prone as it 
involves the use of reverse transcriptase, which lacks proofreading activity (187), and 
emergence of viral escape mutants has been reported when RNAi effecters targeted against 
a single HBV site are utilised (188). Nevertheless, HBV has a limited sequence flexibility 
as a result of its overlapping ORFs and a considerably lower rate of emergence of escape 
mutants compared to other viruses, such as the human immunodeficiency virus (HIV), that 
replicate using reverse transcription of their genomes (189). It has been reported that 
effective inhibition of HIV using a multi-targeted RNAi-based approach required 
simultaneous expression of four potent effecters (182). Accordingly, it is likely that an 
effective anti-HBV RNAi-based multi-targeted approach would require simultaneous 
expression of less than four effecters. The use of highly efficacious Pol II-expressed pri-
miR mimics derived from natural pri-miR-31 targeting a single (monocistronic) (160) and 
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multiple (polycistronic) sites (159) in the conserved HBx ORF was explored in the present 
set of research endeavours to develop an effective RNAi-based therapy for HBV. The HBx 
sequence had been selected as it is common to all viral mRNAs enabling simultaneous 
targeting of all transcripts. In addition, HBx plays a key role in the establishment of viral 
infection (190), viral replication (191) as well as the development of HBV-associated 
hepatocarcinogenesis (7).  
Despite the availability of highly efficacious RNAi-based anti-HBV expression 
systems (159, 160), the development of a clinically relevant RNAi-based therapeutic 
strategy for the treatment of chronic HBV is dependent on the availability of an efficient 
delivery system capable of mediating stable hepatic delivery and durable expression of the 
therapeutic molecules.  
 
1.3 Viral vector delivery of expressed anti-HBV RNAi effecters 
Recombinant viral vectors mediate effective transduction of target tissues and could 
be exploited to accomplish efficient hepatic transfer of expressed anti-HBV pri-miR 
effecters. Adenoviruses (Ads), adeno-associated viruses (AAVs) and retroviruses 
(gammaretroviruses and lentiviruses (LVs)) have been engineered to be effective vehicles 
for the delivery of therapeutic genes. These vectors are increasingly being used for various 
preclinical and clinical gene therapy applications on account of their unique features (192-
194). These include the ability to integrate in the host genome and enable sustained 
expression of therapeutic genes, ease of preparation, broad and/or cell-specific tissue 
tropism, safety and immunogenicity. Viral vector selection for any application will depend 
on the nature of the disease as well as the desired therapeutic outcome. Accomplishing 
effective silencing of a chronic viral infection, such as HBV, would require efficient 
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transduction of the majority of hepatocytes coupled with durable expression of antiviral 
RNAi activators to achieve sustained silencing of HBV gene expression. 
 
1.3.1 Adenoviral vectors 
Recombinant adenoviral vectors are naturally hepatotropic and are capable of 
transducing hepatocytes in vivo with high efficiency, making them attractive candidates for 
delivery of expressed anti-HBV RNAi sequences (157, 158, 195, 196). In addition, 
adenoviral vectors are capable of infecting dividing as well as non dividing cells, do not 
integrate in the host genome, have very high transgene capacity and are amenable to large-
scale, high titre production (197). Consequently, recombinant adenoviral vectors have 
become a frequently utilised delivery tool for various gene therapy applications. First-
generation adenovirus vectors, commonly derived from Ad 2 or Ad 5 serotypes, have been 
generated by substituting the immediate early gene E1 with therapeutic DNA. Deletion of 
E1 results in a replication defective genome. Production of viral particles requires 
supplementation of E1 in trans, usually provided by human embryonic kidney 293 
(HEK293) packaging cells (198). Unfortunately, the use of these vectors has been shown 
to cause direct cytotoxicity and transient gene expression as a result of cytotoxic T-cell 
mediated destruction of transduced hepatocytes (199). Subsequent optimisation of Ad 
vectors included deletion of other early adenoviral genes (E2, E3 and E4) to generate 
second generation Ad vectors (200, 201).  
Parks and colleagues further modified recombinant adenoviral vectors by 
engineering third generation helper dependent Ad (HDAd) vectors that are devoid of all 
viral sequences except those necessary for encapsidation and initiation of viral replication 
(202). The propagation of third generation Ads necessitates expression of all essential viral 
structural proteins in trans by a helper virus (202). Deletion of viral genetic material 
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significantly increased the transgene capacity of the HD or 'gutless' Ad vectors (~36 kb). 
However, efficient encapsidation of recombinant adenoviral particles is dependent on the 
size of the vector genome. As a result the incorporation of DNA stuffer sequences is 
typically required to restore the natural Ad genome size and enable efficient packaging 
(203). The choice of stuffer sequence can affect vector stability, transgene expression and  
immunogenicity (204). 
Nevertheless, systemic administration of first and second generation recombinant 
adenoviruses induces innate and adaptive immune responses involving liver residing 
antigen presenting cells, known as Kupffer cells (205-207). Kupffer cell-mediated uptake 
of Ad particles results in a vigorous immune response against the viral capsid proteins. 
Activation of the PI3K and ERK/MAPK pathways and NFκB induced expression of 
chemokines leads to leukocyte recruitment, immune-mediated clearance of vector 
particles, inflammation and transient liver toxicity (208, 209). Sadly, the highly 
immunogenic nature of adenoviruses led to the first reported death of a patient in a gene 
therapy clinical trial. After intravenous, high-dose administration of the recombinant 
adenovirus the patient developed systemic inflammatory response syndrome and died soon 
thereafter (210). This incident highlighted the risks associated with high-dose, systemic 
administration of adenoviruses.  
A number of strategies has been employed since to improve the safety and efficacy 
of Ad vectors such as: the development of HDAds, immunosuppression, use of different 
serotypes, chemical modifications and genetic engineering of the Ad capsid (211, 212). 
Importantly, ablation of viral genes has considerably improved the immunogenic profile of 
HDAd vectors, allowing for a more sustained, episomal transgene expression following a 
single administration. Gutless Ad vectors have been successfully used for hepatotropic 
delivery of therapeutic genes and recently an RNAi expression cassette in vivo (213-216). 
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Pre-administration of the glucocorticoid drug dexamethasone, has been shown to be useful 
in attenuating Ad vector stimulated immune responses (217). Furthermore polymer 
modification of adenoviral capsids with PEG or poly-N-(2-hydroxypropyl) 
methacrylamide has been demonstrated to be an effective tool in diminishing 
immunostimulation (218). Importantly, PEGylation of recombinant Ads attenuates vector 
immunogenicity and depending on the protocol used, does not interfere with the native, 
hepatotropism of the virus (195, 219). Despite these improvements the utility of these 
delivery vehicles is limited to applications where life-long expression of the transgene is 
not required for the desired therapeutic outcome. In addition, technical considerations limit 
the large-scale propagation of pegylated Ad for clinical use. 
 
1.3.2 Adeno-associated viral vectors 
Recombinant AAV vectors are characterised by episomal persistence and low-
frequency integration with a preference for actively transcribing genes, making them well 
suited for stable delivery and sustained expression of therapeutic genes (220, 221). These 
recombinant viruses are stable, have low pathogenicity, infect dividing and non dividing 
cells and are less immunogenic and safer than recombinant adenoviruses (222, 223). 
However pre-existing immunity to AAVs has been shown to reduce the transduction 
efficiency of recombinant vectors in non human primates, and this has important 
implications for applying this technology to a clinical setting (224). Immunosuppression 
has been explored as a means of overcoming this hurdle and thereby improving the in vivo 
transduction with AAV vectors (225). The AAV genome comprises a ~4.7 kb long, linear 
single stranded DNA (ssDNA) flanked by inverted terminal repeats (ITRs) which include 
cis regulatory elements required for viral replication and packaging (226). Two intervening 
ORFs, rep and cap, encode replication and capsid proteins, respectively (227). 
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Recombinant AAV vectors are devoid of the two ORFs, which are replaced by transgene 
cassettes. Propagation of recombinant AAVs involves a transient transfection of HEK293 
cells with an AAV helper plasmid, encoding rep and cap proteins, the AAV transfer vector 
encoding the two ITRs and transgene of interest as well as an Ad helper plasmid (228). 
Alternatively, recombinant AAV can be produced in insect cells following infection with 
baculoviruses expressing cis-acting elements required for viral replication and packaging 
(229) or by co-infection with wild type Ads or herpes viruses (230). 
A factor contributing to low gene transfer by AAVs has been the requirement for 
nuclear import and capsid uncoating as well as conversion of the ssDNA genome to 
dsDNA before initiation of gene expression (231, 232). The use of double stranded or self 
complementary AAV (scAAV) vectors circumvents the need for dsDNA conversion 
enabling robust transgene expression and efficient transduction using a lower dose of 
recombinant virus (233). However, as a consequence of creating the double stranded 
scAAVs the transgene capacity of these vectors is halved. 
The diverse tissue tropism of AAVs, with over 100 different serotypes described, 
has provided the basis for the development of recombinant AAVs for a broad range of 
gene therapy applications (234). Typically, transgenes flanked by AAV-2 ITRs can be 
cross packaged into virions comprising capsids of different serotypes. This is possible by 
simultaneous expression of AAV-2 rep proteins with capsid proteins of a different serotype 
(235). The AAV-8 vector is of particular interest for liver gene therapy since it has been 
demonstrated to confer efficient hepatocyte transduction (236). AAV-8 vectors have been 
used to deliver expressed anti-HBV RNAi sequences and accomplish potent inhibition of 
HBV replication (165, 237). Sequential use of different hepatotropic AAVs can be 
exploited to overcome pre-existing immunity to a particular serotype and enable long-term 
HBV silencing (167). A recent paper has also demonstrated enhanced in vivo AAV 
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transduction of HBV infected hepatocytes (238). Improved transduction was shown to be 
mediated by HBx. The novel finding could be exploited to develop improved AAV-based 
anti-HBV gene therapy. 
Importantly, unlike their Ad counterparts, recombinant AAV administration in preclinical 
studies has not been associated with significant toxicity (239, 240). Preclinical studies in 
animal models of haemophilia demonstrated durable transgene expression and expression 
at therapeutic levels in the absence of immune responses. However, T cell-mediated 
clearance of transduced cells attributed to short-term transgene expression was observed in 
patients during a clinical trial (241-243). The trial involved administration of recombinant 
AAV-2 carrying the human factor IX gene to haemophilia B patients via the hepatic artery. 
Administration of the recombinant vector was not associated with severe toxicity and a 
therapeutic effect, albeit limited to 8 weeks, was observed. The eventual loss of the 
therapeutic effect correlated with a transient increase in liver transaminases and it was 
concluded that this was as a result of immune-mediated clearance of infected cells. 
Subsequently it was demonstrated that memory CD8+ T-cells against AAV-2 were 
reactivated upon administration of the recombinant vector (244). In addition to mediating 
immune clearance, pre-existing AAV neutralising antibodies can interfere with efficient 
viral vector-mediated gene transfer precluding long-term expression of therapeutic genes. 
Serotype switching or transient immunosuppression can be potentially effective strategies 
to overcome the above limitations (245, 246). Nevertheless, further improvement of these 
vectors is necessary if stable transduction of the liver and sustained expression of 
therapeutic genes is to be realised while administering a minimal virus dose. 
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1.3.3 Lentiviral vectors 
Gamma (γ)- retroviral vectors, derived from the murine leukaemia virus (MLV), 
were the first generation of retroviral vectors used in a clinical setting to demonstrate stable 
gene transfer and successful long-term gene correction in patients with severe combined 
immunodeficiency (SCID) (247-249). However, some of the successfully treated patients 
in the more recent X-linked SCID clinical trial, developed leukaemia as a result of 
retroviral mediated proto-oncogene activation (250). In addition to having a prominent 
genotoxic profile, recombinant retroviruses can only transduce dividing cells which 
complicates and limits their use in treatments requiring gene transfer to non-dividing cells. 
The need for a recombinant vector with an improved safety profile and a wider spectrum of 
target tissues led to the development of recombinant lentiviral vectors (251).  
Lentiviruses are single stranded RNA viruses that belong to the retrovirus class. 
Members of the lentiviral family include viruses such as the human HIV, feline 
immunodeficiency virus (FIV), simian immunodeficiency virus (SIV) and equine 
infectious anaemia virus (EIAV) (reviewed in (252)). Recombinant vectors derived from 
HIV type 1 (HIV-1) (251, 253), are the best characterised and remain the most commonly 
used lentiviral delivery vehicles to date (254). 
Lentiviral vectors have emerged as versatile and efficient transfer tools as a 
consequence of their unique ability to mediate stable transduction of dividing and non-
dividing cells thus allowing for persistent gene expression. Recombinant lentiviral vectors 
exhibit low immunogenicity, have improved capacity to accommodate large transgenes 
and can be pseudotyped with different glycoproteins allowing for transduction of a wide 
range of target cells and tissues (reviewed in (255, 256)). In addition, lentiviruses have a 
favourable safety profile in comparison to oncoretroviral vectors (257, 258). Infection with 
the wild-type HIV-1 virus has detrimental pathological consequences (259). Accordingly, 
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lentiviruses derived from HIV-1 have been meticulously engineered to ensure a high 
degree of bio-safety (260, 261). The following bio-safety precautions have been 
incorporated in the design of late generation lentiviruses: 1) deletion of promoter and 
enhancer elements in the 3' long terminal repeat (LTR) to generate self-inactivating (SIN) 
lentiviral vectors (262); 2) splitting genomic sequences necessary for virus propagation to 
reduce the likelihood of formation of replication-competent viruses during production; 3) 
pseudotyping- the use of heterologous viral envelopes to modify native tropism (reviewed 
in (263)); 4) inclusion of polyadenylation enhancer elements to circumvent read-through 
transcription into neighbouring genomic sequences (264); 5) recoding of splice sites in 
lentiviral constructs to limit aberrant splicing (265). In addition, synthetic DNA insulators 
may be potentially useful in ensuring insulation of the host-genome from internal 
promoters used to drive transgene expression (266-268), however the utility of DNA 
insulators in hepatocytes has not been assessed.  
Replication defective, HIV-derived lentiviral vectors have been generated by 
deleting the gag-pol-env genes required for self-propagation while leaving sequences that 
are required in cis for successful packaging and integration of the viral genome (251). The 
viral structural proteins, enzymes (Integrase and Reverse Transcriptase), heterologous 
envelope glycoproteins as well as some accessory proteins (Rev, Tat), are provided by 
separate packaging constructs in trans. The split vector design (Figure 1.4) has been 
implemented to reduce the potential prospect of homologous recombination and 
subsequent generation of replication-competent species during virus production (269, 270). 
Nevertheless, recombination between sequences in the transfer lentiviral backbone and 
packaging constructs has not yet been observed (271). Accessory HIV-1 genes known to 
contribute to HIV-related pathology such as nef, the virion infectivity factor (vif) as well as 
genes encoding the viral proteins r and u, are not included in packaging plasmids used to 
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Figure 1.4: Production of SIN recombinant lentivirus. 
Recombinant lentiviruses are produced by transient co-transfection of the transfer lentiviral 
plasmid and packaging constructs. The transfer lentiviral vector construct is flanked by the 
3' SIN and 5' LTR sequences and encodes cis-acting sequences necessary for viral 
propagation. Heterologous envelope glycoproteins as well as accessory proteins (Rev, Tat), 
are provided by separate packaging constructs in trans. Infectious viral particles are 
harvested from the supernatant and subjected to additional purification and concentration 
steps depending on the intended downstream application. SIN 3' LTR (LTR with a deletion 
in the U3 region), WPRE (woodchuck hepatitis virus posttranscriptional regulatory 
element), LTR (long terminal repeat), ψ (HIV-1 packaging signal), RRE (rev-responsive 
element), cPPT (central polypurine tract). 
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propagate recombinant lentiviruses (272, 273).  
The minimal cis-acting sequences typically encoded by late generation lentiviral 
transfer vectors include: the HIV-1 packaging signal (Ψ), the Rev responsive element 
(RRE), the woodchuck hepatitis regulatory element (WPRE) and the central polypurine 
tract (cPPT). The RRE interacts with rev to mediate nuclear export of unspliced genomic 
RNA (274, 275) and the packaging signal (Ψ) is required for encapsidation of genomic 
RNA into virions (276). Inclusion of the WPRE has been demonstrated to improve 
transgene expression (277).  
The conversion of the lentiviral single stranded RNA genome into proviral DNA is 
mediated by the viral reverse transcriptase (252). Proviral DNA is complexed with viral 
factors, reverse transcriptase and integrase to form the pre-integration complex (PIC) 
which is capable of translocating across the nuclear membrane and mediating chromatin 
integration of lentiviral DNA (278). The cPPT sequence, typically included in recombinant 
lentiviral vectors, is derived from the Pol reading frame and it was initially proposed to 
enhance nuclear translocation of proviral DNA (279). A triple-strand structure, denoted as 
the central DNA flap, has been proposed to play a key role in cPPT-mediated nuclear 
translocation of the PIC and as a result transduction of non dividing cells including 
hepatocytes (280, 281). Novel mechanisms that could play a role in PIC-mediated nuclear 
translocation have been described (282, 283), however the exact mechanism underlying the 
above process remains to be elucidated.  
The potential of retroviruses to induce aberrant expression of critical cellular genes 
upon proviral DNA integration and induce insertional mutagenesis is well documented 
(284-286). Consequently the engineering of late generation lentiviral vectors has involved 
deletion of promoter and enhancer elements in the 3' LTR to generate SIN lentiviral 
vectors (262) (Figure 1.4). The wild type LTR (U3-R-U5 sequence) contains several 
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elements responsible for transcriptional regulation. The U3 sequence comprises upstream 
regulatory elements as well as a core promoter while the R and U5 sequences comprise 
downstream regulatory elements including a polyadenylation signal (252). In SIN vector 
the deletion of promoter and enhancer elements in the 3' LTR is transferred to the 5' LTR 
during reverse transcription thus abolishing LTR-mediated transcription of the integrated  
lentiviral sequence. Typically, transcription from functional LTRs is activated by Tat 
which interacts with the TAR stem loop RNA structure and functions as a transcriptional 
activator (287). The SIN design of late generation lentiviral vectors has commonly 
included complete replacement of the 5' LTR with a heterologous viral promoter, such as 
the CMV or Rous sarcoma virus (RSV) promoters thus abolishing the need for Tat 
dependant, LTR-driven proviral transcription (261, 269).  
Additionally, a SIN provirus with transcriptionaly inactive LTRs has a reduced risk 
of lentiviral mobilisation by wild-type HIV-1. Nevertheless, the risk of potential 
recombination with a wild-type virus is not fully eliminated as SIN lentiviral vectors have 
been shown to have low-level residual expression from the 5' LTR resulting in the 
production of full-length genomic transcripts competent for encapsidation (288). The 
above safety issue is pertinent to the use of recombinant lentiviruses that target 
haematopoietic tissues which are naturally permissive to wild-type HIV-1 infection.  
Recombinant lentiviruses are typically propagated in HEK293T producer cells 
following transient co-transfection of the transfer plasmid encoding the vector genome and 
the corresponding gag-pol, env and rev packaging constructs (289) (Figure 1.4). Stable 
packaging cells lines for lentivirus production have also been developed (290, 291), 
however constitutive expression of viral protease and VSV-G is cytotoxic and 
accomplishing tight transcriptional control using inducible promoters has proven to be 
difficult. Despite further improvements of inducible packaging cell lines (292), virus 
Chapter 1 
[33] 
 
production through transient transfection of 293T cells remains the gold standard for large-
scale lentivirus production for clinical use (293). A range of different techniques including 
ultracentrifugation, anion exchange chromatography as well as gel filtration can be utilised 
to purify and concentrate recombinant lentiviruses and these are contingent on the 
downstream application for which the virus is being generated (294, 295). Several titration 
methods including quantitative PCR, GFP quantitation by flow cytometry, p24 antigen 
ELISA and measuring reverse transcriptase activity or the concentration of genomic RNA 
can be used to determine the biological and physical titre of lentiviral preparations (296). 
As the use of lentiviruses is being increasingly explored for clinical application, stringent 
protocols following current Good Manufacturing Practices (cGMP) methods must be 
employed for the production of clinical-grade lentiviral preparations (297).  
The tropism of lentiviruses can be broadened and their biodistribution modified by 
pseudotyping these viruses with heterologous viral envelopes. Vesicular Stomatitis Virus 
glycoprotein G (VSV-G) is the most widely used envelope protein for lentivirus 
pseudotyping as it confers broad tropism and stability (298). Various other viral envelopes 
have been used to extend the transduction range of lentiviral vectors, which include 
glycoproteins from measles virus, murine leukaemia virus, rabies, Ross River virus as well 
as Ebola. Baculovirus GP64 as well as hepatitis C virus and Sindai virus F proteins have 
been used to confer hepatotropism (reviewed in (263)). In addition, specific ligands or 
antibodies can be incorporated into the viral envelope and bind to corresponding receptors 
specific for the ligand or antibodies thus restricting lentivirus entry to specific cells 
(reviewed in (256)). The use of LV targeting has been employed successfully to enhance 
transduction of haematopoietic tissue. Nevertheless, the use of a desired envelope might 
not be feasible for therapeutic applications that require high titre lentivirus stocks as 
inclusion of novel envelope glycoproteins often leads to titre reduction. 
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The improved late generation lentiviral vectors with SIN LTRs have emerged as versatile 
transfer tools as a consequence of their improved safety profile (257), the ability to mediate 
efficient gene transfer to non-dividing cells as well as sustained expression of therapeutic 
sequences. In contrast to retroviruses which integrate near gene regulatory areas, lentiviral 
vectors have a preference for transcriptionaly active sites (299), thus reducing the risk of 
induction of insertional mutagenesis. In vivo genotoxicity studies, using tumour prone 
mice, have been utilised to compare the genotoxic potential of γ-retroviral vectors and late 
generation lentiviral vector with SIN LTRs (257, 300). These studies and others (301, 
302), have shown a favourable safety profile for lentiviral vectors with a significantly 
reduced potential to cause insertional mutagenesis with respect to γ-retroviral vectors. 
Nevertheless, the potential of SIN lentiviral vectors to induce genotoxicity is not 
completely abolished as these vectors are capable of inducing aberrant splicing (265, 303, 
304) as well as enhancing the expression of genes neighbouring the integration sites, 
particularly if they encode a strong, internal enhancer/promoter sequence (300-302). The 
use of endogenous cellular promoters to drive transgene expression may reduce the risk of 
lentiviral vector-mediated insertional mutagenesis (268, 305). In addition, the Cre 
recombinase-loxP system (306, 307) could be exploited to add an additional safety switch 
and allow for conditional deletion of integrated lentiviral sequences that comprise loxP 
sites in the LTRs. Thus far, lentivirus-mediated insertional mutagenesis involving proto-
oncogene activation has not been reported in clinical trials assessing the safety and efficacy 
of recombinant lentiviruses for the treatment of Metachromatic leukodystrophy (308), 
Adrenoleukodystrophy (309), Wiskott-Aldrich syndrome (310) and HIV (311, 312). 
Nevertheless, the ability of these vectors to cause insertional mutagenesis remains a 
concern, and is subject to ongoing investigations (268). Currently, a total of 71 clinical 
trials involving lentiviral vector delivery are ongoing or have been completed worldwide, 
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supporting the clinical use of lentiviral vectors as a safer and less toxic alternative to 
retroviral vectors (http://www.abedia.com /wiley/ index.html). Most trials are based on ex 
vivo lentiviral gene modification of peripheral T lymphocytes or haematopoietic stem cells 
(HSC). Researchers at the City of Hope National Medical Centre in collaboration with 
Benitec, have recently completed a phase I clinical trial for the treatment of AIDS 
lymphoma using a lentiviral vector that induces three forms of anti-HIV RNA, including a 
shRNA targeting an exon in HIV-1 tat/rev (313), and the positive results from the trial 
have demonstrated the safety and feasibility of this approach. This trial represents an 
important milestone in the development of clinical, viral vector mediated RNAi technology 
and for the field of gene therapy overall. It was the first to demonstrate the use of an 
expressed RNAi activator in the clinic. In addition, the study highlights the feasibility of 
using lentiviral vectors as a delivery vehicle for expressed RNAi effecters in the setting of 
a chronic viral infection indicating a similar approach could be successfully applied for the 
treatment of other persistent viral infections such as HBV. Similar to ex vivo HSC 
modification, hepatocytes may be efficiently transduced with viral vectors in suspension 
and transfused back into the patient. A recently developed protocol has described efficient 
hepatocyte transduction with lentiviral vectors and immediate transplantation (SLIT) (314). 
The SLIT protocol is clinically applicable and it results in engraftment and proliferation of 
transduced hepatocytes while preserving their functionality. The feasibility and biosafety 
of this approach has been demonstrated in non human primates and the protocol was 
shown to be effective using human hepatocytes (315-317).  
 Efficient in vivo lentiviral gene transfer to hepatocytes following systemic 
administration has been demonstrated by several groups (281, 318, 319). Nevertheless, the 
transduction efficiency of recombinant LVs is influenced by the proliferation and cell cycle 
activation of targeted hepatocytes (320). Accordingly, low transduction efficiencies have 
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been observed following in vivo delivery of VSV-G pseudotyped lentiviruses via the tail 
vein in adult rodents, as most hepatocytes in the adult liver are quiescent. Various 
strategies can be used to induce hepatocyte proliferation and improve gene transfer in adult 
rodents, which include performing partial hepatectomy or administering hepatocyte 
proliferation-enhancing pharmacological agents (320, 321). In addition, the incorporation 
of a central DNA flap sequence in late generation lentiviral vectors has improved 
hepatocyte transduction efficiency of recombinant lentiviruses (319). Lentiviral 
transduction following systemic delivery of recombinant lentivirus has been reported to be 
significantly higher in young and newborn rodents as a result of high hepatocyte 
proliferation (180, 322-324). Naturally, newborn rodents do not have a functional immune 
system, thus lentivirus administration to newborns circumvents stimulation of an immune 
response to virus-encoded transgenes, typically observed in adult immunocompetent mice 
(325). 
Several studies have demonstrated potential utility of lentiviral RNAi-based hybrid 
technology for the treatment of chronic viral infections and liver pathology-causing genes. 
Recombinant lentiviral vectors have been successfully used for the delivery of expressed 
RNAi activators targeting HCC-related genes to hepatocytes (326). In addition, efficient 
lentiviral vector delivery of expressed anti-HIV (327) and anti-HCV (328) RNAi effecters 
has been reported. A recent study has highlighted the importance of considering various 
factors pertaining to the engineering of efficient and functional RNAi-based lentiviral 
vectors encoding expressed pri-miR mimics (329). Careful consideration of these factors is 
required when designing RNAi-based lentiviral vectors, to ensure optimal vector design 
and downstream efficacy. 
The use of lentiviral vectors to deliver anti-HBV RNAi effecters targeting HBV 
replication is an attractive option. Stable lentiviral transfer should be facilitated in the 
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context of an inflamed and regenerating liver (330) and enable sustained expression of the 
therapeutic anti-HBV molecules to counter viral persistence, providing a compelling 
rationale for advancement of lentiviral vector-based RNAi gene therapy for chronic HBV 
infection.  
 
1.4 Models of HBV replication and infection 
Preclinical evaluation of the safety and efficacy of novel RNAi-based anti-HBV 
gene therapy in appropriate in vitro and in vivo experimental models is a fundamental step 
in the development and clinical translation of potential HBV therapeutics. For many years 
the lack of a cell line permissive to HBV infection has hampered efforts to elucidate early 
events of the viral life cycle as well as gain an understanding of important aspects of virus-
host interaction. Consequently, replication-competent plasmid vectors were commonly 
utilised to recapitulate viral replication following in vitro transfection of liver-derived cells. 
Replication-competent HBV plasmids typically encode a greater-than-genome-length 
sequence that upon transfection is capable of driving transcription of the pregenomic RNA. 
HBV replication cell lines, such as the HepG2.2.15 cell line have also been developed. The 
HepG2.2.15 cell line was generated by transforming the HepG2 human hepatoblastoma 
cell line with a greater-than-genome-length HBV sequence (331). HepG2.2.15 cells can be 
used for reliable evaluation of the efficacy of novel HBV therapies in vitro, however like 
replication-competent plasmids this system only recapitulates viral replication and does not 
represent a true model of HBV infection. Another potentially useful cell culture system 
includes the human hepatoma-derived HepaRG cells which are capable of sustaining HBV 
infection following differentiation into hepatocyte-like cells (332, 333). Nevertheless, 
specialised and lengthy cell culture protocols have to be followed to induce differentiation 
into biliary-like and liver-like cells. Additionally, only a minority of the differentiated 
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hepatocyte population is in fact permissive for HBV infection (334). The recent discovery 
that the virus uses the NTCP receptor to enter hepatocytes has accelerated the development 
of improved HBV permissive cell culture systems that could be exploited for routine 
assessment of the efficacy of novel antiviral therapies (8).  
Similarly to in vitro models of HBV infection, the availability of small animal 
models of HBV infection is limited. HBV can be used to infect chimpanzees (335, 336) 
and the Asian tree shrew (337). Woodchucks (77, 338-340) and Peking ducks (341) can be 
infected with HBV-related viruses such as the woodchuck hepatitis virus and the duck 
hepatitis B virus. Although important insights into the life cycle, viral persistence, 
hepatocarcinogenesis as well as the antiviral efficacy of anti-HBV therapies have been 
obtained from these animal models, ethical and practical considerations have limited their 
routine use in the laboratory. Rather, researchers have focused on developing more 
convenient and well-characterised murine models. One such model employs the 
hydrodynamic tail vein injection procedure (342) to deliver a replication-competent HBV 
plasmid to the livers of mice thereby simulating viral replication in vivo (343). A drawback 
of this technique is that it is transient. Furthermore it induces cellular damage and elicits an 
immune response which can complicate the analysis of anti-viral effects. The 
hydrodynamic model of HBV replication however is a very convenient procedure that can 
be employed for short-term efficacy studies. Transgenic mice have been developed that 
contain an integrated replication-competent HBV sequence. Viral replication in HBV 
transgenic mice is therefore constitutive and continues for the duration of the animal’s life 
thereby closely mimicking chronic HBV infection in humans (344, 345). The HBV 
transgenic mouse model has been extensively used to evaluate the antiviral efficacy of 
antiviral drugs including interferon (346),  several nucleoside analogues (347, 348) and 
recently RNAi-based therapeutics (reviewed in (349)). Nevertheless, the hydrodynamic 
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procedure and HBV transgenic mouse models only simulate viral replication and not viral 
infection. In addition, cccDNA is not formed in the hepatocytes of the hydrodynamic 
injection model or transgenic HBV mice (344). Analysing the effects of anti-HBV 
therapies on this persistent HBV replication template would provide deeper insight into 
their efficacy. The uPA-SCID mouse model expresses the toxic urokinase plasminogen 
activator (uPA) gene under the transcriptional control of the albumin enhancer/promoter 
resulting in liver damage (350). Being immunocompromised these mice can be engrafted 
with human hepatocytes without rejection thereby establishing a chimaeric mouse with a 
humanised liver that can be infected with HBV. Transplanted hepatocytes have a growth 
advantage over endogenous hepatocytes in this mouse model which possibly contributes to 
efficient engraftment. Hepatocytes chronically infected with HBV are characterised by 
persistent expression of viral antigens as a result of episomal persistence of cccDNA. 
These mice have been successfully used for infection with both HBV (351) and the 
hepatitis C virus (352) and the model is very promising for evaluating potential antiviral 
therapy. Since delivery remains the greatest hurdle to clinical application of RNAi-based 
therapy, demonstrating efficient and safe delivery and antiviral efficacy in these models is 
likely to accelerate the use of anti-HBV RNAi-based gene therapy in the clinic. 
 
1.5 AIMS 
The objective of the present set of investigations has been the design and 
development of an original strategy to counter chronic HBV infection based on the use of 
lentiviral vectors to deliver RNAi-based anti-viral effecters. To advance the use of 
recombinant lentiviruses for HBV treatment, we have engineered second-generation 
lentiviral vectors to include the liver-specific Pol II cassettes that generate HBV-silencing 
pri-miR mimics. To overcome concerns of insertional mutagenesis, Lox P sites were 
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included in the vector LTRs to allow for excision of the integrated lentiviral sequence 
following de novo expression of Cre recombinase and conditional ablation of transduced 
hepatocytes. 
Broad specific aims included the following: 
1) Engineering second generation SIN recombinant lentiviral vectors for delivery of 
anti-HBV RNAi activators  
This involved the initial generation of liver-specific, Pol II cassettes that express 
HBV-silencing pri-miR mimics. Previously characterised, effective anti-HBV pri-miR 
sequences (159, 160), designed to target single (monocistronic) or multiple (polycistronic) 
sites of the HBV genome, were further optimised by placing them under the control of 
liver-specific transcriptional elements with the aim of accomplishing controllable and 
tissue specific expression.  
2) Characterisation of the RNAi-based HBV-silencing lentiviral vectors in cultured 
cells  
Thorough  assessment of the functionality and antiviral efficacy of the recombinant 
HBV silencing lentiviral vectors encoding mono- and poly- cistronic liver-specific pri-miR 
mimics was carried out in liver-derived cell culture systems.   
3) Assessment of the antiviral efficacy of the HBV-silencing LVs in vivo 
Once recombinant HBV-silencing lentiviruses were propagated and characterised 
in vitro their safety and ability to knockdown viral replication in an in vivo model of HBV 
replication was explored. Accomplishing efficient delivery and sustained expression of 
therapeutic RNAi-based anti-HBV effecters in vivo is a critical step in the process of bench 
to bedside translation of this promising new technology.  
 
 
Chapter 2 
[41] 
 
2 MATERIALS AND METHODS  
2.1 Generation of expression vectors encoding liver-specific anti-
HBV pri-miR mimics  
 
2.1.1 Assessing functionality and tissue-specificity of the liver-specific 
mTTR promoter  
 
2.1.1.1 Construction of the pmTTR Fluc expression vector 
To assess the functionality and tissue specificity of the liver-specific murine 
transthyretin (mTTR) enhancer-promoter sequence, a vector expressing the Firefly 
luciferase transgene under the control of the hepatospecific promoter was constructed and 
designated as pmTTR Fluc. The strategy employed to construct the pmTTR Fluc vector 
involved several cloning steps. Initially a sequence encoding the mTTR promoter was 
amplified from the pRRLsin.cPPT.mTTR.WPRE lentiviral vector (353) using the Expand 
High Fidelity PCR
PLUS
 System (Roche Diagnostics GmbH, Germany). The 
oligonucleotides used were synthesised by standard phosphoramidite chemistry (Inqaba 
Biotech, South Africa) and had the following sequences: mTTR Forward 5'- GAT CAG 
ATC TGT CGA CAA AAT TTT ATC GAT CAC GAG ACT AGC -3' and mTTR Reverse 
5'- GAT CGC TCA CCA TGG TGG TGG CAG GAG CTT -3'. The forward primer was 
designed to introduce BglII and SalI sites at the 5' end of the amplicon.  
Purified amplicons were ligated into a PCR cloning vector pTZ57R/T using the 
InsTAclone PCR cloning Kit (Thermo Scientific, MA, USA). Prepared plasmids were 
subjected to restriction enzyme digestion with DraI and NheI to identify clones which 
contained the mTTR enhancer-promoter sequence inserted in the desired orientation. All 
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selected clones were sequenced (Inqaba Biotech, South Africa). A plasmid containing the 
correct promoter sequence was identified and designated as pTZ-mTTR.  
Finally, the pmTTR Fluc expression vector was generated by replacing the CMV 
immediate-early enhancer promoter sequence within pCMV Fluc (154), a plasmid 
encoding a Firefly luciferase sequence downstream of the CMV promoter, with the mTTR 
promoter sequence. Briefly, the mTTR promoter sequence was excised with BglII and SacI 
and the purified fragment was inserted into equivalent sites of the pCMV Fluc vector 
backbone. While the BglII restriction site was introduced at the 5' end of the amplified 
promoter sequence, the SacI restriction site used was present in the multiple cloning site 
region of the pTZ57R/T vector. Prepared plasmids were subjected to a BamHI and ScaI 
restriction enzyme digestion to select clones containing the desired insert. 
 
2.1.1.2 Transfections of cultured liver- and kidney- derived mammalian cells  
The human hepatoma-derived cell line, Huh7 (354), and HEK293T cells were 
maintained in complete Dulbecco’s Modified Eagle Medium (DMEM): Gibco DMEM 
(Life Technologies Inc., CA, USA) supplemented with 10% heat-inactivated foetal calf 
serum (FCS) (Life Technologies Inc., CA, USA), penicillin (10 000 units/ml) and 
streptomycin (100 µg/ml) (Sigma-Aldrich, MO, USA).  
Human hepatoblastoma-derived cells stably transfected with HBV DNA, 
HepG2.2.15 (331) were maintained in complete William’s E culture medium: Gibco 
William’s E Medium GlutaMAX™ (Life Technologies Inc., CA, USA) supplemented with 
10% heat-inactivated FCS, penicillin (10 000 units/ml), streptomycin (100 µg/ml) and 
Gibco Geneticin selective antibiotic (400 µg/ml) (Life Technologies Inc., CA, USA). 
Huh7, HEK293T and HepG2.2.15 cells were seeded in 24 well culture dishes and 
transfected with 200 ng of pmTTR Fluc or the pCMV Fluc plasmid. In addition, a plasmid 
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that expresses Renilla luciferase constitutively, phRL-CMV (Promega, WI, USA) (200 ng) 
and an enhanced green fluorescent protein (eGFP) expressing plasmid pCI-neo eGFP (120 
ng) were included in each transfection. Transfections were performed using 
Lipofectamine 2000 (Life Technologies Inc., CA, USA) (Appendix A1-2).  
 
2.1.1.3 Quantification of luciferase reporter enzyme activity  
Luciferase activity was measured using the Dual-Luciferase Reporter Assay 
System (Promega, WI, USA). Culture medium was aspirated from wells containing 
transfected cells and 100 µl of Passive lysis buffer was added to each well and lysis 
proceeded with shaking for 15 minutes at room temperature. Ten microlitres of the lysates 
were dispensed into individual wells of a Costar® 96-well assay plate (Corning Inc., NY, 
USA). A Veritas™ Dual Injection Luminometer (Turner BioSystems, CA, USA) was used 
to measure the activity of reporter enzymes, following the addition of 50 µl of their 
corresponding substrates. Firefly luciferase activity was measured 48 hours after 
transfection and normalised to Renilla luciferase activity.  
 
2.1.2 Construction of liver-specific anti-HBV pri-miR expression vectors 
To generate liver-specific anti-HBV pri-miR expression vectors, the CMV 
immediate-early enhancer promoter sequence was removed from the previously described 
pCMV pri-miR-31/5 (160) and pCMV pri-miR-31/5-8-9 (159) vectors and replaced with 
an mTTR promoter sequence (Figure 2.1).  
Briefly, the mTTR promoter sequence was excised from the pTZ-mTTR plasmid 
with BglII and SacI and the purified fragment was ligated to equivalent sites into the 
pCMV pri-miR-31/5 and pCMV pri-miR-31/5-8-9 vector backbones generating 
monocistronic (pmTTR pri-miR-31/5) and polycistronic (pmTTR pri-miR-31/5-8-9) pri-
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miR expression vectors. Prepared plasmids containing the correct insert size were 
identified following a BamHI and SalI restriction enzyme digestion screen. 
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Figure 2.1: Schematic illustration of the construction of liver-specific anti-HBV pri-
miR expression vectors. 
The mTTR promoter sequence which had been inserted in the pTZ57R/T plasmid was 
excised with BglII and SacI and inserted into corresponding sites of pCI-neo derived, CMV 
pri-miR expression vectors (pCMV pri-miR-31/5 and pCMV pri-miR-31/5-8-9) to 
generate the liver-specific pri-miR expression vectors pmTTR pri-miR-31/5 and pmTTR 
pri-miR-31/5-8-9
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2.2 Construction of recombinant lentiviral vectors encoding liver-
specific anti-HBV pri-miR mimics 
The second generation lentiviral plasmid pLVTH (355) was used to generate 
recombinant HBV-silencing lentiviral vectors. To construct the pLVTH-derived vectors 
encoding liver-specific anti-HBV pri-miR mimics, the monocistronic (mTTR pri-miR-
31/5) and polycistronic (mTTR pri-miR-31/5-8-9) pri-miR expression cassettes were 
excised from the pmTTR pri-miR-31/5 and pmTTR pri-miR-31/5-8-9 expression vectors 
with SalI. The purified fragments were inserted into the SalI site of the pLVTH backbone 
generating the pLVTH miR-31/5 and pLVTH miR-31/5-8-9 recombinant lentiviral vectors 
(Figure 2.2). Prepared plasmids were subjected to BamHI and SalI restriction enzyme 
digestion to select clones containing the desired insert.  
 
2.3 Assessment of the efficacy of expressed liver-specific anti-
HBV pri-miR mimics  
 
2.3.1 Target and reporter plasmids 
pCH-9/3091 
The pCH-9/3091 HBV target plasmid has been described earlier (356). The plasmid 
contains an HBV genome sequence, encoding terminal repeats, under the control of the 
CMV immediate-early promoter enhancer. A greater that genome length pgRNA transcript 
is generated following transcription. Once the pgRNA is reverse transcribed viral 
propagation in transfected cells occurs simulating HBV replication.  
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Figure 2.2: Schematic illustration of the cloning strategy used to construct HBV-
silencing lentiviral vectors encoding liver-specific pri-miR mimics.  
Expression cassettes encoding monocistronic (pri-miR-31/5) and polycistronic (pri-miR-
31/5-8-9) pri-miR mimics placed under the control of the liver-specific mTTR promoter 
were excised from the pmTTR pri-miR-31/5 and pmTTR pri-miR-31/5-8-9 expression 
vectors with SalI. The cassettes were inserted into the SalI site of the second generation 
recombinant lentiviral vector pLVTH to generate anti-HBV lentiviral vectors carrying 
monocistronic (pLVTH miR-31/5) and polycistronic (pLVTH miR-31/5-8-9) pri-miR 
mimics. WPRE (woodchuck hepatitis virus posttranscriptional regulatory element), LTR 
(long terminal repeat), SIN 3'LTR (LTR with a deletion in the U3 region), ψ (HIV-1 
packaging signal), RRE (rev-responsive element), cPPT (central polypurine tract). 
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psiCHECK-HBx 
Construction of the psiCHECK-HBx plasmid has been described before (357). The 
plasmid contains the complete HBx sequence downstream of the Renilla luciferase ORF 
within psiCHECK
™
-2 (Promega, WI, USA). 
 
2.3.2 Assessing HBV knockdown efficacy and tissue-specificity of 
expressed liver-specific anti-HBV pri-miR mimics 
Huh7 cells and HEK293T cells were maintained in complete DMEM (Section 
2.1.1.2) and seeded in 24 well culture dishes the day before transfection. Antiviral efficacy 
and tissue-specific expression of the anti-HBV liver-specific pri-miR mimics were 
assessed by co-transfecting 100 ng of the psiCHECK-HBx reporter plasmid with 800 ng of 
individual pCI-neo derived, pmTTR or lentiviral vectors encoding monocistronic or 
polycistronic pri-miR sequences (pCMV miR-31/5, pCMV miR-31/5-8-9, pmTTR pri-
miR-31/5, pmTTR pri-miR-31/5-8-9, pLVTH miR-31/5 or pLVTH miR-31/5-8-9). The 
transfection was performed using Lipofectamine 2000 (Appendix A1-2). One hundred 
and twenty nanograms of an eGFP expressing plasmid (pCI-neo eGFP) was included in 
each transfection. The Dual Luciferase Reporter Assay System described in section 
2.1.1.3 was used to measure luciferase activity forty-eight hours after transfection and the 
ratio of Renilla luciferase to Firefly luciferase activity was determined.  
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2.3.3 Assessing inhibition of HBsAg secretion by expressed liver-specific 
anti-HBV pri-miR mimics  
 
2.3.3.1 Transfections 
Huh7 cells were maintained in complete DMEM (Section 2.1.1.2) and seeded in 24 
well culture dishes the day before transfection. To assess the knockdown efficacy of the 
liver-specific anti-HBV pri-miR mimics, 100 ng of the HBV replication competent plasmid 
pCH-9/3091 were co-transfected with 800 ng of pCI-neo derived expression vectors 
(pmTTR pri-miR-31/5, pmTTR pri-miR-31/5-8-9) and lentiviral vectors (pLVTH miR-
31/5, pLVTH miR-31/5-8-9) using Lipofectamine 2000 (Appendix A1-2). One hundred 
nanograms of an eGFP expressing plasmid (pCI-eGFP) was included in each transfection 
to control for transfection efficiency.  
 
2.3.3.2 HBsAg ELISA 
HBsAg secretion was quantified using the Monolisa
™
 HBsAg ULTRA assay kit 
(Bio-Rad, CA, USA) which works on the principle of sandwich type ELISA. In brief, 48 
hours after transfection with the pCH-9/3091 plasmid, culture medium was harvested from 
wells containing transfected cells and 100 µl of culture medium from each sample was 
added into custom microplate wells coated with mouse monoclonal anti-HBsAg 
antibodies. Fifty microlitres of Conjugate Solution, containing anti-HBsAg mouse 
monoclonal and goat polyclonal antibodies bound to peroxidase, were dispensed into each 
well. The sample-containing microplate was incubated at 37°C for 1 hour and 30 minutes 
(± 5 minutes).  
Next, to remove the unbound conjugate solution, wells were washed a minimum of 
five times using the Washing Solution (Tris NaCl buffer, pH 7.4; 0.04% ProClin™ 300). 
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One hundred microlitres of Development Solution (Citric acid and Sodium acetate 
solution, pH 4.0; 0.015% H2O2; 4% dimethylsulphoxide [DMSO] and tetramethyl 
benzidine) was added to each well. After the plate was incubated for 30 minutes in the dark 
at room temperature and the enzymatic reaction had developed, 100 µl of Stopping 
Solution (1 N H2SO4) was dispensed into each well to stop the reaction. The optical density 
of the samples was measured at 420/690 nm within 30 minutes of addition of the Stopping 
solution using a microplate reader (Bio-Rad, CA, USA). 
 
2.4 Production, concentration and titration of pLVTH-derived 
recombinant lentiviral vectors expressing liver-specific anti-HBV 
pri-miR mimics 
 
2.4.1 Production of VSV-G pseudotyped recombinant lentiviruses 
LV stocks (LVTH, LVTH miR-31/5 and LVTH miR-31/5-8-9) were produced by 
transient calcium phosphate transfection of HEK293T cells with individual lentiviral 
plasmids (pLVTH, pLVTH miR-31/5 or pLVTH miR-31/5-8-9 respectively) and the 
corresponding packaging plasmids (psPAX2 and pMD2.G). The pLVTH, psPAX2 and 
pMD2.G plasmids were made available from the Laboratory of Dr Didier Trono 
(Laboratory of Virology and Genetics, EPFL, Lausanne, Switzerland, 
http://tronolab.epfl.ch/). Additional information regarding the sequences encoded by the 
transfer and packaging recombinant lentiviral plasmids has been included in Table 2.1. 
Low passage HEK293T cells were used for the production of LV stocks. A total of 
1 × 10
6
 HEK293T cells were seeded per one 15 cm
2
 culture dish the day before 
transfection in complete DMEM (Section 2.1.1.2). Cell numbers and viability were 
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determined using a Neubauer haemocytometer and Trypan blue exclusion dye (Lonza, 
MD, USA). For a transient transfection of five 15 cm
2
 culture dishes a multiplasmid 
transfection mix was prepared in a 50 ml sterile tube by adding 150 µg of transfer plasmid, 
112.5 µg of psPAX2 and 75 µg of the pMD2.G plasmid. The final volume of the plasmid 
mix was adjusted to 3.75 ml with deionised water. An equal volume of 0.5 M CaCl2 
solution was added to the plasmid mix and the mixture was vortexed gently. The final 
transfection mixture was prepared by drop wise addition of the CaCl2 - DNA mix to 7.5 ml 
of 2× HEPES-buffered saline while vortexing the solution. The final transfection mixture 
was prepared by drop wise addition of the CaCl2 - DNA mix to 7.5 ml of 2× HEPES-
buffered saline (50 mM HEPES, 1.5 mM Na2HPO4, 280 mM NaCl, 10 mM KCL; pH 7.1) 
while vortexing the solution. The mixture was incubated at room temperature for 15 
minutes to allow formation of DNA precipitates. Three millilitre aliquots were distributed 
into each 15 cm
2
 culture dish and the dishes were gently swirled. Cells were incubated for 
18 hours at 37°C in the presence of 5% CO2. Virus-containing supernatant was harvested 
at 18 and 48 hours after transfection. Transfection efficiency was assessed by examining 
the transfected cells under a fluorescence microscope. Pooled supernatants containing 
infectious lentiviral particles were centrifuged at 1,000 × g for 5 minutes at 4°C and 
subsequently filtered through a 0.45 µm membrane using AcroVac
™
 Filter Units (Pall Life 
Sciences, NY, USA). Clarified virus-containing medium was stored at 4°C for a maximum 
of  3 days before the virus was concentrated. 
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Table 2.1: Description of second-generation, recombinant lentiviral plasmids used for 
the production of HBV-silencing LVs.  
 
 
Plasmid 
 
Description 
 
 
pLVTH 
 
Second generation SIN recombinant lentiviral transfer 
vector encoding a GFP transgene expressed from an internal 
human elongation factor-1 alpha (EF-1 alpha) promoter 
 
 
pLVTH miR-31/5 
 
pLVTH-derived recombinant lentiviral vector encoding a 
monocistronic anti-HBV pri-miR sequence (pri-miR-31/5) 
expressed from an internal  mTTR promoter 
 
 
pLVTH miR-31/5-8-9 
 
pLVTH-derived recombinant lentiviral vector encoding a 
polycistronic anti-HBV pri-miR sequence (pri-miR-31/5-8-9) 
expressed from an internal  mTTR promoter 
 
pMD2.G 
 
 
Second generation packaging plasmid encoding 
VSV-G envelope glycoprotein 
 
psPAX2 
 
Second generation packaging plasmid encoding HIV-1 Gag, 
Pol, Tat and Rev proteins 
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2.4.2 Concentration of recombinant lentiviruses  
2.4.2.1 Ultrafiltration 
Lentivirus concentration by ultrafiltration involved diafiltration of virus-containing 
medium using a VivaFlow50 crossflow filtration cassette (Sartorius Stedim Biotech 
GmbH, Germany). Typically, to achieve 10 fold concentration of the lentivirus-containing 
medium, 200 ml of medium was ultrafiltered through the VivaFlow cassette run by a 
peristaltic pump at a flow rate of 15-30 ml/minute. The cassette was regenerated with 250 
ml of 0.1 N NaOH followed by a rinse with one litre of deionised water. The regenerated 
cassette was stored in 70% ethanol. Fifty microlitre aliquots of the ultrafiltrate were 
dispensed in sterile microcentrifuge tubes and stored at -80°C.  
 
2.4.2.2 Ultracentrifugation 
High-titre LV stocks were prepared by concentrating harvested virus-containing 
medium by ultracentrifugation. Briefly, aliquots of clarified lentivirus medium were 
distributed into SW28 open-top conical centrifuge tubes (Beckman, CA, USA). The tubes 
were centrifuged at 50 000 × g for 90 minutes at 4°C in a Beckman ultracentrifuge using a 
SW28 ultracentrifuge rotor (Beckman, CA, USA). When centrifugation was completed the 
supernatant was poured off and the tubes were inverted and left to dry on a paper towel for 
five minutes. The remaining liquid droplets were aspirated. The translucent pellet from 
each centrifuge tube was resuspended in 30 µl of Dulbecco's Phosphate-Buffered Saline 
(DPBS) without Ca(2+) and Mg(2+)
  
(Life Technologies Inc., CA, USA) by gently 
pipetting up and down. Virus-containing aliquots were pooled and transferred into a sterile 
microcentrifuge tube. Vector stocks were prepared by aliquoting 25 µl fractions of the 
pooled virus-containing solution in sterile microcentrifuge tubes. All vector stocks were 
frozen and stored at -80°C.  
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2.4.3 Titration of recombinant lentiviruses  
Viral preparations were titrated on human cervical cancer-derived HeLa cells using 
a previously described real-time quantitative PCR titration method (314), which allows for 
accurate estimation of the functional titre of a viral preparation i.e. the number of infection-
competent viral particles in the vector stock.  
To determine the functional titre of LV stocks, 5 × 10
4
 HeLa cells, maintained in 
complete DMEM (Section 2.1.1.2), were seeded per well in a 24 well culture plate. The 
following day cells were infected in duplicate with a 100 fold, 10 fold and 0.1 fold dilution 
of a LV stock of unknown titre. After 24 hours, the cells were washed with DPBS without 
Ca(2+) and Mg(2+)
 
and cultured for additional 3 days to decrease carryover plasmid 
contamination. Genomic DNA from these cells was extracted using the FlexiGene DNA 
Kit (Qiagen, GmbH, Germany). 
The number of integrated vector copies per cell was determined using a quantitative 
PCR titration assay, based on amplification of a small fragment of the lentiviral vector-
specific GAG sequence from genomic DNA of lentivirus transduced cells. The human β-
actin (hBA) housekeeping gene was amplified to normalise the amount of genomic DNA 
in the individual samples. Vector copy numbers were determined using a standard curve, 
generated by preparing standards in which the pLVTH plasmid was present at 100, 10, 1, 
0.1, and 0 copies in HeLa genomic DNA.  
The quantitative PCR titration assay was carried out using the Roche Lightcycler 
v.2 (Roche Diagnostics GmbH, Germany) and the LightCycler FastStart DNA 
Master
PLUS
 SYBR Green I kit (Roche Diagnostics GmbH, Germany) with the following 
parameters: a 10 minute hot start at 95°C, 50 cycles of denaturation at 95°C for 15 
seconds, annealing at 63°C for 15 seconds and extension at 72°C for 15 seconds. The 
primer set, GAG Forward: 5’- GGA GCT AGA ACG ATT CGC AGT TA -3’ and GAG 
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Reverse: 5’- GGT TGT AGC TGT CCC AGT ATT TGT C -3’ was used to amplify the 
GAG region from pLVTH and proviral DNA. The following primers were used to amplify 
-actin DNA: BA Forward: 5'- TCC GTG TGG ATC GGC GGC TCC A -3' and BA 
Reverse: 5'- CTG CTT GCT GAT CCA CAT CTG -3'. The oligonucleotide sequences 
used were synthesised by standard phosphoramidite chemistry (Inqaba Biotech, South 
Africa).  
To calculate the titre of the LVs, first the number of proviral genome copies per cell 
was interpolated from the standard curve using the Ct values of the samples (average Ct 
of GAG minus the average Ct of hBA). The standard curve was generated by plotting the 
Ct values of the pLVTH standards against the known copy numbers. The titre of the LV 
was then calculated as follows: 
HeLa
TU/ml = [Number of HeLa cells at time of transduction 
× number of vector copies per cell (quantitative PCR result)] / [volume of diluted vector 
(ml) × vector dilution].   
 
2.5 Transduction of Huh7 cells with recombinant lentivirus 
expressing liver-specific anti-HBV pri-miR mimics 
The day before infection Huh7 cells were seeded in 6 well culture dishes in 
complete DMEM (Section 2.1.1.2). The following day the medium from wells containing 
the cells to be infected was removed and replenished with fresh growth medium. 
Concentrated lentivirus suspension was added to individual wells containing target cells at 
an MOI of 40 and the cells were incubated at 37°C in a humidified incubator with 
atmosphere of 5% CO2  for 24 hours before the virus-containing medium was removed. 
Transduction efficiency was assessed by monitoring GFP expression under a fluorescence 
microscope. Stable transduction was accomplished, demonstrated by long-term persistence 
of GFP-positive hepatocytes. 
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2.5.1 Determination of the number of proviral lentiviral vector copies in 
transduced Huh7 cells 
To determine proviral DNA copy numbers, genomic DNA was extracted from 
transduced cells using the FlexiGene DNA Kit according to the manufacturer's 
instructions. Previously described quantitative PCR assay (section 2.4.3) was used to 
determine the number of vector copies associated with genomic DNA extracted from 
stably transduced cells. 
 
2.6 Assessment of anti-HBV pri-miR mimic processing and 
sequence rearrangement in stably transduced Huh7 cells 
 
2.6.1 Polyacrylamide gel electrophoresis and Northern blot analysis 
Total RNA was extracted from stably transduced Huh7 cells using Tri-Reagent 
(Sigma-Aldrich, MO, USA) according to the manufacturer's instructions. Samples 
containing 30 µg of RNA extracted from Huh7 cells which had been transduced with 
LVTH, LVTH miR-31/5 or LVTH miR-31/5-8-9 lentiviruses, were denatured at 95°C for 
5 minutes and separated on a 15% denaturing polyacrylamide gel. Radiolabelled Decade™ 
RNA molecular weight markers (Life Technologies Inc., CA, USA) were run alongside the 
cellular RNA. RNA quality was verified by briefly staining the polyacrylamide gel in 0.5× 
Tris-Borate EDTA (TBE) solution which contained ethidium bromide at a final 
concentration of 0.5 µg/ml and examining the gel on a UV transilluminator.  
The RNA was transferred to a positively charged nylon membrane (Amersham, NJ, 
USA) by electro-blotting (3 mA/cm
2
) for one hour at 4°C using a Semi-Dry Electroblotting 
Unit Z34,050-2 (Sigma-Aldrich, MO, USA). When the transfer was completed the RNA-
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containing membranes were cross-linked by UV irradiation at 200 000 µJ/cm
2 
using a UV 
crosslinker (UVP Inc., CA, USA). The membranes were placed in hybridisation tubes and 
1 ml of Rapid-hyb buffer (Amersham, NJ, USA) was added per 10 cm
2 
of membrane. 
Next, the membranes were prehybridised by incubating the tubes with rolling agitation in a 
hybridisation oven for 30 minutes at 42°C.  
Oligonucleotides designed to bind to putative guide sequences of pri-miR-31/5 and 
pri-miR-31/5-8-9 were radiolabelled with 20 µCi of [γ-32P]-adenosine triphosphate (ATP) 
using T4 polynucleotide kinase (Thermo Scientific, MA, USA) and used as probes. The 
oligonucleotide probes, synthesised by standard phosphoramidite chemistry (Inqaba 
Biotech, South Africa), had the following sequences: Guide 5: 5'- CCG TGT GCA CTT 
CGC TTC -3', Guide 8: 5'- CAA TGT CAA CGA CCG ACC -3' and Guide 9: 5'- TAG 
GAG GCT GTA GGC ATA -3'. Complementary probes were diluted in hybridisation 
buffer and subsequently added to individual hybridisation tubes at a final concentration of 
10 ng/ml. Hybridisation was performed overnight at 42°C. Following hybridisation, three 
washes were performed to eliminate excess probe as well as non-specific probe-RNA 
hybridisation. A low stringency wash was carried out using 5× SSC, 0.1% sodium dodecyl 
sulphate (SDS) solution at room temperature for 20 minutes. An additional two high 
stringency washes were carried out with a 1× SSC, 0.1% SDS solution at 42°C for 15 
minutes. A 20× SSC stock buffer (3 M NaCl, 0.3 M sodium citrate; pH 7.0) was used to 
make the 5× and 1× SSC solutions. The probed membranes were exposed to imaging 
plates (Fujifilm, Japan) for 10 days. Analysis was carried out using a FLA-7000 
PhosphorImager (Fujifilm, Japan). The probed membranes were stripped with 50 ml 0.1× 
SSC, 1% SDS solution at 80°C for 30 minutes and re-hybridised with a radiolabelled 
oligonucleotide sequence complementary to U6 small nuclear RNA (snRNA). The U6 
oligonucleotide probe was synthesised by standard phosphoramidite chemistry (Inqaba 
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Biotech, South Africa) and had the following sequence: 5’- TAG TAT ATG TGC TGC 
CGA AGC GAG CA -3’. Densitometric analysis was carried out using GeneTools 
software version 4 (SynGene (A division of Synoptics Ltd.), Cambridge, UK). 
 
2.6.2 PCR recombination analysis of integrated polycistronic pri-miR 
mimic sequences in stably transduced Huh7 cells 
PCR-based recombination analysis was performed to verify if sequence 
recombination had occurred during lentivirus reverse transcription between equivalent 
sequences in the polycistronic pri-miR-31/5-8-9 cassette. The PCR was performed using 
genomic DNA extracted from Huh7 cells which had been stably transduced with LVTH 
miR-31/5-8-9 or control LVTH LV. DNA was extracted using the FlexiGene DNA Kit 
according to the manufacturer's instructions. PCR was carried out using the Thermo 
Scientific 2× PCR master mix (Thermo Scientific, MA, USA) with the following 
thermocycling parameters: a 2 minute hot start at 95°C and 30 cycles of denaturation at 
95°C for 30 seconds annealing at 60°C for 30 seconds and extension at 72° for 10 seconds. 
The primer sequences used were: Recombination Forward: 5'- ACT GGA GAG GGG 
TGA AGC GA -3' and Recombination Reverse: 5'- AGA GTC GAC GAT AAG CTT TGC 
A -3' (Inqaba Biotech, South Africa). 
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2.7 Evaluation of the HBV knockdown efficacy of LV-delivered 
anti-HBV pri-miR mimics in stably transduced Huh7 cells 
 
2.7.1 Target and reporter plasmids 
 
2.7.1.1 psiCHECK-mHBx 
The psiCHECK-mHBx luciferase reporter plasmid has been described previously 
(159). The plasmid contains a mutated HBx target sequence downstream of the Renilla 
luciferase ORF within psiCHECK™-2. The mutated HBx target sequence contains several 
point mutations in the region targeted by the putative guide 5 of pri-miR 31/5 and pri-miR 
31/5-8-9 mimics. 
 
2.7.1.2 psiCHECK-5T, psiCHECK-8T and psiCHECK-9T 
Previously described psiCHECK-5T, psiCHECK-8T and psiCHECK-9T reporter 
plasmids (159) contain sequences targeted by putative guides 5 (psiCHECK-5T), 8 
(psiCHECK-8T) and 9 (psiCHECK-9T) downstream of the Renilla luciferase ORF within 
the psiCHECK-2.2 plasmid. 
 
2.7.2 Assessment of HBV knockdown efficiency  
Huh7 cells were cultured in complete DMEM (Section 2.1.1.2). To determine in 
situ knockdown of HBV target gene expression, LVTH, LVTH miR-31/5 and LVTH miR-
31/5-8-9-transduced Huh7 cells were seeded in 24 well culture dishes the day before 
transfection. The cells were transfected with a 100 ng of the psiCHECK-HBx plasmid 
using Lipofectamine 2000 (Appendix A1-2). Forty-eight hours following transfection the 
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cells were lysed and Renilla luciferase activity was measured using the Dual-Luciferase 
Reporter Assay System as described in section 2.1.1.3. Renilla luciferase activity was 
normalised to Firefly luciferase activity.  
 
2.7.3 Assessment of knockdown efficiency against individual HBV target 
sequences  
Huh7 cells were maintained in complete DMEM (Section 2.1.1.2) and seeded in a 
24 well culture dish the day before transfection. To determine in situ knockdown efficiency 
against individual HBV target sequences, Huh7 cells which had been stably transduced 
with control LVTH or therapeutic LVTH miR-31/5-8-9 LV were transfected with a 100 ng 
of individual target plasmids (psiCHECK-5T, psiCHECK-8T or psiCHECK-9T) using 
Lipofectamine 2000 (Appendix A1-2). Forty-eight hours following transfection the cells 
were lysed and Renilla luciferase activity was measured using the Dual-Luciferase 
Reporter Assay System (Section 2.1.1.3) and the ratio of Renilla luciferase to Firefly 
luciferase activity was calculated.  
 
2.7.4 Assessment of anti-HBV pri-miR mediated knockdown against a 
mutant HBx sequence  
Huh7 cells were maintained in complete DMEM (Section 2.1.1.2) and seeded in a 
24 well culture dish the day before transfection. To determine the efficacy of LV-delivered 
pri-miR mimics against a mutant HBx sequence, LVTH-, LVTH miR-31/5- and LVTH 
miR-31/5-8-9- transduced cells were transfected with a 100 ng of the psiCHECK-mHBx 
luciferase reporter plasmid using Lipofectamine 2000  (Appendix A1-2). Forty-eight 
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hours after transfection, knockdown efficiency was assayed by measuring Renilla 
luciferase activity (Section 2.1.1.3) normalised to Firefly luciferase expression. 
 
2.7.5 Assessment of inhibition of viral replication by integrated anti-HBV 
pri-miR mimics  
Huh7 cells were maintained in complete DMEM (Section 2.1.1.2). To assess 
inhibition of HBV replication mediated by LV-delivered pri-miR mimics, Huh7 cells 
which had been stably transduced with LVTH, LVTH miR-31/5 and LVTH miR-31/5-8-9 
were seeded in a 24 well culture dish the day before transfection and transfected with 100 
ng of the HBV replication competent pCH-9/3091 target plasmid using Lipofectamine 
2000 (Appendix A1-2). The cells were incubated for forty-eight hours after transfection 
before the medium of each well was removed for further analysis. HBsAg secretion was 
measured using the Monolisa™  HBsAg ULTRA assay kit as described in Section 2.3.3.2. 
 
2.8 Evaluation of saturation of the endogenous miR pathway by 
LV-delivered anti-HBV pri-miR mimics 
 
2.8.1 Assessment of disruption of endogenous miR-16 function in stably 
transduced cells  
 
2.8.1.1 Sponge and target plasmids 
The U6-driven sponge plasmid- pTZ-U6-miR-16S×7  (159) contains seven copies 
of an imperfectly complementary target of miR-16. The miR-16 dual luciferase target 
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plasmid- psiCHECK-miR-16T×7 (159) contains seven miR-16 sites downstream of the 
Renilla luciferase ORF within psiCHECK™-2. 
 
2.8.1.2 Saturation assay 
To determine whether the LV-delivered liver-specific anti HBV pri-miR mimics 
induce saturation of the natural miR pathway and subsequently interfere with the function 
of endogenous miRs, a saturation assay was performed. The assay involved transfecting   
100 ng of the psiCHECK-miR-16T×7 target plasmid using Lipofectamine 2000 
(Appendix A1-2) into stably transduced LVTH, LVTH miR-31/5 and LVTH miR-31/5-8-9 
Huh7 cells which had been seeded in 24 well culture dishes the day before transfection. As 
a positive control for disruption of miR-16 function, LVTH-transduced Huh7 cells were 
co-transfected with 800 ng of the pTZ-U6-miR-16S×7 sponge plasmid and 100 ng of the 
psiCHECK-miR-16T×7 reporter plasmid using  Lipofectamine 2000 (Appendix A1-2). 
Disruption of endogenous miR-16 function was assayed by measuring Renilla to Firefly 
luciferase reporter gene activity 48 hours following transfection as described in Section 
2.1.1.3. 
 
2.9 Evaluation of the HBV knockdown efficacy of LV-delivered 
anti-HBV pri-miR mimics in stably transduced HepG2.2.15 cells 
 
2.9.1 Transduction of HepG2.2.15 cells with recombinant LV expressing  
a liver-specific anti-HBV polycistronic pri-miR sequence 
HepG2.2.15 cells were maintained in complete William’s E culture medium 
(Section 2.1.1.2). The cells were transduced with LVTH or LVTH miR-31/5-8-9 lentiviral 
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suspensions at an MOI of 40 as described in Section 2.5. Transduction efficiency was 
assessed by monitoring GFP expression under a fluorescence microscope. The number of 
proviral vector copies in transduced cells was determined as described in Section 2.5.1. 
 
2.9.2 Quantification of HBsAg and HBeAg secretion in stably transduced 
HepG2.2.15 cells 
Five hundred thousand HepG2.2.15 cells which had been stably transduced with 
LVTH or LVTH miR 31/5-8-9 lentivirus were seeded in triplicate in 6 well culture dishes 
in complete William’s E culture medium (Section 2.1.1.2). The medium was not replaced 
for the duration of the entire experiment. Five hundred microlitres of medium were 
harvested from individual wells containing LVTH or LVTH miR 31/5-8-9-transduced cells 
at 48, 72 and 96 hours after the cells had been seeded. Secretion of HBsAg, HBeAg as well 
as viral DNA quantity were assayed in the respective samples. 
HBsAg was quantified as described in section 2.3.3.2. HBeAg secretion was 
quantitatively measured using a sandwich type ELISA method (Gentaur, France). Briefly, 
the protocol involved addition of samples of interest along with horseradish peroxidase 
conjugated HBeAg monoclonal antibodies to microwells coated with HBeAg specific 
monoclonal antibodies. In the presence of HBeAg an immunocomplex is formed between 
the antibody conjugated to horseradish peroxidase and HBeAg bound to HBeAg antibody. 
Several washes were performed to remove unbound antibody. After addition of a 
chromogenic solution containing a substrate for horseradish peroxidase, the substrate was 
hydrolysed resulting in colour change. Typically, colour intensity is proportional to the 
amount of HBeAg captured and was measured after the addition of a stopping solution 
using a microplate reader. 
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2.9.3 HBV DNA quantification in stably transduced HepG2.2.15 cells 
Real-time quantitative PCR was performed to assay miR-mediated inhibition of 
viral replication in HepG2.2.15 cells which had been stably transduced with LVTH or 
LVTH miR-31/5-8-9 lentivirus. Virion DNA was measured in culture medium from 
samples harvested at 48, 72 and 96 hours after the cells had been seeded. The Total 
Nucleic Acid Isolation Kit and MagNA Pure LC system (Roche Diagnostics, GmbH, 
Germany) was used to extract HBV DNA from 200 µl of the individual samples according 
to manufacturer's instructions. Viral DNA quantification was performed by real-time 
quantitative PCR carried out using HBV-specific primers and the Roche Lightcycler v.2. 
The primers used were: HBV Forward 5'- TGC ACC TGT ATT CCA TC -3' and HBV 
Reverse 5'- CTG AAA GCC AAA CAG TGG -3'. PCR analysis was performed using the 
SensiMix™ Capillary Kit (Bioline, England, UK) and the following cycling parameters: a 
30 second hot start at 95°C and 50 cycles of denaturation at 95°C for 10 seconds, annealing 
at 58°C for 10 seconds and extension at 72°C for 10 seconds. The HBV DNA 
quantification standard curve used was generated using EuroHep calibrators (358). 
 
2.10 Assessment of long-term transgene expression mediated by 
the liver-specific mTTR promoter in vivo 
 
2.10.1 Generation of a recombinant lentiviral vector expressing the 
Firefly luciferase transgene from an internal mTTR promoter 
Invitrogen's Gateway cloning technology (Life Technologies Inc., CA, USA) was 
used to generate a recombinant bicistronic lentiviral vector (pLNT-mTTR-JDG) encoding 
a Firefly luciferase transgene expressed by the mTTR liver-specific promoter. Briefly, the 
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Gateway cloning system exploits the recombination properties of bacteriophage lambda 
to enable efficient transfer of DNA sequences, flanked by synthetic attachment sites (att), 
between different vectors of interest (359).  
The cloning strategy employed to construct the pLNT-mTTR-JDG lentiviral vector, 
involved cloning of an mTTR promoter sequence into an entry vector (pENTR™1A) 
(Figure 2.3) and subsequent transfer of the promoter sequence into a destination vector 
(pLNT-GW-JDG) via site specific recombination (Figure 2.4). The entry (pENTR™1A) 
and destination (pLNT-GW-JDG) vectors used were kindly provided by the group of Dr 
Simon N. Waddington from University College London, UK.  
In addition, both pENTR™1A-mTTR and pLNT-GW-JDG vectors contain a 
toxic/selection ccdB gene flanked by either attL or attR attachment sequences respectively. 
Following translation, the ccdB protein inhibits the growth of most Escherichia coli (E. 
coli) strains (360) allowing for efficient selection of desired clones that have successfully 
recombined to remove the suicide gene. The pENTR™1A and pLNT-GW-JDG plasmids 
were propagated in the DB3.1 E. coli strain which is resistant to the toxic effects of the 
ccdB gene.  
Importantly, the pLNT-GW-JDG lentiviral vector used to derive the pLNT-mTTR-
JDG construct comprises a 2A-linked Firefly luciferase-eGFP bicistronic expression 
cassette downstream of the ccdB selection gene (Figure 2.4). The presence of the 2A 
proteolytic cleavage site between the Firefly luciferase and GFP sequences should 
potentially allow for stoichiometric expression of both genes (361).   
To clone the mTTR promoter sequence into the pENTR™1A vector, an mTTR 
promoter-encoding sequence was excised with SalI-NheI from the previously described 
pmTTR pri-miR-31/5 vector (Section 2.1.2), and the purified fragment was ligated to 
compatible SalI-XbaI sites of the pENTR™1A backbone, generating the pENTR™1A-
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mTTR entry clone plasmid (Figure 2.3). Prepared plasmids were subjected to a NheI and 
XbaI restriction enzyme digestion to identify clones containing the correct insert.  
To construct the pLNT-mTTR-JDG lentiviral vector a recombination reaction was 
performed using the following components: 150 ng of pENTR™1A-mTTR entry plasmid, 
150 ng of pLNT-GW-JDG destination vector, 1× Gateway LR Clonase™ II enzyme mix 
and TE buffer, pH 8.0 to a final volume of 20 µl. The sample was incubated at room 
temperature for one hour. The reaction was terminated by addition of 2 µl of Proteinase K 
Solution (2 µg/µl) (Life Technologies Inc., CA, USA) followed by an incubation step at 
37ºC for 10 minutes. The sample was used to transform XL-1 blue E.coli bacteria and a 
correct expression clone was selected following a SalI and NcoI restriction digestion of 
prepared plasmids.  
  
Chapter 2 
[67] 
 
 
 
Figure 2.3: Schematic representation of the cloning strategy used for the construction 
of the pENTR™1A-mTTR entry vector.  
The mTTR enhancer-promoter sequence was excised from the pmTTR pri-miR-31/5 
expression vector with SalI and NheI. The fragment was ligated to compatible SalI-XbaI 
sites in the pENTR™1A cloning vector backbone to generate the pENTR™1A-mTTR 
entry clone vector containing an attL-flanked mTTR promoter sequence. 
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Figure 2.4: Schematic representation of Gateway cloning strategy for the generation of the pLNT-mTTR-JDG lentiviral vector. 
The Gateway LR recombination reaction, catalysed by the Gateway LR Clonase™ II enzyme mix was utilised to facilitate the transfer of the 
attL-flanked mTTR promoter sequence from the pENTR™1A-mTTR entry vector into an attR attachment site-containing destination lentiviral 
vector (pLNT-GW-JDG). The end product of the recombination reaction was the pLNT-mTTR-JDG lentiviral vector encoding an attB 
attachment site-flanked mTTR promoter sequence upstream of the Firefly luciferase-2A-eGFP ORF. WPRE (woodchuck hepatitis virus 
posttranscriptional regulatory element), LTR (long terminal repeat), SIN 3' LTR (LTR with a deletion in the U3 region), RRE (rev-responsive 
element), ψ (HIV-1 packaging signal). 
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2.10.2 Production and titration of recombinant pLNT-mTTR-JDG LV 
The second-generation, recombinant lentiviral vector pLNT-mTTR-JDG has been 
described in Section 2.10.1. The Gag-Pol expressing pCMVR8.74 and the VSV-G 
expressing pMD.G2 packaging plasmids were kindly provided by the group of Dr Simon 
N. Waddington from University College London, UK.  
Recombinant pLNT-mTTR-JDG LV was produced by transient co-transfection of 
the transfer lentiviral plasmid and the above mentioned packaging plasmids into HEK293T 
cells using polyethylenimine (PEI) (Polysciences, PA, USA) as a transfection reagent 
(Appendix A1-2). Virus-containing supernatant was harvested at 20 and 48 hours after 
transfection. Pooled virus-containing medium was clarified by centrifugation at 1,000 × g 
for 5 minutes at 4°C and subsequently filtered through a 0.45 µm AcroVac
™
 Filter Unit. 
Clarified virus-containing medium was concentrated using Centricon Plus-70 Centrifugal 
Filter Devices 100,000 nominal molecular weight limit (Merck-Millipore, MA, USA) 
according to the manufacturer’s instructions. Briefly, the filter devices were filled with 70 
ml of 70% ethanol and centrifuged at 3500 × g for 5 minutes. The filters were further 
rinsed twice with 70 ml of DPBS. The remaining solution from the filter cup was 
recovered by centrifuging at 1000 × g for 2 minutes. Next, 70 ml of clarified lentivirus-
containing medium was added to individual filter cups and the devices were centrifuged at 
3500 × g for 35 minutes. Concentrated virus was recovered by centrifuging the concentrate 
cups at 400 × g for 2 minutes. The virus was dispensed in sterile microcentrifuge tubes and 
stored at -80°C. Concentrated pLNT-mTTR-JDG virus was titrated in HeLa cells using the 
Global UltraRapid Lentiviral Titer Kit (System Biosciences, CA, USA) according to the 
manufacturer’s instructions. 
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2.10.3 Neonatal liver gene transfer of recombinant LV expressing a 
Firefly luciferase transgene 
Animal experimentation was conducted in accordance with procedures and 
protocols approved by the University of the Witwatersrand Animal Ethics Screening 
Committee (Appendix A3). Recombinant lentivirus expressing a Firefly luciferase 
transgene transcribed from an internal mTTR promoter was injected into the circulation of 
anaesthetised newborn mice via the superficial temporal vein (362). Gas anaesthesia with 
isoflurane (Safeline Pharmaceuticals (PTY) LTD, South Africa) was used to anaesthetise 
the animals prior to administering the injection. The injections were carried out under 4× 
magnification using a stereo microscope (Wild Heerbrugg, Switzerland) and a 33-gauge, 
16 mm long needle attached to a 100 µl Gastight Hamilton syringe (Hamilton, NV, USA). 
A light guide connected to a KL1500 LED cold light source (Olympus, Japan) was used to 
transilluminate the head of animals and improve visualisation of the superficial temporal 
vein. Each newborn animal (0- to 1- days old) received two injections of a maximum 
injectate volume of 60 µl over two successive days. One additional animal, to be used as 
control, received two 60 µl PBS injections over two days.  
 
2.10.4 In vivo bioluminescence imaging 
In vivo bioluminescence imaging of animals was carried out using the IVIS 
Kinetic imaging system (Caliper Life Sciences Inc., MA, USA). Briefly, animals received 
D-luciferin (Gold Biotechnology, MO, USA) at 150 mg/kg by intra-peritoneal injection 15 
minutes before imaging. A stock solution of D-luciferin was prepared by diluting 1 g of D-
luciferin in 66.6 ml of PBS to a final concentration of 15 µg/µl. The animals were 
anaesthetised with isoflurane. Images were acquired with an automatic exposure and 
analysed using the Living Image Software (Caliper Life Sciences Inc., MA, USA).  
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2.11 In vivo assessment of the antiviral efficacy and toxicity of the 
therapeutic LVTH-LUC miR-31/5-8-9 lentivirus  
 
2.11.1 Construction of recombinant pLVTH- and pLVTH miR-31/5-8-9- 
derived lentiviral vectors expressing a Firefly luciferase transgene 
To construct pLVTH- and pLVTH miR-31/5-8-9-derived lentiviral vectors 
encoding a 2A-linked Firefly luciferase-eGFP bicistronic expression cassette, the existing 
GFP sequence was excised from the pLVTH and pLVTH miR-31/5-8-9 plasmids with 
PmeI and NdeI. The ends of the vector DNA backbones were made blunt using Klenow 
Fragment (Thermo Scientific, MA, USA) and subsequently dephosphorylated using 
FastAP Thermosensitive Alkaline Phosphatase (Thermo Scientific, MA, USA). The 2A-
linked Firefly luciferase-eGFP expression cassette was excised from the pLNT-GW-JDG 
plasmid with BamHI and MluI and the purified fragment was treated with Klenow 
Fragment to fill in the 5' DNA overhangs. The blunt sequence was ligated to the blunted 
and dephosphorylated pLVTH and pLVTH miR 31/5-8-9 vector backbones to generate the 
pLVTH-LUC and pLVTH-LUC miR 31/5-8-9 lentiviral vectors (Figure 2.5). Prepared 
plasmids were subjected to NcoI and Eco91I restriction enzyme digestion to select clones 
containing the insert in the desired orientation.  
 
2.11.2 Production and titration of recombinant LVTH-LUC and LVTH-
LUC miR-31/5-8-9 LV 
Recombinant LVTH-LUC and LVTH-LUC miR-31/5-8-9 LV was produced by 
transient co-transfection of the transfer lentiviral plasmid and packaging plasmids 
(psPAX2 and pMD2.G) into HEK293T cells using PEI as a transfection reagent (Appendix 
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A1-2). Virus-containing supernatant was harvested at 20 and 48 hours after transfection. 
Pooled virus-containing medium was clarified by centrifugation at 1,000 × g for 5 minutes 
at 4°C and subsequently filtered through a 0.45 µm AcroVac™ Filter Unit. Clarified virus-
containing medium was concentrated using Centricon Plus-70 Centrifugal Filter Devices 
as described in Section 2.10.2. Concentrated lentivirus was titrated in HeLa cells using the 
Global UltraRapid Lentiviral Titer Kit according to the manufacturer’s instructions.  
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Figure 2.5: Schematic illustration of the cloning strategy used to construct the 
pLVTH-LUC and pLVTH-LUC miR-31/5-8-9 lentiviral vectors.  
The GFP-encoding sequences were excised from pLVTH and pLVTH miR-31/5-8-9 
lentiviral vectors with PmeI-NdeI and the backbones were treated with Klenow fragment to 
blunt DNA ends. A Klenow-treated GFP-2A-Firefly luciferase fragment was inserted into 
the respective vector backbones to generate the pLVTH-LUC and pLVTH-LUC miR-31/5-
8-9 lentiviral vectors. WPRE (woodchuck hepatitis virus posttranscriptional regulatory 
element), LTR (long terminal repeat), SIN 3' LTR (LTR with a deletion in the U3 region), 
RRE (rev-responsive element), ψ (HIV-1 packaging signal). 
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2.11.3 LVTH-LUC and LVTH-LUC miR-31/5-8-9 LV gene transfer in 
neonatal and adult HBV transgenic mice 
 
2.11.3.1 LV gene transfer via temporal vein injection in neonatal HBV transgenic 
mice 
Recombinant LVs were delivered to the livers of newborn HBV transgenic mice 
via an intravenous temporal vein injection as described in section 2.10.3. Neonatal HBV 
transgenic animals received a single unilateral 60 µl injection of recombinant LVTH-LUC 
or LVTH-LUC miR-31/5-8-9 LV (8.7 × 10
7
 TU per mouse). 
 
2.11.3.2 LV gene transfer via tail vein injection in adult HBV transgenic mice 
Recombinant LVTH-LUC and LVTH-LUC miR-31/5-8-9 LV was injected into the 
tail vein of 21 to 25 day old HBV transgenic mice. All animals that received a LV injection 
had medium to high HBV titres. The final injection volume was 0.5 ml of LVTH-LUC and 
LVTH-LUC miR-31/5-8-9 lentivirus (5.5 × 10
8 
TU per mouse). 
 
2.11.4 Quantification of serum alanine transaminase  
Blood samples were collected at the end of the study from HBV transgenic animals 
that had received LV via a temporal vein injection. Mice that had received recombinant LV 
via a tail-vein injection, were bled at three different time points (48 hours post injection, 
one week post injection and at the end of the study). The samples were incubated at 4°C 
for at least 90 minutes to facilitate coagulation and were subsequently centrifuged at 
10,000 × g for 10 minutes at 4°C. Mouse serum was extracted, diluted 1:2 with saline and 
the levels of serum alanine transaminase (ALT) in the samples were determined by the 
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National Health Laboratory Service at the Charlotte Maxeke Johannesburg Academic 
Hospital. 
 
2.11.5 Quantification of serum HBsAg  
Blood samples were collected weekly from all animals. Mouse serum was diluted 
1:4 with saline and 100 µl of the diluted samples were used to quantify the level of HBsAg 
using the Monolisa
™
 HBsAg ULTRA assay kit as described in Section 2.3.3.2. 
 
2.11.6 Quantification of serum HBV DNA  
The Total Nucleic Acid Isolation Kit and MagNA Pure LC system was used to 
extract 50 µl of mouse serum extracted from blood samples which had been collected on a 
weekly basis. Viral DNA quantification was performed using real-time quantitative PCR 
carried out using HBV-specific primers, described in Section 2.9.3 and the Bio-Rad 
CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, CA, USA). PCR analysis 
was performed using the SsoFast™ EvaGreen Supermix (Bio-Rad, CA, USA) and the 
following cycling parameters: a 30 second hot start at 95°C and 40 cycles of denaturation 
at 95°C for 10 seconds, annealing at 58°C for 10 seconds and extension at 72°C for 10 
seconds. EuroHep standards were used to generate a standard curve for the quantification 
of viral particle equivalents (VPEs) in the individual samples (158). 
 
2.11.7 Tissue collection  
Mice were sacrificed at the completion of each study and the livers from individual 
animals were harvested. Livers were cut in three equal samples. The tissue samples were 
used to extract DNA and RNA. 
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2.11.8 Determination of vector copy number in mouse liver tissue  
Genomic DNA was extracted from 25 mg of homogenised liver tissue using the 
QIAamp DNA Mini Kit (Qiagen, GmbH, Germany) according to the manufacturer's 
instructions. The Global UltraRapid Lentiviral Titer Kit was used to determine the number 
of vector copies associated with genomic DNA extracted from individual mouse liver 
samples. 
 
2.11.9 Quantitative reverse transcriptase PCR of intrahepatic HBV RNA  
Total RNA was extracted from mouse livers using Tri-Reagent and reverse 
transcribed with the QuantiTect Reverse Transcription Kit (Qiagen GmbH, Germany) 
according to the manufacturer's instructions. The following primer sets mGAPDH F: 5’- 
TTC ACC ACC ATG GAG AAG GC -3’  and mGAPDH R: 5’- GGC ATG GAC TGT 
GGT CAT GA -3’, HBV Surface F 5'- TGC ACC TGT ATT CCA TC -3' and HBV 
Surface R 5'- CTG AAA GCC AAA CAG TGG -3', HBV Core F: 5'- ACC ACC AAA 
ATG CCC CTA T -3' and HBV Core R: 5'- TTC TGC GAG GCG GCG A -3' were used to 
amplify murine glyceraldehyde-3-phosphate dehydrogenase (GAPDH), HBV surface and 
core mRNA respectively. The oligonucleotide sequences used were synthesised by 
standard phosphoramidite chemistry (Inqaba Biotech, South Africa).  PCR analysis was 
performed using the SsoFast™ EvaGreen Supermix as described in Section 2.11.6. 
Specificity of the PCR products was verified by melting curve analysis. HBV surface and 
core gene mRNA levels were normalised to GAPDH mRNA. 
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2.11.10 Detection of mature miR-31/5 in liver tissue of lentivirus-injected 
HBV transgenic mice 
The Custom TaqMan Small RNA Assay (Life Technologies Inc., CA, USA) was 
used to detect and quantify the putative mature miR-31/5 guide sequences of pri-miR-31/5-
8-9 in liver tissue samples. The assay involved performing reverse transcription with a 
stem-loop primer designed to bind specifically to the mature miR/31-5 sequence followed 
by a two step real-time PCR for detection of the mature miR sequence of interest. The 
basic principle of the assay is illustrated in Figure 2.6. Total RNA was extracted from 
mouse livers using Tri-Reagent and reverse transcribed with the TaqMan MicroRNA 
Reverse Transcription Kit (Life Technologies Inc., CA, USA) and a specific stem-loop 
reverse transcription primer according to the manufacturer's instructions. PCR analysis was 
performed using the products from individual reverse transcription reactions, TaqMan 
Small RNA Assay custom designed for miR-31/5 or endogenous U6 snRNA and the 
TaqMan 2× Universal PCR Master Mix with AmpErase UNG (Life Technologies Inc., 
CA, USA) according to the manufacturer's instructions. 
 
Statistical analysis 
Data are expressed as the mean ± standard error of the mean (SEM). Statistical 
difference was calculated using the Student's paired two-tailed t-test and was considered 
significant when P was less than 0.05. Calculations were performed with the GraphPad 
Prism software package (GraphPad Software Inc., CA, USA). 
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Figure 2.6: TaqMan Small RNA Assay-based quantification of mature miR 
sequences. 
The TaqMan Small RNA Assay entails performing a two-step reverse transcription PCR 
procedure to detect specific small RNA sequences present in a sample of interest. A) 
Complementary DNA is transcribed from total RNA using a stem loop primer that has 
been designed bind specifically to a mature miR sequence of interest. B) During PCR the 
TaqMan probe anneals to a sequence located between the forward and reverse primer 
binding sites. The probe includes a minor groove binder at its 3' end (MGB) and a non 
fluorescent quencher (NFQ) as well as a FAM reporter dye linked to its 5'end (R). If the 
target sequence is present the probe will specifically hybridise and will be subsequently 
cleaved by DNA polymerase (DNA Pol). Cleavage causes separation of the quencher from 
the reporter dye resulting in an increased  fluorescence signal. 
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3 ENGINEERING SECOND GENERATION SIN 
RECOMBINANT LENTIVIRAL VECTORS FOR 
ANTI-HBV RNAI GENE THERAPY  
 
3.1 Introduction 
The use of expressed anti-HBV RNAi effecters has been shown to be a valuable 
therapeutic strategy to target viral replication and accomplish effective antiviral silencing 
(159, 160, 363, 364). Successful bench to bedside translation of anti-HBV RNAi-based 
gene therapy is contingent on accomplishing sustained and potent silencing of viral 
replication. Expressed RNAi effecters, allow for sustained production of therapeutic 
sequences from stable DNA templates and are compatible with both non-viral and viral 
vectors. In contrast to their non-viral counterparts, viral vectors are capable of mediating 
efficient transduction of target organs and long-term expression of therapeutic sequences, 
suited to countering persistent HBV infection. The selection of a particular viral vector for 
a specific application, is dependent on the nature of the disease as well as the desired 
therapeutic outcome. Stable integration of transgenes that may be achieved with 
recombinant lentiviruses makes these vectors useful for attaining sustained expression of 
antiviral RNAi activators.  
To advance the use of recombinant lentiviruses for HBV treatment, SIN lentiviral 
vectors were engineered to express liver-specific, HBV silencing pri-miR-mimics. The 
expressed pri-miR mimics are derived from natural pri-miR-31 and have been engineered 
to generate anti-HBV RNAi guide sequences targeting single (monocistronic pri-miR 
sequences) or multiple (polycistronic pri-miR sequences) sites within the HBx ORF of the 
HBV genome (159, 160). Meticulous design of potentially effective therapeutics at the 
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bench is required to allow for future clinical application.The molecular engineering of 
HBV silencing lentiviral vectors involved careful design and consideration of various 
factors capable of influencing the efficacy and suitability of this strategy for anti-HBV 
RNAi-based gene therapy.  
As mimics of naturally occurring pri-miRs, expressed anti-HBV pri-miR mimics 
are compatible with expression from Pol II promoters and have the associated advantages 
of controllable and tissue-specific expression. The design of previously characterised 
mono- and poly- cistronic anti-HBV pri-miR-31 expression cassettes (159, 160), was 
further optimised by replacing the promiscuous CMV promoter with the liver-specific 
mTTR promoter to facilitate hepatotropic expression and to ensure compatibility with the 
lentiviral delivery system. The use of a hepatospecific promoter, such as mTTR, allows for 
simultaneous expression of the therapeutic effecters in hepatocytes while regulating the 
dose of expressed therapeutic effecters. Liver-specific expression should also eliminate 
off-target effects that could arise from constitutive expression of the pri-miR mimics in 
non-targeted tissues. While the mTTR promoter has been successfully exploited to drive 
long-term expression of transgenes in the context of lentiviral vectors (180),  shutdown of 
CMV promoter activity in the murine liver has been reported. (176, 177). Furthermore the 
CMV promoter has been reported to affect viral titres negatively when used to control miR 
expression in the context of lentiviral vectors (329).  
The use of a moderate internal Pol II promoter, such as mTTR, (305) as well as the 
inclusion of LoxP sites in the 3' LTR of the SIN pLVTH lentiviral vector, allowing for 
conditional ablation of LV-transduced hepatocytes is likely to improve the biosafety 
profile of the HBV silencing lentiviral vectors. Additional features incorporated to improve 
functionality and efficacy of our strategy, included the exclusion of an internal 
polyadenylation signal downstream of the liver-specific pri-miR sequences in the lentiviral 
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vectors as well as placing the therapeutic expression cassettes in the sense orientation with 
respect to the lentiviral genome. Placing the a miR expression cassette in reverse 
orientation has been reported to hamper the expression of active miR sequences (329). The 
polyadenylation signal was excluded to prevent premature termination of the full length 
viral RNA genomic transcripts and consequently reduction in viral titre (365). 
The aim of the next set of experiments was to evaluate the antiviral efficacy and 
tissue-specificity of the mono- and poly- cistronic pri-miR mimics expressed from the 
liver-specific mTTR promoter in cultured liver-derived cells. Furthermore, the 
compatibility of the novel, liver-specific pri-miR-31/5 and pri-miR-31/5-8-9 expression 
cassettes with the SIN second-generation pLVTH lentiviral vector was assessed.   
 
3.2. Design and efficacy of monocistronic and polycistronic liver-
specific anti-HBV pri-miR mimics 
 
3.2.1 The mTTR promoter is capable of driving tissue-specific expression 
of the Firefly luciferase transgene 
The mTTR enhancer-promoter sequence comprises the TTR enhancer and Pol II 
promoter to which a synthetic liver-specific enhancer sequence has been appended (366). 
The enhancer element has been designed to include binding sites for several hepatic 
transcription factors critical for initiating hepatotropic expression in vitro and in vivo 
(Figure 3.1 A).  
To examine the tissue-specificity and functionality of the mTTR promoter the 
efficiency of mTTR driven expression of the Firefly luciferase transgene was assayed in 
liver-derived, Huh7 and HepG2.2.15 cells as well as kidney-derived HEK293T cells. 
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Figure 3.1: Firefly luciferase expression from CMV and mTTR promoter sequences in liver- and kidney-derived cells. 
(A) Schematic representation of plasmids encoding the Firefly luciferase transgene under the control of a promiscuous CMV promoter (pCMV 
Fluc) or a liver-specific murine transthyretin (mTTR) promoter (pmTTR Fluc). The different elements of the mTTR promoter and transcription 
factor binding sites in the synthetic enhacer sequence - CCAAT/enhancer binding protein (C/EBP), hepatic nuclear factor (HNF) 1, HNF3, HNF4 
and HNF 6 are indicated. (B) Firefly luciferase expression in liver (Huh7 and HepG2.2.15)- and kidney (HEK293T)-derived cells transfected 
with pCMV Fluc and pmTTR Fluc plasmids. A plasmid constitutively expressing Renilla luciferase (phRL-CMV) was included in all 
transfections. Data are represented as mean ratios of Firefly to Renilla luciferase activity and the bars represent  the SEM from three independent 
experiments. 
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Firefly luciferase activity was measured in Huh7, HepG2.2.15 and HEK293T cells 
transfected with constructs encoding the Firefly luciferase transgene under the control of  
the promiscuous CMV immediate early promoter enhancer element (pCMV Fluc) or the 
liver-specific mTTR promoter (pmTTR Fluc). As anticipated, strong Firefly luciferase 
expression was observed in all cell populations transfected with the CMV expressing 
Firefly luciferase plasmid (Figure 3.1 B). 
The capacity of the CMV promoter to drive constitutive, high-level albeit variable 
expression of transgenes in different mammalian cell lines has been well characterised 
(367, 368). Strong Firefly luciferase expression was also detected in Huh7 and HepG2.2.15 
cells transfected with the mTTR expressing plasmid demonstrating that the mTTR 
promoter sequence is functional (Figure 3.1 B). In contrast, particularly low Firefly 
luciferase activity was measured in kidney-derived cells transfected with the mTTR 
expressing plasmid, confirming the tissue-specific expression profile of the mTTR 
promoter sequence. 
 
3.2.2 Pri-miR mimics expressed from the mTTR promoter mediate 
tissue-specific HBV knockdown 
Following demonstration of functionality as well as tissue-specific expression 
(Section 3.2.1), the mTTR Pol II transcriptional sequence was identified as a suitable 
promoter that could be utilised to drive liver-specific expression of the monocistronic and 
polycistronic anti-HBV pri-miR mimics. Liver-specific pri-miR expression cassettes were 
generated by placing monocistronic and polycistronic anti-HBV pri-miR sequences, 
originally embedded in CMV expression cassettes (159, 160), under the control of the 
mTTR promoter. The HBV-silencing pri-miR mimics are derived from natural pri- miR-31 
and have been designed to target single (monocistronic pri-miR-31/5) or multiple 
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(polycistronic pri-miR-31/5-8-9) sites within the HBx ORF of the HBV genome (159, 160). 
The conserved HBx sequence is common to the 3' end of all HBV transcripts. As a result 
targeting HBx enables simultaneous knockdown of all viral mRNAs (158). A dual 
luciferase reporter gene assay was used to assess the knockdown efficacy of the liver-
specific monocistronic and polycistronic pri-miR mimics (Figure 3.2). CMV-driven 
monocistronic (pCMV miR-31/5) and polycistronic (pCMV miR 31/5-8-9) pri-miR 
expression constructs which have been previously shown to mediate efficient knockdown 
(159, 160) were also included in the experiment.  
Potent knockdown of HBV reporter gene expression was mediated by CMV-
expressed pri-miR mimics in both liver- (Huh7) and kidney-derived (HEK293T) cells 
(Figure 3.2). Similarly, significant HBV knockdown was observed in liver-derived cells 
transfected with expression plasmids encoding mTTR-driven pri-miR mimics (pmTTR 
miR-31/5 and pmTTR miR-31/5-8-9) (Figure 3.2 B). However, a less pronounced 
silencing effect was observed in kidney-derived cells transfected with plasmids encoding 
mTTR-expressed pri-miR sequences (Figure 3.2 C). The low level of mTTR-driven pri-
miR expression, observed in HEK293T kidney-derived cells, is likely to be attributable to 
the availability of a subset of the transcription factors required for optimal mTTR 
expression (369, 370). Overall these data indicate that pri-miR mimic sequences expressed 
from the mTTR promoter are capable of mediating potent and tissue-specific knockdown 
of HBV gene expression.  
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Figure 3.2: HBV knockdown efficacy of liver-specific pri-miR expression cassettes.  
(A) The psiCHECK-HBx dual luciferase reporter vector contains the complete wild-type 
HBx target sequence (indicated in pink) downstream of the Renilla luciferase ORF within 
psiCHECK
TM
-2. The psiCHECK-HBx reporter vector was co-transfected with plasmids 
encoding monocistronic and polycistronic pri-miR expression cassettes. Forty eight hours 
after transfection, Renilla and Firefly luciferase activity was measured in lysates of Huh7 
(B) and HEK293T cells (C) cells. Data are represented as mean ratios of Renilla to Firefly 
luciferase activity (±SEM., n=3) and are normalised relative to mock-treated cells. p < 
0.05,  p < 0.01. 
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3.3 Design of the second generation SIN pLVTH-derived lentiviral 
vectors encoding liver-specific anti-HBV pri-miR mimics 
A number of intricate factors were taken into account when designing the HBV-
silencing lentiviral vectors to ensure optimal transgene functionality and downstream 
efficacy. To generate recombinant RNAi-based anti-HBV lentiviral vectors, expression 
cassettes encoding monocistronic and polycistronic liver-specific pri-miR mimics (Figure 
3.3) were incorporated into the second generation SIN lentiviral vector, pLVTH (Figure 
3.4). The HIV-1 derived minimal cis-acting elements encoded in the pLVTH lentiviral 
vector backbone include: HIV-1 5' LTR, a splice donor site, HIV-1 encapsidation signal 
(ψ), a truncated gag sequence, RRE, a splice acceptor site, an internal EF-1 alpha 
promoter, cPPT, GFP reporter transgene, WPRE and a 3' SIN LTR encompassing LoxP 
sites. Incorporation of additional sequences such as the WPRE, cPPT and RRE generally 
improves the overall vector efficiency by stimulating nuclear import of the PIC and 
cytoplasmic export of lentiviral mRNA as well as trafficking of unspliced genomic RNA to 
the cytoplasm (274, 277, 279). In addition, the cPPT facilitates efficient transduction of 
quiescent hepatocytes (281).  
The VSV-derived glycoprotein G was selected to pseudotype the anti-HBV pri-
miR-encoding pLVTH-derived LVs as it confers broad vector tropism as well as increased 
stability of lentiviral particles which allows for efficient large-scale LV production as well 
as efficient cell transduction (298). In addition to the importance of successfully 
propagating recombinant lentivirus capable of efficient transduction, it is critical to ensure 
the lentiviral construct used has a high-degree of predictable biosafety. The  SIN 
configuration of pLVTH markedly reduces the risk of potential LV mediated insertional 
mutagenesis (311) as the vector encompasses a 3' LTR devoid of viral enhancer sequence 
(262). 
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Figure 3.3: Schematic illustration of the mono- and poly- cistronic liver-specific pri-
miR expression cassettes. 
Monocistronic (A) and polycistronic (B) anti-HBV pri-miR sequences, originally 
embedded in CMV expression cassettes, were placed under the control of the enhanced 
mTTR promoter to generate liver-specific pri-miR expression cassettes. Putative 
processing of pri-miR mimics to generate mature anti-HBV miR sequences is shown.  
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Figure 3.4: Schematic illustration of the second-generation SIN pLVTH- derived HBV-silencing lentiviral vectors. 
Schematic of the pLVTH miR-31/5 (A) and pLVTH miR-31/5-8-9 (B) lentiviral vectors encoding monocistronic (pri-miR-31/5) and 
polycistronic (pri miR-31/5-8-9) liver-specific anti-HBV pri-miR mimics, respectively. The arrangement of the mTTR pri-miR expression 
cassettes in the context of the lentiviral construct is indicated. LTR (long terminal repeat), ψ (HIV-1 packaging signal), RRE (rev-responsive 
element), cPPT (central polypurine tract), WPRE (woodchuck hepatitis virus posttranscriptional regulatory element), SIN 3' LTR (long terminal 
repeat with a deletion in the U3 region). 
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Moreover, a LoxP site has been included in the 3' pLVTH LTR to add an additional safety-
switch and enhance the biosafety profile of pLVTH-derived recombinant lentivirus. During 
reverse transcription the 3’ LTR sequence is copied to the 5’ end simultaneously copying 
the LoxP site. Consequently the integrated LV sequence would be flanked by LoxP sites 
allowing it to be excised following Cre-recombinase treatment of transduced cells (371, 
372).  
The design of the transgene expression cassette intended for insertion into an 
RNAi-based anti-HBV lentiviral construct can influence the titre of the lentivirus as well 
as the expression of the therapeutic RNAi molecule. The inclusion of a promiscuous CMV 
Pol II promoter in the context of miR-based lentiviral vector expression systems has been 
demonstrated to result in severe LV titre reduction (329), indicating that the CMV 
promoter sequence or activity is incompatible with the lentiviral system. The inclusion of 
the Pol II mTTR promoter driving pri-miR mimic expression did not result in any 
significant titre reduction when compared to the titre obtained for LV propagated using the 
pLVTH lentiviral backbone (Table 3.1).  
Incorporating a polyadenylation signal immediately downstream of the transgene 
could improve expression (373), however the presence of an additional polyadenylation 
signal in a lentiviral construct would result in premature termination of the full length, 
transduction-competent genomic transcripts and a severe reduction in viral titre (365). 
Placing the a miR expression cassette in reverse orientation has been reported to hamper 
the expression of active miR sequences (329) possibly as a result of the absence of a 
polyadenylation signal which is typically located in the 3' LTR of lentiviral vectors. The 
pri-miR expression cassette was inserted in the pLVTH backbone in the forward (sense) 
orientation without a polyadenylation signal. The 3' LTR polyadenylation signal would 
contribute to improved stability of the pri-miR transcript produced from the liver-specific 
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encoded in the pLVTH lentiviral vector in the forward orientation, resulting in robust 
expression of mature miR sequences. In addition, Drosha-mediated recognition and 
processing of miR precursors encoded in the sense orientation of the viral genome, can 
potentially result in the production of truncated, non-functional genomic transcripts and 
reduced viral titres (329). Nevertheless, efficient production of anti-HIV LVs expressing 
miR precursors has been reported (182, 185). 
 
Table 3.1: Average viral titres obtained for pLVTH and pLVTH-derived HBV- 
silencing LVs.  
 
Lentivirus 
 
 
Viral titre 
HeLa
TU/ml 
LVTH 
 
~ 1.5 × 10
7
 
LVTH miR-31/5 
 
~ 1.3 × 10
7
 
LVTH miR-31/5-8-9 
 
~ 1.3 × 10
7
 
 
 
3.3.1 Lentiviral vector-encoded liver-specific pri-miR mimics mediate 
effective knockdown of viral replication 
To assess the functionality of the anti-HBV mTTR monocistronic and polycistronic 
pri-miR expression cassettes in the context of the RNAi-based lentiviral vector system, 
Huh7 cells were co-transfected with a replication competent HBV plasmid (pCH-9/3091) 
(Figure 3.5) and lentiviral vectors encoding the mTTR pri-miR-31/5 (pLVTH miR-31/5) or 
mTTR pri-miR-31/5-8-9 (pLVTH miR-31/5-8-9) expression cassette. An HBsAg ELISA 
assay was performed to measure the inhibition of HBsAg secretion in transfected cells. 
Significant inhibition of HBsAg secretion (~90%) was observed in cells transfected with 
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the pLVTH miR-31/5 and pLVTH miR-31/5-8-9 lentiviral vector plasmids (Figure 3.5).  
The expressed, liver-specific pri-miR sequences, now encoded in the pLVTH-derived 
lentiviral constructs, were demonstrated to mediate effective inhibition of HBV replication 
(Figure 3.5). These data corroborate the potent HBV knockdown mediated by liver-
specific anti-HBV pri-miR mimics encoded in mammalian expression vectors (Section 
3.2.2).  
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Figure 3.5: Assesement of inhibition of HBsAg secretion by lentiviral vector encoded 
liver-specific anti-HBV miR mimics.  
(A) Schematic illustration of HBV ORFs organisation within the pCH-9/3091 target 
vector. HBV transcripts terminating at a common 3' end have been indicated in puple and 
include miR-31/5 and miR-31/5-8-9 targets. (B) HBsAg secretion was measured in Huh7 
cells co-transfected with the pCH-9/3091 HBV target vector and pLVTH-derived lentiviral 
vectors encoding liver-specific mono- and poly- cistronic pri-miR mimics. HBsAg 
measurements from quantitative ELISA are given as normalised means (±SEM., n=3) 
relative to mock-treated cells. p < 0.05 
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3.4 Conclusion 
To advance the use of recombinant lentiviruses for HBV treatment, we engineered 
RNAi-based HBV silencing lentiviral vectors encoding mono- and poly- cistronic pri-miR 
sequences expressed from the liver-specific mTTR promoter. Initial evaluation of the 
functionality and tissue-specificity of the murine mTTR enhancer-promoter sequence, 
revealed that the promoter is capable of driving robust and tissue-specific expression of the 
Firefly luciferase transgene in liver-derived Huh7 cells. Following validation of the mTTR 
promoter, the anti-viral efficacy and tissue-specific expression of the monocistronic and 
polycistronic pri-miR mimics, placed under the control of the mTTR promoter, was 
assessed. Similarly to their CMV promoter counterparts, the monocistronic and 
polycistronic pri-miR mimics expressed from the liver-specific mTTR promoter were 
equally capable of mediating efficient knockdown of HBV gene expression.  
Following demonstration of antiviral efficacy of the liver-specific pri-miR mimics, 
the sequences were incorporated into the pLVTH lentiviral backbone in the forward 
orientation without a polyadenylation signal. Finally, the antiviral efficacy of the anti-HBV 
pri-miR mimics in the context of the pLVTH-derived lentiviral vectors was assessed in 
liver-derived Huh7 cells. The liver-specific monocistronic and polycistronic pri-miR 
mimics encoded in the pLVTH lentiviral vector backbone were demonstrated to mediate 
efficient knockdown of HBV replication. Accomplishing robust viral knockdown indicated 
that the design of the HBV silencing lentiviral vectors was functional and efficient.  
The above findings highlight potential utility of the novel RNAi-based HBV 
silencing lentiviral vector for the development of safe and effective therapy for chronic 
HBV. The efficacy of currently available treatments for chronic HBV infection is limited, 
as treatment using these therapeutic agents does not allow for durable silencing of HBV 
gene expression and it is associated with the emergence of viral escape mutants (374). In 
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addition, the risk of developing HCC remains undiminished in the majority of chronic 
carriers receiving currently licensed treatments (43). Globally, chronic HBV infection 
remains a significant cause of public health problems and the development of improved 
anti-HBV therapies is therefore a priority. Advancing the use of lentiviruses for RNAi-
based anti-HBV gene therapy could be a potentially valuable strategy to allow for durable 
silencing and ultimately effective eradication of chronic viral infection. 
In the following chapter the usefulness of the pLVTH-derived HBV silencing 
lentiviral vectors for the production of functional and potentially effective LVs to counter 
chronic HBV infection is explored.  
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4 CHARACTERISATION OF THE RNAi-BASED HBV-
SILENCING LENTIVIRAL VECTORS IN VITRO 
 
4.1 Introduction 
Lentiviral vector delivery allows for sustained, long-term expression of therapeutic 
anti-HBV pri-miR mimics, making this delivery method particularly suited to countering 
persistent HBV infection. Several groups have reported efficient lentiviral vector delivery 
and sustained expression of expressed RNAi effecters (313, 326, 327). Data described in 
the previous chapter demonstrated that the design of the tailor-made RNAi-based HBV-
silencing lentiviral vectors allows for optimal expression of the antiviral pri-miR mimics. 
Nevertheless, the functionality and efficacy of HBV silencing LVs, propagated using the 
SIN pLVTH-derived lentiviral vectors encoding monocistronic (LVTH miR-31/5) and 
polycistronic (LVTH miR-31/5-8-9) liver-specific anti-HBV pri-miR mimics, requires 
thorough assessment of transduction efficiency, antiviral efficacy and safety in pertinent 
cell culture systems.  
Stable LV integration can be easily assessed by monitoring the expression of 
marker transgenes, such as GFP, frequently incorporated into recombinant lentiviral 
vectors including pLVTH. Additionally, genomic quantitative PCR analysis can be 
performed to determine the number of integrated lentiviral copies in stably transduced 
cells. Furthermore it is important to determine whether the integrated pri-miR sequences 
are being processed by the cellular RNAi machinery according to their intended design and 
whether recombination is occurring between equivalent sequences in the polycistronic pri-
miR transcript during lentivirus transduction. Recombination-mediated deletion of pri-miR 
sequences in the context of a polycistronic scaffold has been reported previously (183, 
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185) and deletion events seem to be more prominent when an increasing number of 
hairpins, four hairpins or more, is included in the polycistronic pri-miR transcript (185). 
Nevertheless, a multitargeted RNAi approach, such as the use of polycistronic anti-HBV 
pri-miR mimics, is likely to be valuable in preventing the emergence of viral escape 
mutants while simultaneously enabling long-term sustained silencing of chronic HBV 
infection.  
Recent evidence of saturation of the natural miR biogenesis pathway following 
AAV-8-mediated anti-HBV shRNA delivery has highlighted the need for careful analysis 
of unintended toxic effects following the delivery of exogenous RNAi effecters (165). The 
anti-HBV pri-miR mimics encoded in pLVTH-derived lentiviral vectors are expressed by 
the liver-specific mTTR Pol II promoter which allows for controllable and tissue specific 
expression. Although, saturation of the endogenous miR biogenesis pathway using the 
respective pri-miR mimics is not likely to occur (127), assessing potential saturation of the 
endogenous miR pathway following expression of LV-delivered anti-HBV pri-miR mimics 
is important. 
Finally, evaluating the antiviral efficacy of HBV silencing LVs in relevant cell 
culture systems is an important objective in the preclinical development of potential 
lentiviral vector-based anti-HBV RNAi gene therapy. Antiviral efficacy can be evaluated 
in liver-derived cells that had been stably transduced with HBV silencing LVs and the 
subsequent transfection of replication-competent HBV plasmids. Additionally, HBV 
replication cell lines, such as the HepG2.2.15 cell line which had been generated by 
transforming the HepG2 human hepatoblastoma cell line with HBV DNA (331), can be 
used for rigorous evaluation of the efficacy of novel HBV therapies in vitro. 
The aim of the next set of experiments was to assess the delivery efficiency and antiviral 
efficacy of pLVTH-derived VSV-G-pseudotyped RNAi-based HBV silencing LVs in vitro.  
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Characterisation of the RNAi-based HBV silencing lentiviral vectors in vitro entailed 
thorough assessment of: transduction efficiency, processing of integrated pri-miR mimics, 
potential saturation of the endogenous miR biogenesis pathway, utility of the integrated 
polycistronic anti-HBV pri-miR mimics in improving effectiveness against viral escape 
mutants and finaly evaluating antiviral efficacy in liver-derived Huh7 and HepG2.2.15 cell 
lines. 
 
4.2 Propagation of HBV silencing LVs and processing of LV-
delivered anti-HBV pri-miR mimics in stably transduced cells 
VSV-G pseudotyped LVTH and HBV silencing, LVTH miR-31/5 as well as LVTH 
miR-31/5-8-9 LV were produced by transient transfection in HEK 293T cells. Similar 
titres were obtained for LVTH LV and the HBV silencing, LVTH-derived LVs, indicating 
that Drosha-mediated processing of the miR precursors in the HBV silencing LVs did not 
affect viral titres significantly.  
Liver-derived Huh7 cells were transduced with LVTH, LVTH miR-31/5 and 
LVTH miR-31/5-8-9 lentiviral preparations at a MOI of 40. Genomic quantitative PCR 
analysis revealed that the LVTH and LVTH miR-31/5 lentiviruses were integrated at a 
copy number of 1.8 per cell, while LVTH miR-31/5-8-9-transduced cells had 1.2 copies of 
integrated LV per genome. To determine whether the integrated pri-miR sequences are 
being processed according to the intended design, low molecular weight Northern blot 
analysis was carried out.  
Effective processing of the integrated pri-miR mimics by the cellular RNAi 
machinery was revealed by the presence of 20-22 nucleotide putative guide sequences 
(Figure 4.1). Bands corresponding to pri-miR and pre-miR precursor transcripts were not 
detectable, indicating that the exogenous pri-miR mimics are efficiently processed by the 
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cellular RNAi machinery. A single guide sequence, corresponding to the intended miR-
31/5 guide, was detected in Huh7 cells which had been stably transduced with the LVTH 
miR-31/5 lentivirus. Hybridisation with probes complementary to anticipated miR-31/5, 
miR-31/8 and miR-31/9 guide sequences confirmed the formation of three individual guide 
sequences in LVTH miR-31/5-8-9 transduced cells.  
Quantification of relative band intensities showed variation in the amounts of 
individual guides, processed from the integrated polycistronic pri-miR-31/5-8-9 scaffold. 
The miR-31/5 guide sequence was present in high quantity in stably transduced cells, 
followed by guide 8, while miR-31/9 guide sequence was the least abundant.  
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Figure 4.1: Processing of lentiviral vector-delivered liver-specific pri-miR mimics in stably transduced Huh7 cells.  
Northern blot analysis was carried out using RNA extracted from Huh7 cells which had been stably transduced with LVTH, LVTH miR-31/5 and 
LVTH miR-31/5-8-9 LV preparations. Blots were probed using radiolabelled oligonucleotides complementary to the putative mature guide 
sequences of pri-miR-31/5 (A), pri-miR-31/8 (B) or pri-miR-31/9 (C). Bands equivalent to the guide sequence are indicated by an arrow. 
Molecular weight (MW) marker indicating fragment sizes of radiolabelled RNA is shown on the left of the autoradiographs. Blots were stripped 
and re-hybridised to a probe complementary to endogenous small nuclear U6 RNA to confirm equal loading of cellular RNA. 
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4.3 Recombination between repeated pri-miR scaffold sequences is 
not detectable in LVTH miR-31/5-8-9-transduced Huh7 cells 
Recombination events between repeated sequences in the RNA genome can 
potentially occur at certain stages in the progression of reverse transcription as the viral 
reverse transcriptase processes templates with sequence repeats poorly (375, 376). 
Recombination-mediated deletion of pri-miR sequences in the context of a polycistronic 
scaffold has been reported previously (183). To investigate whether recombination had 
occurred between equivalent sequences in the polycistronic pri-miR-31/5-8-9 cassette 
during lentivirus transduction, genomic DNA extracted from LVTH miR-31/5-8-9 
transduced Huh7 cells was analysed by PCR (Figure 4.2). PCR was performed using 
primers that span the mTTR pri-miR-31/5-8-9 cassette. A single 493 base pair (bp) band, 
corresponding to the size of the mTTR pri-miR-31/5-8-9 cassette, was amplified from 
LVTH miR-31/5-8-9 genomic DNA. Additional smaller size bands which could be 
indicative of sequence rearrangements in the integrated pri-miR 31/5-8-9 scaffold were not 
observed. However, minor background smearing is noticeable and this could be interpreted 
as evidence for some recombination occurring during LV transduction. Nevertheless, the 
intended band is dominant indicating that an intact polycistronic pri-miR-31/5-8-9 cassette 
is present in the genome of most transduced cells. 
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Figure 4.2: PCR analysis of integrated anti-HBV pri-miR expression cassettes.  
(A) A schematic of the pLVTH miR-31/5-8-9 lentiviral vector in proviral form. The position of the primers (depicted as green arrows) relative to 
the pri-miR cassette in proviral DNA integrated in stably transduced cells is indicated. (B) Genomic DNA extracted from LVTH miR-31/5-8-9-
transduced Huh7 cells (lane 2) was analysed for pri-miR sequence recombination by PCR, using an intronic forward primer and EF-1 alpha 
reverse primer. pLVTH miR-31/5-8-9 plasmid DNA (lane 1) and genomic DNA extracted from untransduced Huh7 cells (lane 3) were included 
as positive and negative controls respectively. MW (molecular weight). 
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4.4 Expression of lentiviral vector-delivered anti-HBV pri-miR 
mimics does not disrupt the endogenous miR pathway  
In a pivotal study, Grimm and colleagues demonstrated saturation of the natural 
miR biogenesis pathway following AAV-8-mediated anti-HBV shRNA delivery (165). 
The high transduction efficiency achieved with the AAV-8 vector coupled with the strong 
expression of shRNA from the U6 promoter was shown to contribute to severe toxicity in 
vivo as a consequence of disruption of endogenous miR biogenesis. A saturation assay, 
which involved the assessment of miR-16 translational repression, was performed to verify 
that the LV-delivered anti-HBV pri-miR mimics do not saturate the endogenous miR 
pathway and effect perturbations in cellular miR function (159). The wide tissue 
expression profile of miR-16 allows for convenient assessment of potential disruption of 
endogenous miR function. A psiCHECK-derived reporter vector that encodes seven copies 
of an imperfect miR-16 target downstream of the Renilla luciferase ORF (psiCHECK-
miR-16T×7) was used to measure cellular miR-16-mediated knockdown (159) (Figure 
4.3). A sponge plasmid encoding seven partly complementary miR-16 target sites (pTZ-
U6-miR-16S×7) was used as a control for loss of miR-16 silencing activity (Figure 4.3). 
Incorporation of partly complementary miR targets in sponge vectors, instead of perfectly 
complementary miR target sites, allows for effective competition with natural miR targets 
and subsequent association with activated RISCs, as most endogenous miRs are partly 
complementary to their targets and mediate silencing by translational repression and/or 
deadenylation (377). 
As expected, co-transfection of the psi-miR-16T×7 vector and the pTZ-U6-miR-
16S×7 sponge plasmid in LVTH-transduced Huh7 cells revealed disruption of miR-16 
silencing function (Figure 4.4). In contrast, no disruption of miR-16 function was observed 
in LVTH, LVTH miR-31/5 and LVTH miR-31/5-8-9-transduced cells transfected with the 
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psi-miR-16T×7 vector (Figure 4.4). These data indicate that LV- delivered anti HBV pri-
miR mimics do not have a repressive effect on endogenous miR-16 silencing activity and 
are not likely to cause saturation of cellular miR function. Accomplishing controllable and 
tissue-specific expression of potentially therapeutic pri-miR sequences is of great 
importance. Selection of a tissue-specific Pol II promoter, such as mTTR, allows for 
limited expression of the pri-miR mimics in non target tissues and tighter regulation of the 
dose of expressed pri-miR molecules in hepatocytes. As a result Pol II-mediated 
expression of pri-miR mimics reduces the potential of exogenously introduced pri-miR 
mimics to saturate components of the endogenous miR pathway and consequently 
disrupting natural miR biogenesis. 
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Figure 4.3: Illustration of constructs used to assess saturation of endogenous miR-16 function.  
(A) Schematic of psiCHECK-miR-16T×7 dual luciferase reporter vector. The plasmid comprises seven miR-16 targets downstream of the 
Renilla luciferase ORF. (B) Schematic of miR-16 sponge expression cassette encoded within the pTZ-U6-miR-16S×7 plasmid. The cassette is 
expressed by a U6 Pol III promoter and generates a transcript that contains seven imperfectly matched miR-16 targets.  
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Figure 4.4: Assessment of off target effects of integrated anti-HBV pri-miR mimics on 
endogenous miR-16 function.  
Stably-transduced Huh7 cells were transfected with the psiCHECK-miR-16T×7 reporter 
vector. As a control, LVTH-transduced Huh7 cells were transfected with both psiCHECK-
miR-16T×7 target and pTZ-U6-miR-16S×7 sponge plasmids. Renilla luciferase activity 
was measured in the lysates of transfected cells forty-eight hours following transfection. 
Firefly luciferase constitutively expressed from psiCHECK-miR-16T×7 was used to 
normalise data. Data are presented as mean ratios of Renilla to Firefly luciferase activity 
(±SEM., n=3, p < 0.05, p < 0.01). 
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4.5 Silencing efficacy of the lentiviral vector-based anti-HBV miR 
system in stably transduced Huh7 cells 
 
4.5.1 LV-delivered anti-HBV pri-miR mimics silence HBV gene 
expression and viral replication 
The preceding data demonstrate that the LVs encoding liver-specific anti-HBV pri-
miR mimics are capable of effectively transducing liver-derived cells and mediating stable 
integration of the therapeutic pri-miR sequences into the genome of transduced 
hepatocytes. Furthermore, Northern blot and saturation analysis showed that the pri-miR 
mimics are effectively processed to intended mature miR guide sequences without 
saturating the endogenous miR pathway. Next, a dual luciferase HBV reporter gene assay 
and a HBsAg ELISA was performed to assess the antiviral efficacy of LV-delivered 
monocistronic and polycistronic pri-miR mimics. HBV reporter gene expression was 
measured in Huh7 cells which had been stably transduced with LVTH miR-31/5 and 
LVTH miR-31/-5-8-9 lentiviral preparations at a MOI of 40. Significant inhibition of 
Renilla luciferase activity (Figure 4.5 A, B) was observed in transduced cells which had 
been transfected with the psiCHECK-HBx reporter vector (Section 3.2.2). Furthermore, 
potent inhibition of HBsAg secretion was measured in LVTH miR-31/5 and LVTH miR-
31/5-8-9-transduced Huh7 cells (Figure 4.5 C, D) following a transfection of the pCH-
9/3091 HBV replication competent plasmid. These findings confirm that the LV-delivered 
anti-HBV pri-miR mimics are capable of mediating powerful suppression of viral 
replication. 
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Figure 4.5: HBV knockdown in stably transduced Huh7 cells. 
HBV knockdown was measured in Huh7 cells that had been stably transduced with LVs encoding monocistronic pri-miR-31/5 (A, C) and 
polycistronic pri-miR-31/5-8-9 (B, D) pri-miR mimics using a dual luciferase reporter gene assay (A, B) and a HBsAg ELISA (C, D). 
(A, B) Huh7 cells were transfected with the dual luciferase HBV reporter vector psiCHECK-HBx. Forty-eight hours after transfection, Renilla 
luciferase and Firefly luciferase activities were measured in lysates of transfected cells. Data are presented as mean ratios of Renilla to Firefly 
luciferase activity (±SEM., n=3, p < 0.05, p < 0.01) and are normalised relative to LVTH-transduced cells. (C, D) HBsAg secretion was 
measured in stably transduced Huh7 cells, forty-eight hours after transfection with the pCH-9/3091 HBV target vector. Quantitative ELISA 
HBsAg measurements are given as a normalised mean (±SEM., n=3, p < 0.05, p < 0.01) relative to LVTH-transduced cells. 
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4.5.2 Integrated polycistronic anti-HBV pri-miR mimics mediate effective 
knockdown of individual viral target sequences 
Northern blot analysis carried out on genomic DNA extracted from LVTH miR-
31/5-8-9-transduced Huh7 cells revealed the presence of three putative mature miR guide 
sequences (Section 4.2). Nevertheless, variation was observed in the quantities of the 
individual mature miR guide sequences detected.  
To assess the silencing efficacy of the individual miR effecters generated from a 
polycistronic miR scaffold, a dual luciferase reporter assay was performed. Vectors 
comprising individual sites targeted by putative miR-31/5 (psiCHECK-5T), miR-31/8 
(psiCHECK-8T) and miR-31/9 (psiCHECK-9T) guide sequences downstream of the 
Renilla luciferase ORF (Figure 4.6 A) were transfected in LVTH miR-31/5-8-9 transduced 
Huh7 cells.  
Renilla luciferase activity was measured in transfected cells (Figure 4.6 B) to 
determine the knockdown efficacy of each miR effecter. Although Renilla luciferase 
expression from each reporter vector was significantly inhibited, variable knockdown 
efficacy was observed against the different HBV targets. Knockdown of the psiCHECK-5T 
mediated by the pri-miR-31/5 sequence was the most potent, while moderate silencing 
activity was observed by the miR-31/9 sequence. The silencing activity of the individual 
guide sequences corresponded to the quantity of guide sequence detected by Northern blot 
analysis. 
Chapter 4 
[109] 
 
 
Figure 4.6: Silencing of individual HBV targets by polycistronic LV-delivered anti-HBV pri-miR mimics.  
(A) Schematic illustration of dual luciferase reporter vectors comprising target sequences complementary to putative miR guides 5 (psiCHECK-
5T), 8 (psiCHECK-8T) and 9 (psiCHECK-9T) downstream of the Renilla lucuferase ORF in psiCHECK
TM
-2. (B) Huh7 cells that had been 
stably transduced with LVTH miR-31/5-8-9 recombinant lentivirus were transfected with individual dual luciferase reporter vectors (psiCHECK-
5T, psiCHECK-8T and psiCHECK-9T). Forty eight hours after transfection Renilla and Firefly luciferase activities were measured and the 
efficacy of miR-mediated knockdown of the individual target sequences was determined. Data are presented as mean ratios of Renilla to Firefly 
luciferase activity (± SEM., n=3, p < 0.01) and are normalised relative to LVTH-transduced cells.  
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4.5.3 Integrated polycistronic anti-HBV pri-miR mimics mediate 
knockdown of a mutant HBx target sequence  
Simultaneous expression of several anti-HBV miR sequences from polycistronic 
cassettes could be potentially valuable in limiting the emergence of viral escape mutants. A 
dual-luciferase reporter assay using a psiCHECK-derived reporter vector encoding an HBx 
sequence with mutations in the site targeted by miR-31/5, was performed to assess the 
ability of the LV-delivered monocistronic and polycistronic pri-miR mimics to inhibit viral 
replication of a mutated HBV sequence (Figure 4.7 A & B). While the monocistronic anti-
HBV pri-miR-31/5 sequence was capable of mediating potent inhibition of wild-type HBx 
gene expression, only modest suppression of mutant HBx gene expression was observed in 
cells transfected with the psiCHECK-mHBx vector (Figure 4.7 C). In contrast, LV-
delivered polycistronic pri-miR-31/5-8-9 sequences effectively silenced the expression of 
both wild-type and mutated HBx, indicating that the polycistronic anti-HBV pri-miR 
configuration could be potentially useful in improving effectiveness against viral escape 
mutants. 
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Figure 4.7: Pri-miR-mediated silencing of wild-type HBx and mutant HBx target gene  expression. 
Schematic illustration of the psiCHECK-HBx (A) and psiCHECK-mHBx (B) dual luciferase reporter vectors. psiCHECK-mHBx comprises an 
HBx target sequence with point mutations in the pri-miR-31/5 target site (highlighted in pink), downstream of the Renilla luciferase ORF in 
psiCHECK
TM
-2. (C) Huh7 cells which had been stably transduced with LVTH miR-31/5 or LVTH miR-31/5-8-9 recombinant lentivirus were 
transfected with the psiCHECK-HBx or psiCHECK-mHBx reporter vectors. A dual luciferase reporter gene assay was performed to assess 
knockdown efficiency against the mutated HBx sequence. Data are presented as mean ratios of Renilla to Firefly luciferase activity (±SEM., n=3, 
p < 0.05) and are normalised relative to LVTH-transduced cells. 
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4.6 Evaluation of the knockdown efficacy of the lentiviral vector-
based anti-HBV miR system in stably transduced HepG2.2.15 cells  
To evaluate the knockdown efficacy of LV-delivered polycistronic pri-miR 
sequence in the liver-derived HepG2.2.15 HBV replication cell line, HepG2.2.15 cells 
were stably transduced with LVTH or LVTH miR-31/5-8-9 virus at a MOI of 40. Stable 
integration was confirmed by genomic quantitative PCR analysis and monitoring GFP 
reporter gene expression.  
 
4.6.1 Integrated anti-HBV pri-miR mimics mediate powerful inhibition 
of HBsAg and HBeAg secretion in HepG2.2.15 cells 
To assess the antiviral effects of the polycistronic anti-HBV pri-miR mimic in 
HepG2.2.15 cells, HBsAg and HBeAg secretion in the supernatant of LVTH- and LVTH 
miR-31/5-8-9-transduced cells was measured by a quantitative ELISA at 48, 72 and 96 
hours after an equal number of cells was seeded for each cell population (Figure 4.8). 
Significant inhibition of both HBsAg and HBeAg secretion was observed in LVTH miR-
31/5-8-9-transduced HepG2.2.15 cells. While a similar trend in HBsAg and HBeAg HBV 
knockdown was observed, there was a more marked effect on HBsAg knockdown.  
The LV-delivered pri-miR-31/5-8-9 therapeutic sequence mediated stable 
inhibition of HBsAg and HBeAg secretion in spite of the fast rate of HepG2.2.15 virion 
secretion. It is possible that not all individual cells in the LVTH miR-31/5-8-9-transduced 
population had been stably transduced with the pri-miR-31/5-8-9 encoding LV, which 
could result in an imbalanced virion secretion-miR mediated knockdown rate leading to an 
observation of an underestimated antigen knockdown. 
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Figure 4.8: HBV antigen quantification in HepG2.2.15 culture supernatants. 
Inhibition of HBsAg (A) and HBeAg (B) secretion over a time period of 96 hours was assessed in HepG2.2.15 cells which had been stably 
transduced with LVTH miR-31/5-8-9 LV. HBsAg and HBeAg measurements from quantitative ELISA are given as a normalised mean relative 
to LVTH-transduced cells. Graphs indicate mean ± SEM from three independent experiments, p < 0.05, p < 0.01. 
Chapter 4 
[114] 
 
4.6.2 Integrated anti-HBV pri-miR mimics mediate effective reduction of 
viral particle equivalents in HepG2.2.15 culture supernatants 
Real-time quantitative PCR was performed to quantify HBV DNA in the 
supernatant of LVTH- and LVTH miR-31/5-8-9-transduced cells (Figure 4.9). HBV DNA 
was measured at three different time points (48 hours, 72 hours and 96 hours) to assess the 
antiviral effect of pri-miR-31/5-8-9 over an extended time period. 
A significant reduction in the number of HBV VPEs was observed in HepG2.2.15 
cells which had been transduced with the LVTH pri-miR-31/5-8-9 encoding lentivirus. The 
reduction in VPEs was maintained over the 96 hour time period, indicating that the pri-
miR-31/5-8-9 sequence is capable of mediating stable suppression of HBV replication in a 
cell culture model characterised by particularly high viral replication. These data 
corroborate previously obtained results in HepG2.2.15 and Huh7 cells and highlight the 
antiviral efficacy of the lentiviral vector-based anti-HBV miR system. 
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Figure 4.9: HBV DNA quantification in stably transduced HepG2.2.15 cells. 
HBV viral load was measured in LVTH and LVTH miR-31/5-8-9-transduced HepG2.2.15 cells at 48 hours, 72 hours and 96 hours. HBV DNA 
secreted from stably transduced cells was determined by real-time quantitative PCR using HBV-specific primers (mean  SEM., n=3, p < 0.05). 
Virion copy numbers were determined using EuroHep HBV standards.  
Chapter 4 
[116] 
 
4.7 Conclusion 
The design of transgene expression cassettes intended for incorporation into RNAi-
activating lentiviral vector constructs may influence LV titre as well as expression of the 
therapeutic RNAi molecule. HBV silencing expression cassettes encoding mono- and poly- 
cistronic pri-miR mimics were inserted in the second-generation SIN pLVTH lentiviral 
vector in the forward (sense) orientation without a polyadenylation signal. The pLVTH and 
pLVTH-derived HBV silencing lentiviral vectors were used to propagate VSV-G 
pseudotyped recombinant LV. Significant differences in the titre obtained for pLVTH and 
pLVTH-derived LVs encoding pri-miR mimics were not observed. This could be attributed 
to Drosha saturation in the producer cells and/or RRE-Rev mediated nuclear export of 
unspliced and singly-spliced genomic lentiviral RNA (183, 274). 
Stable transduction of liver-derived Huh7 and HepG2.2.15 cells was achieved using 
the therapeutic LVs and this was evident from the long-term sustained expression of the 
GFP marker transgene in transduced cells. In addition, genomic quantitative PCR analysis 
revealed that the LVTH and LVTH miR 31/5 lentiviruses were integrated at a copy number 
of 1.8 per cell, while LVTH miR-31/5-8-9-transduced cells had 1.2 copies of integrated LV 
per genome. Northern blot analysis of RNA from stably transduced Huh7 cells verified that 
the integrated anti-HBV pri miR sequences were efficiently processed to form RNAi-
activating guide strands according to the intended design. Consistent with previous work 
(159), variation in the amounts of individual guides processed from the integrated 
polycistronic pri-miR-31/5-8-9 scaffold was notable, with the miR-31/5 guide sequence 
being the most abundant sequence present in stably transduced cells. Saturation assays 
revealed that there was limited disruption of endogenous cellular miR function in cells 
which had been stably transduced with HBV silencing LVs, indicating that the therapeutic 
LVs are safe and not likely to induce toxic effects resulting from saturation of the 
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endogenous miR biogenesis pathway. PCR analysis of genomic DNA extracted from Huh7 
cells which had been stably transduced with the polycistronic HBV silencing LV, revealed 
that recombination had not occurred between equivalent sequences in the polycistronic pri-
miR-31/5-8-9 cassette during lentivirus transduction, in contrast to previous reports (183, 
186). The extent of recombination occurring may be influenced by the particular pri-miR 
scaffolds as well as the configuration of polycistron used (185). 
Following demonstration of stable integration and expression of the therapeutic pri-
miR mimics with limited disruption of endogenous miR function, the antiviral efficacy of  
the RNAi-based HBV silencing LVs was evaluated. When stably transduced Huh7 cells 
were transfected with a HBV replication-competent plasmid, potent inhibition of markers 
of viral replication was achieved. In addition, the silencing activity of the individual guide 
sequences corresponded to the quantity of guide sequence detected by Northern blot 
analysis. Assessing silencing of a mutated HBV sequence revealed that the polycistronic 
mTTR-expressed pri-miR-31/5-8-9 sequence has superior silencing activity and could be 
potentially useful in limiting the emergence of viral escape mutants. Finally, powerful 
knockdown of markers of viral replication and circulating VPEs was demonstrated in 
HepG2.2.15 cells which had been stably transduced with a HBV silencing LV encoding 
the polycistronic pri-miR-31/5-8-9 sequence. The profile of HBV replicative intermediates 
in this cell line was found to closely mimic the profile observed in individuals chronically 
infected with the HBV virus (378), making the HepG2.2.15 cell line a stringent system for 
in vitro evaluation of  the efficacy of novel antiviral therapies. 
Thorough characterisation of the HBV silencing LVs in liver-derived Huh7 cells 
and demonstration of potent antiviral efficacy in the HepG2.2.15 HBV replication cell line 
lay the foundation for further in vivo evaluation of our strategy. In the next chapter we set 
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to explore whether the in vitro efficacy of the RNAi-based HBV-silencing LVs can be 
translated to efficient HBV knockdown in an animal model of viral replication. 
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5 COUNTERING VIRAL REPLICATION IN VIVO 
WITH HBV-SILENCING LENTIVIRUSES  
 
5.1 Introduction 
Comprehensive data from in vitro characterisation of the HBV-silencing LVs 
presented in the preceding chapters, has demonstrated potent inhibition of markers of viral 
replication as well as sustained, hepatospecific HBV knockdown with limited off-target 
effects. The above findings prompted further evaluation of the antiviral efficacy of the 
HBV-silencing LVs in vivo.  
Preclinical evaluation of safety and efficacy of the novel antiviral therapeutic 
strategies in appropriate in vivo experimental models, is a fundamental step in the 
development and clinical translation of potential HBV therapeutics. HBV transgenic mice 
contain an integrated replication-competent HBV sequence, consequently viral replication 
in this murine model is constitutive and continues for the duration of the animal’s life 
thereby mimicking chronic HBV infection of humans (345, 379). Accordingly, the HBV 
transgenic mouse model is suitable for rigorous evaluation of the antiviral efficacy of novel 
therapies. 
Inclusion of the Firefly luciferase transgene in recombinant lentiviral vectors 
allows for non-invasive, long-term follow up of transgene expression as well as vector 
persistence in individual animals following LV administration. Although the use of 
reporter transgenes is convenient and useful for the assessment of transduction efficiency 
as well as biodistribution of therapeutic viruses, both Firefly luciferase and eGFP reporter 
genes encoded in the HBV silencing recombinant LVs can induce transgene-specific 
immune responses following systemic administration (380-382). Humoral and cellular 
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antigen-specific immune responses to LV-encoded GFP have been reported to induce 
clearance of transduced cells thus curtailing long-term expression of therapeutic transgenes 
(325).  
Several groups have demonstrated stable transfer of therapeutic sequences to the 
liver following systemic delivery of recombinant LVs (180, 281, 318, 321, 382, 383). 
However, the transduction efficiency of recombinant LVs is influenced by the proliferation 
and cell cycle activation of targeted hepatocytes (320). Transduction following systemic 
delivery of recombinant lentiviruses has been reported to be significantly higher in young 
and newborn rodents as a result of high hepatocyte proliferation (180, 322-324). Highly 
efficient liver transduction and long-term transgene expression has been reported following 
LV delivery via an intravenous injection into the superficial temporal vein in neonatal mice 
(180, 322, 324). Successful transduction when using this approach is not surprising as 
vector genomes increase in number with the proliferating hepatocytes following LV gene 
transfer to neonatal mice. In addition, the immune-system of the newborn animal is not 
fully functional circumventing the induction of an immune response to reporter gene 
products and allowing for sustained expression of the anti-HBV pri-miR molecules. The 
distinct benefits of the above approach deemed it suitable for the delivery of HBV-
silencing LVs and long-term evaluation of antiviral efficacy in the HBV transgenic mouse 
model.  
The aim of the next set of experiments was to evaluate preclinical proof of principle 
of the efficacy of the novel anti-HBV lentiviral vector RNAi-hybrid technology in the 
HBV transgenic mouse model.  
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5.2 The mTTR promoter is capable of driving long-term stable 
transgene expression in vivo 
To evaluate the efficiency and tissue-specificity of the mTTR promoter in vivo, a 
lentiviral vector encoding a mTTR-driven Firefly luciferase transgene (pLNT-mTTR-JDG) 
was generated (Figure 5.1 A). LVs expressing Firefly luciferase under the control of the 
mTTR promoter were administered to neonatal mice via an intravenous injection in the 
superficial temporal vein (Figure 5.1 B). Firefly luciferase expression can be sensitively 
detected in live animals using a bioluminescence imaging system following the 
administration of a substrate for the reporter enzyme. The bioluminescence imaging system 
typically comprises a charge-coupled device camera which captures light photons 
generated upon substrate oxidation (384). Bioluminescence imaging was used to analyse 
Firefly luciferase expression in mice that had received LVs encoding the Firefly luciferase 
transgene. Stable expression was recorded in the livers of imaged animals over a period of 
12 months (Figure 5.2). These data corroborate previous reports demonstrating efficiency 
and functionality of the mTTR promoter in vivo (180, 385, 386) and indicate that the 
mTTR promoter is capable of driving sustained and hepatospecific gene expression, 
making it a valuable accessory for the development of liver-directed gene therapy. 
Chapter 5 
 
[122] 
 
 
Figure 5.1: LNT-mTTR-JDG LV transfer to neonatal HBV transgenic mice. 
(A) Schematic of the pLNT-mTTR-JDG lentiviral vector. The vector comprises a 2A-linked Firefly luciferase-eGFP bicistronic expression 
cassette (FLuc-2A-eGFP) downstream of an internal mTTR promoter. LTR (long terminal repeat), ψ (HIV-1 packaging signal), RRE (rev-
responsive element), attB (synthetic attachment site), cPPT (central polypurine tract), WPRE (woodchuck hepatitis virus posttranscriptional 
regulatory element), SIN 3' LTR (long terminal repeat with a deletion in the U3 region). (B) LV transfer to neonatal HBV transgenic mice via 
intravenous injection into the superficial temporal vein. 
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Figure 5.2: Long-term follow-up of Firefly luciferase expression in LNT-mTTR-JDG 
LV-injected mice. 
(A) Experimental outline. Neonatal HBV transgenic mice received two bilateral superficial 
temporal vein intravenous injections of LNT-mTTR-JDG LV (6 × 10
7
 TU per mouse) 
expressing Firefly luciferase or PBS at day 0 and 1 after birth. Firefly luciferase expression 
was analysed by bioluminescence imaging using the IVIS Kinetic imaging system. (B) 
Images of two LNT-mTTR-JDG LV-injected mice (right) and PBS-injected control 
animals (left) are shown in the top (I) and bottom (II) panels. Mice were imaged at 10 
week intervals for the duration of the study. 
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5.3 pLVTH- and pLVTH miR-31/5-8-9- derived LVs encoding the 
Firefly luciferase transgene mediate stable transgene delivery in 
vivo 
The HBV-silencing lentiviral vector encoding the polycistronic pri-miR molecule, 
selected for in vivo evaluation of viral efficacy, was further modified to include a 2A-
linked Firefly luciferase-eGFP bicistronic expression cassette generating the LVTH-LUC 
miR-31/5-8-9 lentiviral vector (Figure 5.3). The above modification allows for 
simultaneous assessment of transfection efficiency by fluorescence imaging as well as 
delivery efficiency by bioluminescence imaging. Control LVTH-LUC or HBV-silencing 
LVTH-LUC miR-31/5-8-9 LVs were administered to neonatal and adult HBV transgenic 
mice via a superficial temporal vein or tail vein injection respectively. LV administration 
via the tail vein was performed in groups of young adult mice (~ 3 weeks old) to improve 
transduction efficiency. In contrast to neonatal animals, sera of adult animals can be 
collected and analysed before LV administration allowing for convenient monitoring of 
markers of HBV replication in individual mice prior to and after administration of 
therapeutic virus. Bioluminescence imaging was performed to analyse Firefly luciferase 
expression in neonatal and adult mice that had received recombinant LV.  
Stable LV-mediated liver transduction was achieved as evidenced by the variable 
but sustained Firefly luciferase expression observed in the livers of LV-injected animals 
(Figure 5.4 and 5.5). It is likely that the variability in expression between individual mice 
is as a result of the varying efficiency of the superficial temporal vein injection procedure. 
Nevertheless, the level of Firefly luciferase expression was fairly consistent in the livers of 
individual mice for the duration of the study. In several animals transgene expression was 
also evident at the site of LV injection, specifically in the cheek region of animals that 
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received temporal-vein LV injection as well as the tail and hind limbs of mice that received 
LV via their tail-veins (Figure 5.4 and 5.5). LV leakage and subsequent transduction of the 
surrounding tissue is likely to account for the above. Furthermore, the content of vector 
DNA in the livers of LV-injected mice that received recombinant LV was quantified by 
real-time PCR. Average vector DNA levels in the livers of mice that received tail vein 
injection or neonatal superficial temporal vein injection were 0.25 copies per genome and 
0.45 copies per genome respectively, indicating that the LVs are capable of mediating 
efficient transduction of the liver following in vivo administration. 
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Figure 5.3: Schematic of pLVTH-LUC and pLVTH-LUC  miR-31/5-8-9  lentiviral vectors. 
pLVTH-LUC (A) and pLVTH-LUC miR-31/5-8-9 (B) lentiviral vectors were derived from the parental pLVTH and pLVTH miR-31/5-8-9 
plasmids respectively. The vectors encode a 2A-linked Firefly luciferase-eGFP bicistronic expression cassette (FLuc-2A-eGFP) downstream of 
an internal EF1-α promoter. LTR (long terminal repeat), ψ (HIV-1 packaging signal), RRE (rev-responsive element), cPPT (central polypurine 
tract), WPRE (woodchuck hepatitis virus posttranscriptional regulatory element), SIN 3' LTR (long terminal repeat with a deletion in the U3 
region). 
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Figure 5.4: Long-term follow-up of Firefly luciferase expression following LVTH-
LUC and LVTH-LUC miR-31/5-8-9 LV delivery to neonatal HBV transgenic mice. 
Neonatal HBV transgenic mice received a single unilateral injection of LVTH-LUC miR-
31/5-8-9 (N1-N4) or LVTH-LUC (N5-N7) LV (2.7 × 10
8
 TU per mouse) into the 
superficial temporal vein. Firefly luciferase expression was analysed by bioluminescence 
imaging using the IVIS Kinetic imaging system. Bioluminescence images from LVTH 
miR-31/5-8-9- (A) and LVTH-injected (B) mice imaged at 2 week intervals for a period of 
12 weeks are shown. 
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Figure 5.5: Bioluminescence imaging of Firefly luciferase expression following 
systemic LV delivery to adult HBV transgenic mice. 
LVTH-LUC miR-31/5-8-9 (A1-A4) or LVTH-LUC (A5-A7) LV (8.5 × 10
8
 TU per mouse) 
was delivered to adult HBV transgenic mice via tail vein injection. Firefly luciferase 
expression was analysed by bioluminescence imaging using the IVIS Kinetic imaging 
system. Bioluminescence images from LVTH miR-31/5-8-9- (A) and LVTH-injected (B) 
mice imaged at 2 week intervals are shown. 
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5.4 The LVTH-LUC miR-31/5-8-9 LV silences HBV replication in 
vivo  
To determine the antiviral efficacy of the LVTH-LUC miR-31/5-8-9 LV following 
in vivo administration to neonatal and adult HBV transgenic mice, the concentration of 
HBsAg was analysed in sera of LV-injected animals. Significant reduction of serum 
HBsAg was achieved in animals that received neonatal temporal vein or adult tail vein 
injection of LV expressing the polycistronic pri-miR-31/5-8-9 molecule compared to mice 
injected with control LVTH LV (Figure 5.6 A and 5.7 A).  
While long-term stable inhibition of HBsAg secretion was maintained until the end 
point of the study in neonatal mice that received a temporal vein injection (Figure 5.6 A), 
only a transient inhibition of HBV replication was observed in mice that received the 
HBV-silencing LV systemically (Figure 5.7 A). Similarly, quantitative real-time PCR 
analysis of circulating VPEs revealed sustained long-term reduction in the level of serum 
HBV DNA in the neonatal cohort that received the anti-HBV LV via the temporal vein 
(Figure 5.6 B) compared to the short-term attenuation of viral replication observed in tail-
vein injected adult HBV transgenic animals (Figure 5.7 B). Inhibition of HBsAg secretion 
and circulating VPEs in adult tail vein-injected mice was apparent over the first four weeks 
after systemic LV administration (Figure 5.7). Significant inhibition of markers of viral 
replication, observed at weeks 2, 3 and 4 following LV delivery was followed by a rapid 
increase in HBsAg levels and circulating virion counts (Figure 5.7 A; A4) as well as a 
sudden diminution in the level of reporter transgene expression (Figure 5.5 A; A4).  
The above observation was not unexpected and is consistent with reports of limited 
LV expression as a result of the development of transgene product-specific immune 
responses and clearance of transduced cells following systemic LV administration in 
immunocompetent mice (382, 387, 388). Typically, widespread LV transduction can be 
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observed in the liver, bone marrow and spleen, after systemic LV administration (319). De 
novo expression of proteins in LV-transduced cells results in antigen presentation by 
professional APCs (Kupffer cells, dendritic cells) and non-professional APCs (liver 
sinusoidal endothelial cells) subsequently initiating a transgene product-specific immune 
response and elimination of transduced cells (382, 389). The HBV-silencing LV expresses 
both GFP and Firefly luciferase transgenes from an internal constitutive EF1-α promoter. 
It is likely that presentation of the GFP and Firefly luciferase antigens by hepatocytes and 
liver APCs or expression of these proteins in LV-transduced haematopoietic APCs (281) 
initiated the development of an immune response and subsequent elimination of LV-
transduced cells in the liver.  
In conclusion, the neonatal temporal vein injection was demonstrated to be a 
suitable approach for the evaluation of long-term antiviral efficacy of the HBV-silencing 
LVs. Data generated from the neonatal temporal injection model show that the HBV-
silencing LVTH-LUC miR-31/5-8-9 LV is capable of mediating stable delivery of 
therapeutic anti-HBV pri-miR molecules and sustained silencing of viral replication in an 
in vivo model that simulates chronic HBV replication.  
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Figure 5.6: Evaluation of long-term effects of HBV-silencing LV on HBsAg production and circulating viral particle equivalents in vivo. 
One day-old HBV transgenic mice received LVTH-LUC or LVTH-LUC miR-31/5-8-9 LV (2.7 × 10
7
 TU per mouse) intravenously via a 
temporal vein injection. Twenty one days later, blood samples were collected from all animals at two week intervals (time points are indicated by 
pink arrows) and analysed by quantitative HBsAg ELISA (A) and real-time quantitative PCR (B). A time course of relative serum HBsAg 
concentrations (A) and viral loads (B) is shown (mean  SEM., n3, p < 0.05). EuroHep standards were used to determine virion copy numbers. 
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Figure 5.7: Assessment of the effects of HBV-silencing LV on HBsAg production and circulating viral particle equivalents after LV 
administration to adult HBV transgenic mice. 
LVTH-LUC or LVTH-LUC miR-31/5-8-9 LV (2.5 × 10
8
 TU per mouse) were delivered to adult HBV transgenic mice via a tail-vein injection. 
Blood samples were collected from all animals at two week intervals (time points are indicated by pink arrows) and analysed by quantitative 
HBsAg ELISA (A) and real-time quantitative PCR (B). A time course of relative serum HBsAg concentrations (A) and viral loads (B) is shown 
(mean  SEM., n3, p < 0.05). Data points were normalised relative to baseline HBsAg and viral load values obtained 2 days before LV 
administration. EuroHep standards were used to determine virion copy numbers. 
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5.5 LV-delivered polycistronic pri-miR sequences mediate 
intrahepatic knockdown of HBV gene expression 
Following demonstration of knockdown of HBV gene expression at protein and 
DNA levels in vivo, the effects of the HBV-silencing LV encoding the polycistronic pri-
miR-31/5-8-9 mimic on viral RNA levels in the liver of transgenic animals were assessed 
by a quantitative reverse transcriptase PCR.  
A considerable reduction in intrahepatic HBV surface mRNA concentration 
relative to GAPDH mRNA was observed in transgenic mice that had received anti-HBV 
LV via a temporal vein or adult tail-vein injection compared to control injected mice 
(Figure 5.8 B and 5.9 B). However, the concentration of core HBV mRNA in both 
neonatal and adult HBV transgenic animals that received therapeutic LVTH-LUC miR-
31/5-8-9 LV was not significantly diminished when compared to the LVTH-injected 
mouse cohort (Figure 5.8 A and 5.9 A). The above is consistent with the findings of a 
previously published report evaluating the efficacy of RNAi-based anti-HBV gene therapy 
in the HBV transgenic mouse model (157). Uprichard and colleagues observed that despite 
effective shRNA-mediated knockdown of HBV replication, the 3.5 kb pregenomic HBV 
mRNA transcript, encoding the core sequence, appeared to be more resistant to RNAi-
mediated degradation. Nonetheless, the above findings indicate that the HBV-silencing LV 
encoding the polycistronic pri-miR-31/5-8-9 sequence mediates considerable intrahepatic 
knockdown of HBV gene expression and the degree of RNA inhibition achieved is 
sufficient to effect significant knockdown of HBV replication in vivo. 
Chapter 5 
 
[134] 
 
 
 
 
Figure 5.8: Concentration of core and surface HBV mRNA in the livers of temporal vein LV-injected HBV transgenic mice. 
Total RNA was isolated at necropsy from the livers of HBV transgenic mice which had been injected with LVTH-LUC or LVTH-LUC miR-
31/5-8-9 LV via the temporal vein. The concentration of core and surface HBV mRNA was determined by a quantitative reverse transcriptase 
PCR. Average core and surface mRNA levels relative to GAPDH mRNA from individual mice are shown (mean  SEM., n3, p < 0.05). ns 
(not significant). 
Chapter 5 
 
[135] 
 
 
 
Figure 5.9: Concentration of core and surface HBV mRNA in the livers of tail vein LV-injected HBV transgenic mice. 
Total RNA was isolated at necropsy from the livers of HBV transgenic mice which had been injected with LVTH-LUC or LVTH-LUC miR-
31/5-8-9 LV via the tail-vein and subjected to quantitative reverse transcriptase PCR to determine the concentration of core and surface HBV 
mRNA. Ratios of the levels of core and surface mRNA normalised to GAPDH mRNA from individual mice are shown (mean  SEM., n=3, p < 
0.05). ns (not significant). 
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5.6 HBV-silencing lentiviruses do not induce hepatotoxicity  
To determine whether LVTH-derived LVs induce toxic responses in the liver 
following intravenous administration, ALT levels were analysed in sera collected from 
HBV transgenic animals that had received LVTH-LUC and LVTH-LUC miR-31/5-8-9 LV 
via a tail vein or superficial temporal vein injection. Serum ALT levels in mice that had 
received LV via a temporal vein injection were within the normal range at necropsy (Table 
5.1) indicating that the LVs did not cause chronic hepatotoxicity. Similarly, ALT levels in 
adult HBV transgenic mice that received LVTH-LUC and LVTH-LUC miR-31/5-8-9 LV 
via a tail-vein injection were not raised following LV administration or at necropsy except 
for a minor increase observed in a single mouse (A1) (Table 5.1).  
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Table 5.1: Alanine transaminase (U/L) in sera of HBV transgenic mice that received 
LV intravenously. 
 
Mouse ID 
 
LV
1
 
 
ALT 
48 hours 
 
ALT * 
1 week 
 
ALT  
at necropsy 
N1 LVTH-LUC miR-31/5-8-9 
 
- - 34 
N2 LVTH-LUC miR-31/5-8-9 
 
- - 34 
N3 LVTH-LUC miR-31/5-8-9 
 
- - 58 
N4 LVTH-LUC miR-31/5-8-9 
 
- - 46 
N5 LVTH-LUC 
 
- - 70 
N6 LVTH-LUC 
 
- - 56 
N7 LVTH-LUC 
 
- - 50 
A1
1
 LVTH-LUC miR-31/5-8-9 
 
48 75 124 
A2 LVTH-LUC miR-31/5-8-9 
 
48 66 64 
A3 LVTH-LUC miR-31/5-8-9 
 
40 64 86 
A4 LVTH-LUC miR-31/5-8-9 
 
52 60 54 
A5 LVTH-LUC 
 
40 48 42 
A6 LVTH-LUC 
 
60 64 72 
A7 LVTH-LUC 
 
66 44 56 
 
1 HBV transgenic mice received LVTH-LUC and LVTH-LUC miR-31/5-8-9 LV via an 
intravenous temporal (N1-N7) or tail- vein (A1-A7) injection.  
* ALT values below100 (U/L) are considered normal for laboratory mice. 
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5.7 The polycistronic pri-miR-31/5-8-9 sequence is efficiently 
processed in the livers of LV-injected mice  
To verify that the LV-delivered polycistronic miR sequence is being processed 
according to the intended design, total RNA extracted from mouse livers at necropsy was 
analysed by a two step reverse-transcriptase real-time PCR assay (Illustrated in Section 
2.11.10) for the presence of the putative mature miR-31/5 guide sequences of pri-miR-
31/5-8-9. Young adult mice that received LV via tail vein injection were sacrificed prior to 
induction of immune-mediated clearance of LV-transduced cells (A1-A3). Expression of 
the mature guide sequence was normalised to an endogenous U6 snRNA control, to correct 
for variation in the amount of RNA in the different samples. Mature miR-31/5 guide 
sequence was detected in the livers of HBV transgenic mice that received the LVTH-LUC 
miR-31/5-8-9 LV via a temporal or tail vein injection and was undetectable in the livers of 
mice that received LVTH-LUC LV (Table 5.2).  
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Table 5.2: Detection of mature miR-31/5 sequence in liver tissue of LV-injected HBV 
transgenic mice. 
 
Mouse ID 
Average Ct  
miR-31/5 
Average Ct  
U6 snRNA 
Ct 
(Ct U6 snRNA-Ct miR-31/5) 
N1-N4
1
 19.65 21.41 1.76 
N5-N7
2
 - 21.62 - 
A1-A3
1
 21.17 21.68 0.51 
A5-A7
2
 - 21.96 - 
 
1 HBV transgenic mice that had received LVTH-LUC miR-31/5-8-9 LV via a temporal 
vein (N1-N4) or tail-vein (A1-A3) injection. 
2 HBV transgenic mice that had received LVTH-LUC LV via a temporal (N5-N7) or tail-
vein (A5-A7) injection. 
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5.8 Conclusion 
Preclinical proof of principle of the efficacy of the novel RNAi-based lentiviral 
vector system was determined by administration of HBV silencing LVs in transgenic mice. 
Incorporation of the Firefly luciferase transgene in previously characterised HBV-silencing 
lentiviral vectors (Chapter 4) allowed for convenient assessment of transduction efficiency 
and stable expression of integrated sequences in live animals. The mTTR promoter, 
selected to drive expression of anti-HBV pri-miR mimics, was demonstrated to mediate 
stable expression of the Firefly luciferase transgene over a period of 12 months (study end 
point). These data validate previous reports demonstrating efficiency and functionality of 
the mTTR promoter in vivo (180, 385, 386) and indicate that the mTTR promoter is 
capable of driving sustained and hepatospecific gene expression. Hence, the mTTR 
promoter sequence is a suitable alternative to other Pol II promoters and can be utilised to 
accomplish controllable and liver-specific expression of therapeutic RNAi effecters. 
Efficient transduction of the liver was accomplished following LV delivery to 
young adult (via tail vein injection) and neonatal (via superficial temporal vein injection) 
HBV transgenic mice, evidenced by robust expression of Firefly luciferase in both animals 
cohorts. Importantly long-term sustained inhibition of markers of viral replication and 
circulating virion counts was observed in animal cohorts that received the HBV-silencing 
LV via temporal vein injection. In contrast, a sudden diminution in the level of reporter 
transgene expression accompanied by an increase in HBsAg serum levels as well as an 
increase in circulating VPEs was observed in transgenic mice subjected to systemic tail-
vein LV delivery. The above observation was not unexpected and is consistent with reports 
of limited LV expression as a result of the development of transgene product-specific 
immune responses and clearance of transduced cells following systemic LV administration 
in immunocompetent mice(390). Nevertheless, even though the inclusion of GFP and 
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Firefly luciferase transgenes in the HBV-silencing LV facilitated convenient monitoring of 
LV transduction and expression, exclusion of the GFP-2A-Firelfy luciferase expression 
cassette will not have any consequences on the therapeutic efficacy of the approach. 
Importantly, the inclusion of liver-specific transcription regulatory elements in our 
therapeutic LV should preclude expression of the polycistronic pri-miR mimic in non-
hepatic cells including APCs, largely improving the overall efficacy and safety of the 
HBV-silencing LV. 
Data presented in this chapter demonstrate that the RNAi-based HBV-silencing LV 
is capable of mediating stable hepatic delivery and sustained expression of anti-HBV pri-
miR sequences in vivo. Furthermore, the therapeutic sequences are processed according to 
the intended design and mediate powerful knockdown of markers of viral replication, 
circulating VPEs and intrahepatic viral RNA without inducing hepatotoxicity. To our 
knowledge this is the first demonstration of stable inhibition of viral replication in HBV 
transgenic mice using a LV that encodes an antiviral liver-specific polycistronic pri-miR 
sequence. 
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6 DISCUSSION  
Over the past decade, the therapeutic potential of harnessing the RNAi pathway to 
achieve specific and potent silencing of pathology-causing genes has been widely explored 
(reviewed in (148, 391)). The field has been progressing with incredible speed and 
continual advancements have renewed enthusiasm for the development of novel and 
improved treatments for many diseases with limited treatment options, including chronic 
HBV infection. Persistent infection with HBV remains an important public health problem 
as the risk for development of serious life-threatening complications such as cirrhosis and 
HCC is significantly increased in chronic HBV carriers (40). HCC is the sixth most 
common cancer globally (35) and this aggressive malignancy has very poor prognosis (40). 
The efficacy of currently available therapies for chronic HBV infection is variable and 
long-term treatment using these agents is associated with the development of unwanted 
side effects as well as the emergence of resistance. Improved barrier to resistance and 
potent suppression of viral replication has been reported with some of the newer 
nucleoside/nucleotide analogues, such as entecavir and tenofovir (392, 393), nevertheless 
cessation of treatment results in recurrence of viral replication. This is as a result of the 
inability of this class of therapeutic agents to induce eradication of nuclear cccDNA from 
infected hepatocytes (394). Persistence of the episomal cccDNA minichromosome (17) 
allows for continual transcription of all HBV mRNA transcripts as well as pgRNA which 
serves as a template for reverse transcription perpetuating viral replication (341). Another 
shortcoming of nucleoside/nucleotide inhibitors is their limited ability to lessen the high 
HBV antigen load typically seen in chronic HBV infection (395). High antigenaemia in 
chronically infected individuals is likely to contribute to the development immunotolerance 
as well as chronic inflammation allowing for persistence of infected hepatocytes and 
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stimulating the development of a microenvironment that favours malignant transformation 
(34, 43). Nevertheless, the risk of developing HCC remains unchanged in the majority of 
chronic carriers receiving treatment and this is perhaps the most significant limitation of 
currently licensed therapies for HBV. Translation of the success observed using anti-HBV 
RNAi-based gene therapy in preclinical studies (153, 156, 157, 159, 160) could potentially 
provide the long-awaited novel and improved therapy for the approximately 350 million 
individuals worldwide that have been infected with HBV and progressed to chronicity (23)  
HBV is amenable to direct RNAi-mediated silencing as the viral replication cycle 
involves the use of an RNA replication intermediate. The compact arrangement of the 
HBV genome limits the ability of the virus to mutate. In addition, all major HBV viral 
transcripts terminate at a common 3' end, allowing for simultaneous silencing of multiple 
HBV transcripts with a single RNAi effecter. The availability of a novel and potent 
silencing technology that could potentially be effective in overcoming some of the major 
limitations of currently licensed treatments for chronic HBV infection, spurred renewed 
enthusiasm for the development of anti-HBV RNAi-based gene therapy.  
 An abundance of preclinical studies has demonstrated the utility of highly effective 
expressed RNAi-based effecters to accomplish impressive silencing of HBV gene 
expression in vitro and in vivo (153, 156, 157, 159, 160). Nevertheless, rigorous preclinical 
testing of the efficacy of anti-HBV RNAi-based expression systems, revealed that several 
hurdles remain to be overcome before this novel technology can live up to its potential in a 
clinical setting. These include, optimisation of RNAi effecters to avoid unwanted toxicity 
(arising from immunostimulation, off-target silencing of cellular genes as well as 
saturation of the endogenous miR biogenesis pathway), accomplishing efficient delivery of 
RNAi effecters to the liver as well as the development of improved, suitable disease 
models for comprehensive testing of the efficacy of RNAi-based strategies.  
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Successful treatment of persistent HBV infection with RNAi-based therapy will necessitate 
long-term, sustained expression of active therapeutic effecters to counter chronic viral 
replication. Expressed RNAi effecters have the useful property of sustained production 
from a stable DNA template, making these silencing molecules better suited to treatment of 
chronic HBV infection than use of unmodified siRNAs. Initially, expression of shRNA 
sequences from U6 or H1 Pol III promoters (161, 396) was extensively applied as a means 
of activating RNAi to cause powerful silencing of HBV replication in vitro and in vivo 
(153, 156-158). Subsequently, Grimm and colleagues demonstrated that strong, U6-driven 
expression of these types of sequences, especially of shRNAs, resulted in severe toxicity in 
vivo and fatality as a consequence of saturating components of the RNAi pathway (165, 
166). These studies highlighted the need to optimise the safety and efficacy of expressed 
anti-HBV RNAi effecters to allow for clinical advancement of this novel technology. 
Expressed RNAi-activating anti-HBV sequences should be capable of effecting potent 
knockdown of HBV gene expression when expressed at a low level. In addition, mature 
miR guide strands processed from these therapeutic effecter should be designed such that 
their incorporation into RISC is favoured to ensure specific and intended silencing. 
Concerted efforts to optimise RNAi expression cassettes led to the development of highly 
sophisticated and effective, Pol II-based expression systems encoding effecters that mimic 
naturally occurring pri- or pre- miRs and exhibit highly potent silencing activity (127, 159, 
160, 182). Use of Pol II promoters to express silencing sequences allows for greater control 
over the dose of expressed effecters as well as for tissue-specific and/or inducible 
expression.  
Expressed pri-miR mimics, derived from natural pri-miR-31 and engineered to 
generate anti-HBV RNAi guide sequences targeting single (monocistronic pri-miR 
sequences) or multiple (polycistronic pri-miR sequences) sites within the HBx ORF of the 
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viral genome have been developed in our laboratory (159, 160). Targeting of the highly 
conserved multifunctional HBx sequence (47, 190, 191) that shares sequence homology 
with all HBV viral transcripts enables simultaneous and potent knockdown of all HBV 
mRNAs. These silencing sequences have been demonstrated to be capable of mediating 
efficient, potent and safe knockdown of viral replication in vitro and in vivo. Nevertheless, 
accomplishing safe and efficient hepatic delivery of antiviral RNAi effecters remains the 
greatest challenge impeding the clinical translation of RNAi-based anti-HBV gene therapy.  
Successful clinical application of RNAi-based anti-HBV therapy will depend on the 
availability of an efficient delivery system capable of mediating stable delivery to 
hepatocytes and sustained, long-term expression of the therapeutic effecters. Viral vector-
mediated delivery allows for long-term expression of therapeutic genes, making this 
delivery method suited to countering persistent HBV infection. The use of viral vectors is a 
potentially effective and clinically relevant strategy (http://www.wiley.com//legacy/ 
wileychi/genmed/clinical/, accessed 12 March 12) for in vivo delivery of expressed RNAi 
activators. Adenoviral (157, 158, 397, 398) and adeno-associated viral (165, 167) vectors 
have been exploited to achieve efficient hepatic delivery and sustained expression of RNAi 
effecters following systemic administration. Nevertheless, to accomplish durable silencing 
of persistent HBV infection, long-term and perhaps indefinite expression of therapeutic 
RNAi effects, which is not attainable with the existing Ad and AAV vectors, is likely to be 
required. Recombinant adenoviruses are highly immunogenic and are known to induce 
potent innate and adaptive immune response after systemic administration (205-209). 
Sadly the highly immunogenic nature of adenoviruses led to the first reported death of a 
patient in a gene therapy clinical trial, following an intravenous, high-dose administration 
of recombinant adenovirus (210). A number of strategies has been employed since to 
improve the safety and efficacy of Ad vectors (reviewed in (399)). HDAd vectors have 
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been developed that are devoid of sequences encoding viral proteins and allow for 
sustained transgene expression (196, 214). Importantly, PEGylation of recombinant Ads as 
well as HDAds attenuates vector immunogenicity (219, 400, 401) and may further 
attenuate immunostimulation. Nevertheless technical considerations limit the large-scale 
propagation of pegylated Ads for clinical use. Although, recombinant AAV vectors have a 
considerably improved safety profile compared to Ad vectors (reviewed in (402)), 
accomplishing sustained expression of therapeutic genes using these vectors has proven to 
be a challenging task. Data from a recent clinical trial, using AAV vectors for the treatment 
of haemophilia, demonstrated that long-term transgene expression was precluded following 
the induction of an adaptive immune response and clearance of transduced cells (243, 244). 
Further improvement of AAV vectors (245, 246) can potentially overcome some of the 
existing challenges and enable long-term, durable transgene expression. 
Recombinant lentiviral vectors derived from HIV-1 (251), have emerged as 
versatile and efficient transfer tools as a consequence of their unique ability to mediate 
stable transduction of dividing and non-dividing cells which allows for long-term and 
potentially indefinite gene expression. The transduction efficiency of recombinant LVs is 
enhanced when the virus is delivered to cells in the G1 phase of the cell cycle (320). While 
the majority of hepatocytes in a healthy adult liver are quiescent, lentivirus transduction is 
likely to be facilitated in the chronically infected liver where cell division is occurring as a 
result of HBV-induced chronic inflammation, cirrhosis and/or HCC (403, 404). These 
properties make recombinant LVs advantageous for gene transfer of expressed RNAi anti-
HBV sequences to infected hepatocytes and for accomplishing the long-term sustained 
silencing of HBV gene expression necessary to counter chronic HBV.  
Although accomplishing stable integration is useful to achieve durable silencing, 
lentiviral integration can result in genotoxicity. SIN lentiviral vectors have considerably 
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improved safety profiles in comparison to γ-retroviral vectors (257, 299, 300), however the 
ability of these vectors to cause insertional mutagenesis is not completely abolished and it 
is subject to ongoing investigations (268). Nevertheless, lentivirus-mediated insertional 
mutagenesis involving proto-oncogene activation has not been reported in ongoing clinical 
trials based on ex-vivo modification of HSC (308-311). Unlike hematopoietic systems 
where there is clonal expansion of individual LV-modified progenitor cells (250), liver 
regeneration involves generalised proliferation of residual hepatocytes (reviewed in (405)) 
thus clonal expansion of LV-modified hepatocytes is less likely to occur. 
To advance potential clinical application of RNAi-based anti-HBV gene therapy, 
an original strategy was designed and evaluated in vitro and in an animal model of HBV 
replication. The novel strategy is based on the use of second generation, SIN lentiviral 
vectors with LoxP-containing LTRs to deliver potent and liver-specific HBV silencing pri-
miR-31 mimics to infected hepatocytes while allowing for conditional ablation of 
transduced hepatocytes. This novel therapeutic approach aims to overcome concerns of 
LV-induced insertional mutagenesis and enable sustained and/or potentially indefinite 
knockdown of HBV gene expression to counter and possibly eradicate persistent viral 
infection. 
Targeting expression of therapeutic transgenes to hepatocytes is an important 
method that can be exploited to achieve hepatospecificity of liver directed RNAi-based LV 
gene therapy. The incorporation of liver-specific promoters (179, 180) to limit expression 
of therapeutic genes to hepatocytes allows for efficient liver-specific expression while 
avoiding unintended off-target effects in non-targeted tissues and the induction of an 
immune repose by LV-transduced APCs (382). To generate liver-specific HBV silencing 
pri-miR mimics and optimise compatibility with the pLVTH lentiviral vector, the 
promiscuous CMV promoter, used to drive expression of previously characterised, mono- 
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and poly- cistronic pri-miR mimics (160, 406), was replaced with the mTTR enhancer-
promoter sequence (180). Importantly, the constitutively active CMV promoter has been 
reported to affect viral titres negatively when used to control miR expression in the context 
of lentiviral vectors (329) and shutdown of CMV promoter activity in the murine liver has 
been reported (176, 177). Thus the use of tissue-specific Pol II promoters is a more suitable 
alternative. 
Evaluation of the functionality and tissue-specificity of the mTTR enhancer-
promoter sequence, revealed that the promoter is capable of driving robust and tissue-
specific expression of the Firefly luciferase transgene in liver-derived Huh7 cells. 
Moreover, similarly to their CMV promoter counterparts, the monocistronic and 
polycistronic pri-miR mimics expressed from the liver-specific mTTR promoter were 
equally capable of mediating efficient knockdown of HBV gene expression. Furthermore, 
the mTTR promoter mediated stable and long-term ( 12 months) expression of the Firefly 
luciferase transgene in HBV transgenic mice that received Firefly luciferase-expressing 
LV via a neonatal superficial temporal vein injection. These data corroborate previous 
reports demonstrating capability of the mTTR promoter to drive sustained gene expression 
in vivo (180, 385, 386), and indicate that the mTTR promoter sequence can be exploited to 
accomplish controllable and liver-specific expression of therapeutic RNAi effecters. In 
addition, a recent study has demonstrated that moderate internal promoters in the context 
of SIN lentiviral vectors, are less likely to induce insertional mutagenesis by enhancer-
mediated activation of oncogenes in comparison to strong enhancer-promoter sequences 
(268).  
Following demonstration of functionality and antiviral efficacy of the liver-specific 
mono- and poly- cistronic pri-miR mimics, the HBV silencing expression cassettes were 
incorporated into second generation SIN pLVTH lentiviral vectors. Molecular engineering 
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of the HBV silencing lentiviral vectors involved meticulous design to ensure the generation 
of functional and effective therapeutic constructs that are suitable for potential clinical 
application. The mTTR pri-miR-encoding expression cassettes were inserted in the 
lentiviral vector in the sense orientation, with respect to the lentiviral genome, to ensure 
efficient expression of anti-HBV miR sequences. An internal polyadenylation signal, 
downstream of the liver-specific pri-miR expression cassettes was not included to prevent 
premature termination of the full length viral RNA genomic transcripts and the consequent 
reduction in viral titre (365). Assessment of antiviral efficacy of the liver-specific 
monocistronic and polycistronic pri-miR mimics in the context of the pLVTH lentiviral 
vector indicated that design of the HBV silencing lentiviral vectors was functional and 
efficient. It is likely that the polyadenylation signal in the viral 3' LTR contributes to 
improved stability of pri-miR transcript produced from the liver-specific anti-HBV pri-miR 
cassette, resulting in robust expression of mature miR sequences 
The functionality of the novel anti-HBV RNAi-based lentiviral vectors was further 
validated following the propagation of VSV-G pseudotyped HBV silencing LVs. Previous 
reports indicated that Drosha-mediated recognition and processing of the pri-miR 
sequences present in the sense orientation of the genomic RNA transcript can negatively 
affect viral titre (329). However, a significant difference in viral titres of LVTH and 
LVTH-derived HBV silencing LVs was not observed. The above observations indicated 
that the design of the RNAi-based lentiviral vectors is functional and that these vectors are 
amenable to large-scale production. The absence of a negative effect on viral titre by 
Drosha-mediated processing of lentiviral vector-encoded miR sequences could be 
attributed to: 1) Drosha saturation, as numerous genomic RNA transcripts containing  pri-
miR sequences are being continually generated in producer cells and 2) effective nuclear 
export of unspliced and singly-spliced genomic lentiviral RNA, mediated by the Rev 
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protein interacting with the RRE sequence encoded in the genomic lentiviral transcript 
(183, 274). A nuclear export complex comprising RRE-containing lentiviral RNA, Rev and 
the CRM1 nuclear export factor is formed co-transcriptionaly and is likely to mediate 
evasion of Drosha recognition and processing of the pri-miR sequence (407).  
The HBV silencing lentiviruses stably transduced liver-derived Huh7 and 
HepG2.2.15 cells. Northern blot analysis of RNA from stably transduced Huh7 cells 
verified that the integrated anti-HBV pri miR sequences were processed to form RNAi-
activating guide strands according to the intended design. The pri-miR sequences were 
efficiently processed as unprocessed precursors (pri and pre- miR transcripts) were not 
detectable. This is in contrast to shRNA expression systems which often yield large 
amounts of unprocessed precursors and cause saturation of the endogenous miR biogenesis 
pathway, inducing severe toxicity in vivo (127, 165). Saturation assays revealed that there 
was limited disruption of endogenous miR function in cells which had been stably 
transduced with HBV silencing LVs, indicating that expression of integrated liver-specific 
pri-miR sequences is not likely to induce saturation of components of the endogenous miR 
biogenesis pathway and unintended toxic effects. PCR analysis of genomic DNA extracted 
from Huh7 cells, which had been stably transduced with the polycistronic HBV silencing 
LV, showed a lack of evidence for major recombination-mediated deletion of repeated 
sequences in the pri-miR-31 scaffold, in contrast to previous reports (183, 186). The extent 
of recombination occurring may be related to particular pri-miR scaffolds used as well as 
the number of miR effecters within the polycistron (185). It is likely that there is low 
frequency of recombination-mediated deletion when a polycistronic pri-miR-31 sequence 
encoding three miR effecters is used. Nevertheless, extrapolation of results obtained for a 
multi-targeted anti-HIV RNAi approach indicates that an effective anti-HBV RNAi-based 
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multi-targeted approach is not likely to necessitate simultaneous expression of more than 
three miR effecters (182).  
Potent knockdown of HBsAg, a marker of HBV replication, was observed when a 
HBV-replication competent plasmid was transfected in LVTH-, LVTH miR-31/5- and 
LVTH miR-31/5-8-9- transduced Huh7 cells. Furthermore, a dual luciferase reporter assay 
demonstrated that effective knockdown of HBV gene expression was mediated by all three 
miR effecter sequences in Huh7 cells which had been stably transduced with LVTH- and 
LVTH-derived HBV silencing LVs. Nevertheless, knockdown potency corresponded to the 
quantity of guide sequence detected by Northern blot analysis, with the miR-31/5 guide 
sequence being most effective at silencing gene expression. Assessment of the ability of 
the LV-delivered liver-specific monocistronic and polycistronic pri-miR mimics to inhibit 
viral replication of a mutated HBV sequence revealed that only the polycistronic pri-miR-
31/5-8-9 sequence was capable of silencing the expression of both a wild-type and mutated 
HBx sequence. These observations are likely to be the result of additive knockdown effects 
arising from simultaneous expression of several active anti-HBV pri-miR molecules and 
possibly enhanced processing of the polycistronic pri-miR transcript (408). The use of a 
multitargeted RNAi approach is likely to be beneficial in limiting the emergence of viral 
escape mutants and allow for improved barrier to the emergence of resistance in a clinical 
setting.  
As the polycistronic anti-HBV, liver-specific pri-miR sequence was shown to have 
superior efficacy to the monocistronic pri-miR sequence, further evaluation of antiviral 
efficacy was carried out using LVs expresing the polycistronic pri-miR mimic. Powerful 
knockdown of markers of viral replication and circulating VPEs was demonstrated in 
LVTH miR-31/5-transduced HepG2.2.15 cells. Rigorous evaluation of the anti-HBV 
efficacy of the polycistronic silencing LV in the HepG2.2.15 HBV replication cell line 
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(378) and demonstration of potent antiviral activity augured well for further in vivo 
evaluation of the novel RNAi-based lentiviral vector HBV silencing strategy.  
Preclinical analysis of the efficacy of the RNAi-based lentiviral vector system was 
assessed using the HBV transgenic mouse model which is well suited for rigorous 
evaluation of the antiviral efficacy of novel therapies (345, 379). LVTH- and LVTH-
derived HBV silencing LVs encoding a liver-specific polycistronic pri-miR 31/5-8-9 
sequence, were delivered to young adult animals (~3 weeks old) via a tail-vein injection as 
well as to neonatal mice via a superficial temporal vein injection. Both LVTH and LVTH 
miR-31/5-8-9 LV were modified to encode the bicistronic 2A-linked Firefly luciferase-
eGFP expression cassettes placed under the control of an internal EF1-α promoter.  
Lentiviral transduction following systemic delivery of recombinant lentivirus has 
been reported to be significantly higher in young and newborn rodents (180, 322-324). 
Thus, the aforementioned LV delivery methods were exploited to allow for optimal 
assessment of the antiviral efficacy of the HBV silencing RNAi-based lentiviral vector 
therapy. Robust expression of Firefly luciferase in both animal cohorts indicated that 
efficient liver transduction was accomplished following systemic LV delivery to young 
adult and neonatal HBV transgenic mice. Nevertheless, genomic qPCR analysis revealed 
that significantly higher transduction efficiency was accomplished when the LVs were 
delivered to neonatal mice. Reduction of serum HBsAg and HBV DNA was significant in 
animals that received neonatal temporal vein or adult tail vein injection of LV expressing 
the polycistronic pri-miR-31/5-8-9 molecule when compared to mice injected with control 
LVTH LV. In addition to knockdown of HBV gene expression at protein and DNA levels 
in vivo, a significant reduction in the concentration of intrahepatic HBV surface mRNA 
was mediated following LV-delivered polycistronic pri-miR sequences. While long-term, 
sustained inhibition of HBsAg secretion and circulating VPEs was observed over a 12 
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week period (study end point) in mice that received HBV silencing LV via  temporal vein 
injection, only short-term attenuation of HBV replication (~4 weeks) was observed in mice 
subjected to systemic tail-vein LV delivery.  
The transient inhibition of HBV replication observed in transgenic mice to which 
LV was delivered via the tail vein is likely to have resulted from the induction of a specific 
immune response to GFP and/or Firefly luciferase transgenes expressed by the internal 
EF1-α promoter (380, 381). Development of transgene product-specific immune responses 
and clearance of transduced cells following systemic LV administration in 
immunocompetent mice has been previously reported (390). Induction of a transgene-
specific immune response was not observed in neonatal mice that received LV via a 
superficial temporal vein injection as the immune-system of these newborn animals was 
not fully functional at the time of LV administration and the response to foreign antigens 
was likely to have been decreased. Antigen-specific adaptive immune responses to LV-
encoded GFP can be attenuated by targeting transgene expression to hepatocytes (382) or 
incorporation of haematopoietic lineage-specific miR targets in the 3' UTR of the transgene 
to negatively regulate transgene expression in APCs (318, 387). Although the above 
approaches are clinically relevant to reduce immunogenicity of the HBV silencing LVs, 
full exclusion of the marker transgene-encoding cassette will not have any consequences 
on the therapeutic efficacy of the approach. Finally, analysis of serum ALT levels in both 
neonatal (superficial temporal vein LV injection) and young adult (tail-vein LV injection) 
cohorts did not reveal significant hepatotoxicity associated with the administration (young 
adult cohort) or LV persistence (neonatal cohort). Processing of the integrated pri-miR 
mimics was according to their intended design as mature miR-31/5 guide sequence could 
be detected at necropsy in the livers of HBV transgenic mice that received the LVTH-LUC 
miR-31/5-8-9 LV via a temporal or tail vein injection. 
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Data presented in this thesis demonstrate that the RNAi-based HBV-silencing LVs 
encoding a liver-specific polycistronic pri-miR sequence are capable of mediating stable 
hepatic delivery and sustained expression of anti-HBV pri-miR sequences in vivo. 
Furthermore, the therapeutic sequences are processed according to the intended design and 
mediate powerful knockdown of markers of viral replication, circulating VPEs and 
intrahepatic viral RNA without inducing hepatotoxicity. To our knowledge this is the first 
study to evaluate the efficacy of RNAi-activating anti-HBV lentiviral vectors in the HBV 
transgenic mouse model. Although this constitutes a preliminary step towards clinical 
application of HBV silencing RNAi-based lentiviral vectors, it has provided proof of 
principle for a therapeutic strategy that can be potentially useful for the treatment of 
chronic HBV infection.  
RNAi-activating HBV silencing lentiviruses could be used in combination with 
currently existing treatments. Combining the potent inhibition of viral replication that 
could be achieved with nucleoside/nucleotide analogues with effective silencing of HBV 
gene expression mediated by highly efficacious LV-delivered polycistronic anti-HBV 
RNAi sequences has the potential to enable simultaneous inhibition of persistent viral 
replication and high load of HBV antigen while providing a high barrier to emergence of 
escape mutants. Sustained reduction of viraemia and antigenaemia, accomplished by 
RNAi-activating LVs or in conjunction with available therapies, should provide a relief 
from immune exhaustion (30), stimulating an adaptive immune system response and 
potentially eradicating the infection. Importantly, activation of the adaptive immune 
system will fuel clearance of infected cells stimulating cell division which will in turn lead 
to dilution of the cccDNA pool and formation of a population of hepatocytes free of 
cccDNA (reviewed in (409)). Studies have shown that following recovery of chronic 
infection the population of hepatocytes that are not infected is in fact derived from 
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parentally infected cells (410, 411). Ultimately, the treated liver might be repopulated by 
healthy hepatocytes as they may have a growth advantage.  
Furthermore, the lentiviral vector platform that has been developed and 
characterised as part of the current set of investigations may be beneficial for advancing 
potential clinical application of RNAi-based gene therapy for other persistent hepatic viral 
infections, such as HCV. 
Although the long-term antiviral efficacy of novel therapies can be rigorously 
assessed in the HBV transgenic model, cccDNA is not formed in the hepatocytes of HBV 
transgenic mice (344). Further development of the RNAi activating HBV silencing 
lentiviral vectors into a clinically relevant anti-HBV therapeutic will necessitate evaluation 
in an animal model that supports the formation of cccDNA. Analysing the effects of RNAi 
activating HBV silencing LVs on this persistent HBV replication template would provide 
deeper insight into their efficacy and ability to eradicate persistent viral infection. The 
uPA-SCID mouse model (350) may be exploited to assess the potential clinical utility of 
the anti-HBV RNAi lentiviral vector hybrid technology. Human hepatocytes can be 
transduced ex vivo with the anti-HBV RNAi-activating LVs and subsequently transplanted 
into uPA/SCID mice. Following successful grafting, animals may be infected with HBV 
(351) to determine whether HBV-targeting lentiviruses confer viral resistance. Successful 
methods for ex vivo LV-modification of human hepatocytes and subset transplantation, 
corroborate the feasibility of using the uPA/SCID mouse model (412) to provide insights 
into the potential utility of ex vivo gene therapy for serious chronic viral infections of the 
liver. 
Ex vivo gene therapy has been the method of choice for lentiviral vector-based 
therapies currently being assessed in clinical trials (http://www.abedia.com/ 
wiley/vectors.php, accessed 15 March 2014). Most trials are based on ex vivo lentiviral 
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gene modification of peripheral T lymphocytes or HSC, and these studies highlight the 
feasibility of ex vivo therapy with RNAi-activating HBV silencing LVs. Similar to ex vivo 
HSC modification, hepatocytes may be efficiently transduced with viral vectors in 
suspension and transfused back into the patient. A recently developed protocol has 
described efficient hepatocyte transduction with lentiviral vectors and immediate 
transplantation. (314-317). The SLIT protocol is clinically applicable and it results in 
engraftment and proliferation of transduced hepatocytes while preserving their 
functionality. The feasibility and biosafety of this approach has been demonstrated in non 
human primates and the protocol was shown to be effective using human hepatocytes (315-
317), corroborating potential feasibility of lentiviral vector-based ex vivo therapy for 
hepatic diseases and/or viral infections 
An ex vivo gene therapy approach to transfer therapeutic RNAi activators to the 
liver offers several advantages when compared to in vivo liver gene transfer. Although 
recombinant viruses can readily reach the liver via the blood circulation, in vitro 
hepatocyte manipulation allows for selective modification of hepatocytes, eliminating the 
possibility of immune stimulation as a result of antigen-presenting cell transduction, 
avoiding VSV-G inactivation in human serum as well as general toxicity or inflammatory 
responses following systemic administration (reviewed in (413)). 
Ex vivo modification of hepatocytes with a lentiviral vector carrying a therapeutic 
anti-HBV RNAi molecule, prior transplantation would inhibit viral replication and 
decrease antigen expression. As a result, these engineered cells will be invisible to 
circulating immune cells, gaining growth advantage over endogenous hepatocytes and 
possibly repopulating the liver. Preclinical studies have demonstrated that hepatocytes 
transplanted in the liver or spleen can engraft, survive and function in the native liver and 
also in the setting of a cirrhotic rat liver (414-416). However, obtaining successful 
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hepatocyte engraftment and survival in humans has proven to be a challenging undertaking 
(417-419). Recently described technological advances allowing for the generation of 
induced pluripotent stem cells (iPSCs) by reprogramming and differentiating somatic cells 
have renewed enthusiasm in the field (reviewed in (420)). New developments in the field 
(421-423) can potentially allow for the generation of an unlimited source of patient-
specific autologous hepatocytes, available for ex vivo modification and transplantation. 
Nevertheless, expansion of hepatocytes following transplantation has been one of the 
major hurdles impeding clinical translation of this approach (424, 425). A recent study has 
demonstrated the generation of hepatocyte-like cells differentiated from multipotent 
progenitor cell (iMPC) capable of proliferating following transplantation and repopulating 
the liver of immunodeficient mice (426). Translation of promising preclinical data may 
lead to potential clinical success of ex vivo RNAi-based lentiviral vector therapy for liver-
related disease. 
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APPENDIX 
A1 GENERAL LABORATORY METHODS AND PROTOCOLS 
 
A1-1 Plasmid DNA purification 
 
Plasmid DNA preparation 
Reagents 
Luria Bertani medium  
Luria Bertani medium was prepared by dissolving 10 g of tryptone (Oxoid, England, UK), 
10 g NaCl and 5 g of yeast extract (Oxoid, England, UK) in one litre of deionised water. 
The solution was sterilised by autoclaving at 121°C for 15 minutes and stored at room 
temperature. 
 
1000× Ampicillin 
Five grams of ampicillin (Sigma-Aldrich, MO, USA) was dissolved in 50 ml of 50% 
ethanol and stored at -20°C. 
 
1000× Kanamycin 
Five hundred milligrams of kanamycin (Sigma-Aldrich, MO, USA) was dissolved in 10 ml 
of deionised water and stored at -20°C. 
 
Procedure 
Plasmid DNA was prepared using the Qiagen Plasmid Maxi or Giga Kit (Qiagen, GmbH, 
Germany). The steps involved in preparing transfection-grade plasmid DNA are  
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summarised in the table below (Table 6.1).  
 
Table 6.1: Preparation of transfection grade plasmid DNA using Qiagen Plasmid 
Maxi and Giga Kits.  
 
Step 
 
Description 
 
Maxi Kit 
 
Giga Kit 
I Luria Bertani medium was inoculated with a 
single colony containing the desired 
plasmid. 
The cultures were incubated at 37°C with 
shaking (200 rpm) for 16 hours.  
100 ml 
Luria Bertani 
(100 µg/ml 
ampicillin) 
 
2.5 litres 
Luria Bertani 
(100 µg/ml 
ampicillin) 
II Bacterial cells were harvested by 
centrifugation at 6000 × g for 20 minutes at 
4°C and the pellet was resuspended in 
chilled buffer P1 (50 mM Tris-HCl, pH 8.0; 
10 mM EDTA, 100 µg/ml RNase A). 
10 ml 
Buffer P1 
125 ml 
Buffer P1 
III Buffer P2 (200 mM NaOH; 1% SDS) was 
added and the cell suspension was mixed 
thoroughly followed by a 5 minute 
incubation at room temperature. 
 
10 ml 
Buffer P2 
125 ml 
Buffer P2 
IV Chilled Buffer P3 (3 M Potassium acetate, 
pH 5.5) was added to the cell suspension 
which was then incubated on ice for 30 
minutes.  
10 ml 
Buffer P3 
 
125 ml 
Buffer P3 
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To clarify the lysate, the suspension was 
centrifuged at 20,000 × g for 30 minutes at 
4°C. 
V Buffer QBT (750 mM NaCl; 50 mM 
MOPS, pH 7.0; 15% Isopropanol; 0.15% 
Triton X-100) was applied to the column 
to equilibrate the resin. The clarified lysate 
was added to the column and allowed to 
drain by gravity flow. 
10 ml 
Buffer QBT 
75 ml 
Buffer QBT 
VI Two washes were performed using buffer 
QC 
 (1 M NaCl; 50 mM MOPS, pH 7.0; 15% 
Isopropanol) 
60 ml 
Buffer QC 
600 ml 
Buffer QC 
VII To elute plasmid DNA bound to the resin, 
buffer QF (1.6 M NaCl; 50 mM MOPS, pH 
7.0; 15% Isopropanol) was dispensed into 
the column. 
Isopropanol was added to the eluted solution 
followed by centrifugation at 15,000 × g for 
60 minutes at 4°C. 
15 ml 
Buffer QF 
 
 
10.5 ml 
Isopropanol 
100 ml 
Buffer QF 
 
 
70ml 
Isopropanol 
VIII 
 
The supernatant was decanted and the DNA 
pellet was washed with 70% ethanol, air-
dried and resuspended in a suitable volume 
of deionised water. 
5 ml 
70% Ethanol 
10 ml 
70% Ethanol 
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A1-2 qPCR vector copy number quantification data 
 
 
WPRE Ct UCR1 Ct 
Average 
WPRE 
Average 
UCR1 dCt 2-Ct VCN 
C0 
  
22.92 27.03 -4.11 17.26765 0 
C0 
       
        C1 
  
22.91 27.98 -5.07 33.59093 0.6 
C1 
       
        C3 
  
22.25 27.44 -5.19 36.50444 2 
C3 
       
        C4 
  
21.69 27.74 -6.05 66.25696 3 
C4 
       
        C5 
  
21.62 28.75 -7.13 140.0696 8.3 
C5 
       
        
 
 
       
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
 
x 
   
y 
  
 
Average 
WPRE 
Average 
UCR1 dCt 2-Ct vector CN 
  LVTH  21.82 26.85 -5.03 32.67238802 1.7741107 
  LVTH miR-31/5 22.28 27.32 -5.04 32.89964245 1.7864506 
  LVTH miR-31/5-8-9 22.47 27.03 -4.56 23.58830748 1.2808451 
  
 
 
y = 0.0543x 
R² = 0.9262 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
0 50 100 150 
Series1 
Linear (Series1) 
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A1-2 Cell culture 
 
Reagents and Solutions 
Gibco TrypLE™ Express Trypsin (Life Technologies Inc., CA, USA) 
Gibco Opti-MEMI (Life Technologies Inc., CA, USA) 
Linear 25 kDa PEI (Polysciences, PA, USA) 
Saline (Dismed CritiCare, South Africa)  
0.4% Trypan blue stain (Lonza, MD, USA) 
DMSO (Sigma-Aldrich, Germany) 
Saline-EDTA: saline containing 1 mM ethylenediamine tetraacetic acid (EDTA)  
Freezing medium (DMEM, 40% FCS and 10% DMSO) 
PEI stock solution (1 mg/ml PEI in sterile 150 mM NaCl (pH 7.0)  
 
Maintenance of cultured cells 
Cells were incubated at 37°C in a humidified incubator with atmosphere of 5% 
CO2. HEK293T, HeLa and Huh7 cells were maintained in complete DMEM (Section 
2.1.1.2). HepG2.2.15 cells were maintained in complete William’s E culture medium 
(Section 2.1.1.2). Cells were passaged before reaching confluence by enzymatic 
dissociation. Briefly, a thorough saline wash was carried out before the cells were 
incubated in saline-EDTA solution for 5 minutes at 37°C. Following removal of the saline-
EDTA solution, an appropriate volume of TrypLE™ Express Trypsin was added and an 
additional 5 minute incubation step at 37°C was carried out. Cells were detached by gently 
tapping the culture dish, followed by addition of pre-warmed, complete culture medium. 
An appropriate volume of the cell suspension was aliquoted into sterile culture dish 
containing complete growth medium and the cells were returned to the incubator. 
Typically a 1:10 subculturing ratio was used when passaging HEK293T cells, while Huh7 
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and HepG2.2.15 cells were passaged at a 1:3 ratio. The growth medium was replenished 
when a drop in pH was evident until further cell passaging was required. Before seeding 
cells for an experiment that involved transfection or lentivirus infection, the number of 
viable cells was determined using trypan blue exclusion and a Neubauer hemacytometer. 
 
Cryopreserving cultured cells and thawing cryopreserved cells 
To prepare stocks of cultured cells for freezing, cells were detached as described 
above and the number of viable cells was determined using trypan blue exclusion and a 
Neubauer hemacytometer. The cells were centrifuged at 200 × g for 4 minutes and  
resuspended in the appropriate volume of freezing medium (1 × 10
7
 cells/vial). Finally, the 
cell suspension was aliquoted in cryogenic vials (Corning Inc., NY, USA). The cell-
containing cryogenic vials were slowly frozen at -80°C overnight in a freezing container 
and transferred to liquid nitrogen for long-term storage. 
To thaw cells stocks, cryogenic vials containing frozen cells were taken out of 
liquid nitrogen storage and immediately placed into a 37°C water bath for less than 5 
minutes. The tube was sterilised with 70% ethanol and the cell suspension was added drop 
wise into a 25 cm
2 
tissue culture flask containing 10 ml of pre-warmed complete culture 
medium appropriate for the respective cell line.  
 
Transfection of cells 
Lipofectamine-mediated transfection 
The day before transfection was carried out cells were trypsinised and seeded in 24 
well culture plates at a density of 80 000 cells/well (Huh7 cells) or 50 000 cell/well 
(HEK293T). Cells were plated in complete growth medium and allowed to grow overnight 
at 37°C and 5% CO2. The growth medium was removed the following day and replaced 
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with complete culture medium. To prepare a transfection mixture, 1 µg of DNA was 
diluted into 50 µl of OPTI-MEM and 1 µl of Lipofectamine was diluted into 50 µl of Opti-
MEM for each well of cells to be transfected. The mixes were incubated at room 
temperature for 5 minutes before the DNA:Opti-MEM mix was added to the 
Lipofectamine:Opti-MEM mix and the final transfection mix was incubated at room 
temperature for an additional 20 minutes. One hundred microlitres of the final transfection 
mix was added to each well and the cells were incubated at 37°C in a CO2 incubator for 5 
hours. After 5 hours the growth medium was removed and fresh, complete growth medium 
was added to the each well. 
 
PEI-mediated transient transfection of HEK293T cells for lentivirus production 
Six million HEK293T cells were seeded in a 15 cm
2 
culture dish in a final volume 
of 18 ml of complete DMEM without phenol red on the day before transfection. The 
following day a plasmid DNA mix containing 30 µg of transfer lentiviral vector, 22 µg of 
psPAX2 or pCMVR8.74 and 15 µg of pMD2.G was prepared and diluted in 1 ml of 
sterile 150 mM NaCl solution (pH 7.0). One millilitre of PEI stock solution was added to 1 
ml of the plasmid DNA mix. The DNA:PEI transfection mixture was briefly vortexed and 
incubated at room temperature for 10 minutes. Finally, the transfection mixture was added 
to each 15 cm
2
 dish in a circular drop wise manner. The plates were incubated for 12 hours 
at 37°C in the presence of 5% CO2. After 12 hours the growth medium was removed and 
20 millilitres of fresh, complete growth medium was added to the dish. Transfection 
mixture volumes and the corresponding amount of plasmid DNA were scaled up 
accordingly for large scale lentivirus production. 
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A3 ANIMAL ETHICS CLEARANCE CERTIFICATES 
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